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ABSTRACT 
 
Chapter one reviews the recent progress in the synthesis of phosphonopeptides, 
pseudopeptides containing a phosphinic, phosphonic or phosphonamide linkage in place 
of an amide (peptide) linkage. It describes some of the general methods for the synthesis 
of these pseudopeptides; for example through couplings to the nitrogen of an α-
aminophosphonic acid, or Michael addition to acrylates, as well as other methods, the 
scope for which are not as wide yet. It also provides a summary of the reported 
biological activities of this class of pseudopeptides. 
Chapter two contains the results and discussion for a novel method for the synthesis of   
α-hydroxy phenylphosphinate oligomers as well as hybrid oligomers containing α-
hydroxy phenylphosphinic acid and α-amino carboxylic acids. In particular, synthesis of 
a series of dimeric α-hydroxy phenylphosphinates are reported. The analysis of these 
dimers by a combination of NMR spectroscopy, X-ray crystallography and 
computational methods shows intramolecular hydrogen bonding in these molecules 
depends on the relative configuration of the carbon and phosphorus atoms. However, 
although the development of the synthetic methods was successful, the separation and  
isolation of the diastereomers was not always possible, which hindered a more 
comprehensive analysis of folding patterns in these molecules. 
Chapter three contains the experimental procedures, preparation and spectroscopic 
characterisation of all the chemical compounds.  
Crystal data and details of crystal structures are in the Appendix. 
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ABBREVIATIONS 
 
Å  angstrom 
Ac  acetyl 
ACE  angiotensin converting enzyme 
AHEP  1-amino-2-(4-hydroxyphenyl) ethylphosphonic acid 
APP  amyloid precursor protein 
app.  apparent 
atm.  atmosphere 
aq.  aqueous   
BACE1 human β-secretase  
Bn  benzyl 
BOC  
t-
butoxycarbonyl 
BOP  benzotriazole-1-yl-oxy-tris(dimethylamino)phosphonium                                                                                
hexafluorophosphate 
BSA  bistrimethylsilylacetamide 
BTSA  bis(trimethylsilyl)amine 
Bu  butyl 
Bz  benzoyl 
Cal B  Candida antarctica lipase B 
cat.  catalyst 
cbz  carbobenzyloxy / benzyloxycarbonyl 
cod  1,5-cyclooctadiene 
conc.  concentrated 
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CPA  carboxypeptidase A 
CSA  camphor-10-sulfonic acid 
DBU  1,8-diazabicyclo[5.4.0]undec7-ene 
DCC  N,N'-dicyclohexylcarbodiimide 
DDQ  2,3-dichloro-5,6-dicyanobenzoquinone 
DEAD  diethyl azodicarboxylate 
DIC  1,3-diisopropylcarbodiimide 
dioxane [1,4]-dioxane  
DIPEA diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DPP IV dipeptidyl peptidase IV  
EDCI  1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
Et  ethyl 
eq.  equivalent 
Fmoc  9-fluorenylmethoxycarbonyl 
HBTU  O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HIV-1  human immunodeficiency virus 1 
HMDS  hexamethyldisilazane 
HOBt  1-Hydroxybenzotriazole 
HOESY heteronuclear overhauser enhancement spectroscopy 
HPLC  high performance liquid chromatography 
IC50  Half maximal inhibitory concentration 
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Kcal  kilocalorie 
lit.  literature 
m  meta 
Me  methyl 
MMP  matrix metalloproteinase 
Ms  methanesulfonyl (mesyl) 
MW  microwave 
p-NA  p-nitroaniline 
NAPAP N
α
-(2-naphthyl-sulfonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine 
NEM  N-ethylmorpholinium acetate 
nm  nanometer 
NMP  N-methylpryyolidine 
NMR  nuclear magnetic resonance 
NOESY nuclear overhauser enhancement spectroscopy 
o  ortho 
p  para 
PDT  photodynamic therapy 
Ph  phenyl 
PMB  p-methoxybenzyl 
ppm  parts per million 
i
Pr  isopropyl 
py  pyridine 
PyPOP  (pentafluorophenyl) oxytripyrrolidinophosphonium hexafluorophosphate 
Rf  retention factor 
9 
 
rt  room temperature 
SrtA  Staphylococcus aureus sortase transpeptidase 
TBAF  tetra-n-butyl ammonium fluoride 
TBDMS 
t-
butyldimethylsilyl  
TBTU  O-benzotriazole-1-yl-1,1,3,3-tetramethyluronium tetrafluoroborate 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
TMS  trimethylsilyl 
TMSBr bromotrimethylsilane 
TMSCl trimethylsilylchloride / chlorotrimethylsilane  
TMSI  iodotrimethylsilane 
Trt  triphenylmethyl (trityl)  
Ts  4-methylbenzenesulfonyl (tosyl) 
UA  Ursolic acid 
uPA  urokinase plasminogen activator 
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1. Chapter One: Recent advances in 
the chemistry of phosphonopeptides 
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1.1. Introduction 
Phosphonopeptides are structural analogues of peptides in which one or more of the 
amide functions have been replaced by a phosphono function. A variety of different 
phosphonopeptides exist depending on the phosphono group. The phosphorus atom may 
be bonded to a nitrogen atom, an oxygen atom or a carbon atom (Figure 1). 
 
Figure 1 Comparison of amide and phosphono groups. 
Recent years have seen an increasing interest in synthetic and naturally occurring 
phosphonopeptides as a significant class of peptidomimetics in medicinal and 
bioorganic chemistry.
1,2,3 
Phosphonopeptides are useful in developing peptidase enzyme 
inhibitors, since the phosphono functions may be construed as transition state analogs of 
the scissile amide bond (Figure 2)
4,5,6
 as well as haptens for producing catalytic 
antibodies with esterase activity.
7,8
 Many phosphonopeptides have been shown to be 
useful as anticancer, antibiotic and antibacterial agents.
9,10
  In addition, over the last 
decade, a number of phosphonopeptides with α-aminophosphonic acid at the C terminus 
have been synthesised as herbicides.
11
 
 
 
Figure 2 Comparison of amide-enzyme intermediate and tetrahedral phosphono group. 
This review covers the recent reports of the preparation of phosphonopeptides.  
Synthesis of phosphonopeptides has been comprehensively reviewed previously
12,13
 and 
older synthetic approaches to them can be ascertained from the references cited there as 
12 
 
well as the body of this review. Phosphopeptides, peptides that contain one or more 
phosphate groups, resulting from phosphorylation of the hydroxyl function in tyrosine 
or serine residues, will not be covered in this review as their chemistry and application 
are considerably different. 
 
1.2. Reaction involving coupling of an α-aminophosphonate and an 
acid 
One of the most common routes to phosphonopeptides is to ligate an existing α-
aminophosphonic moiety to the carboxy terminus of a peptide. There are already a large 
number of methods for the synthesis of α-aminophosphonates (some of which will also 
be shown here for the sake of completeness) as well as for the formation of peptide 
bonds. Therefore, this method has the dual advantage of being both general and reliable. 
In line with a similar methodology in peptide chemistry, coupling of an α-
aminophosphonate with the acid chloride of a suitably protected α-amino carboxylic 
acid is a straight forward route to a phosphonopeptide. The method, which is 
exemplified shortly, obviously requires synthesis of an α-aminophosphonic acid to start 
with, but it also suffers in that acid chlorides of suitably protected α-amino carboxylic 
acids are difficult to produce with chiral integrity. 
13 
 
 
Scheme 1 Retrosynthetic analysis of ursolic acid phosphonopeptide derivative. 
Deng et al.
14
 synthesised a series of novel phosphonopeptide derivatives of naturally 
occurring 3β-hydroxyurs-12-en-28-oic acid (ursolic acid, UA) (1a-j) (Scheme 4), and 
have reported on their broad spectrum of biological activity. The retrosynthetic analysis 
for formation of the phosphonopeptides is outline in Scheme 1. Ursolic acid has been 
shown to be a potential chemotherapeutic and chemopreventive agent
15,16,17,18
 with some 
derivatives showing potential activity against human immunodeficiency virus 1 (HIV-
1).   
 
Scheme 2 Reagents and conditions: (i) AcOH, 80-85 °C, 2 h; (ii) HBr/AcOH, rt, 2 h; (iii) Et3N/THF. 
 
The synthesis was divided into three parts. First a number of α-aminophosphonates were 
synthesised using a three-component Mannich type reaction as the key step (Scheme 2).  
14 
 
Secondly, phosphonodipeptides and their homologs were synthesised through coupling 
of the α-aminophosphonates with an acid chloride of protected glycine or -alanine 
(Scheme 3). Finally, phosphonodipeptide conjugates of ursolic acid and their homologs 
were synthesised by condensation of the chloride of UA with the phosphonodipeptides 
and their homologs (Scheme 4). 
The α-aminophosphonates were synthesised according to Scheme 2. A one-pot, three 
component (benzyl carbamate, various aldehydes and triphenylphosphite) reaction was 
used to obtain a varied range of N-protected α-aminophosphonates, 5. Deprotection was 
carried out using hydrogen bromide and acetic acid to give compounds, 6 which were 
then treated with triethylamine in THF to afford the desired α-aminophosphonates 4. 
 
Scheme 3 Reagents and conditions: (i) 185-200 °C, 15 min; (ii) SOCl2, 60 °C, 3 h; (iii) 2 eq. 
Et3N/THF, 0 °C, 15 min; then rt, overnight; (iv) NH2NH2.H2O, EtOH, rt, 16 h. 
 
The synthesis of the phosphonodipeptides and homologs was carried out as outlined in 
Scheme 3. Condensing the α-amino acids with phthalic anhydride afforded 7. The N-
protected amino acid was chlorinated using thionyl chloride to afford acid chloride 8. 
The acid chloride 8 was coupled with α-aminophosphonate 4 (previously synthesised) 
using triethylamine to give the protected phosphonodipeptide 9.  Hydrazine was used to 
15 
 
remove the phthalyl protecting group to give the desired phosphonodipeptide and 
homolog 10. Finally, new phosphonodipeptide conjugates of ursolic acid were 
synthesised according to Scheme 4.  To form the phosphorus conjugates of UA 1, it first 
had to be appropriately protected.  The hydroxyl group in ursolic acid 11 was converted 
to an acetate, 2, which was then chlorinated using thionyl chloride to give the 
corresponding acid chloride 12. Phosphonodipeptide 10 was condensed with acid 
chloride 12 to give the final compound 1. 
 
 
Scheme 4 Reagents and conditions: (i) Ac2O, DMAP, py, rt, 2.5 h; (ii) SOCl2, 65 °C, 5 h; (iii) 10a-j, 
Et3N/THF, 0 °C, 0.5 h; then rt, overnight.  
 
An alternative, less forcing method, is to convert the carboxylic acid to a mixed 
anhydride via treatment with a chloroformate. This protocol was used by Li et al.
19
 for 
the synthesis of novel thrombin inhibitors containing phosphinic peptide mimetics 
through structure-based design. Thrombin is the final protease involved in a complex 
process that leads to blood coagulation; therefore its role in thrombosis and haemostasis 
16 
 
is significant. The inhibitors synthesised in the work are based on the structure of N
α
-(2-
naphthyl-sulfonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP) (Figure 3) 
which has been shown to be a potent antithrombotic. 
 
 
Figure 3 Structure of NAPAP. 
 
 
Scheme 5 Reagents and conditions: (i) AcOH, rt, overnight; (ii) H2O, 60%; (iii) 30% HBr/AcOH, 1 h, 
rt, 83-91%; (iv) R
1
NHCHR
2
CO2H, EtOCOCl, Et3N, THF, -4 °C, 1 h; then rt, 24 h, 23-40%; (v) 
HCl/CHCl3/MeOH, 0-4 °C, 2 d; (vi) NH3/MeOH, rt, 2 d; (vii) 30% HBr/AcOH, rt, 1 h, 90%. 
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The syntheses of the phosphinic peptide mimics are carried out as shown in Scheme 5. 
The Cbz-protected phosphinic amino acids 13 were synthesised in a one pot reaction of 
4-substituted phenylacetaldehydes with dichlorophenylphosphine and benzyl carbamate 
in acetic acid (also see Scheme 48). 
Deprotection of 13 using hydrogen bromide in acetic acid afforded compounds 14, 
which were then coupled with the N-protected amino acids that had been activated with 
ethyl chloroformate to give the mixed anhydrides, affording the dipeptide mimetics 15. 
It is worth noting that the hydroxyl group of the phosphate does not undergo the 
coupling reaction. The final step involved conversion of the cyano group of 15 into an 
amidino group to give compounds 16 and 17. Compound 17 required further 
deprotection with hydrogen bromide in acetic acid to afford 18. 
Once the inhibitors had been synthesised they were evaluated for potency in thrombin 
inhibition by use of a chromogenic substrate S-2238, monitoring the release of 
nitrophenol at 405 nm. Based on the inhibition data (Table 1) it could be concluded 
replacement of the indole ring by the 2-naphthyl ring improved activity. The increased 
potency of 18 compared to 17 can be explained by the deblocking of the N-terminus of 
17 that could give favourable electrostatic interactions with the side chain due to the 
positive charge on the nitrogen. 
 
Inhibitor IC50 (µM) 
22 70 
23 7.5 
24 3.6 
25 0.6 
Table 1 In vitro inhibition by phosphinic dipeptide mimetics. 
The chloroformate approach was also used by D’Alessio et al.20 in the synthesis of 
phosphonate analogues of snake venom peptides as inhibitors of adamalysin II and 
matrix metalloproteases (MMPs). In this investigation, phosphonate analogues of the 
18 
 
peptidomimetic N-(furan-2-yl)carbonyl-Leu-Trp-OH (Fur-Leu-Trp-OH) were 
synthesised for evaluation of the effect of replacing a phosphonate for carboxylate in 
binding with MMPs (see also Scheme 7). 
The synthesis of phosphonate analogues 22a-b (Scheme 6) began by coupling 19 with 
20 using a chloroformate activation to give 21.  Compound 21 was subsequently 
deprotected to give the phosphonate analogues of Fur-Leu-Trp-OH 22a-b.  The 
synthesised compounds were tested as adamalysin and MMPs 2, 3, 8 and 9 inhibitors 
(Table 2). 
 
Scheme 6 Reagents and conditions: (i) ibutyl chloroformate, N-methylmorpholine, 4 °C, 12 h, 65%; (ii) 
N,O-bis-trimethylsilyl-trifluoroacetamide, TMSI, CH2Cl2, 25 °C, 2 h, 79-82%. 
 
 
No. Inhibitor IC50 (µM) 
adamalysin MMP-2 MMP-9 MMP-8 MMP-3 
22a Fur-Leu-(S)-Trp(P)-(OH)2 0.4 60 - >100 - 
22b Fur-Leu-(R)-Trp(P)-(OH)2 70 - - - - 
23 Fur-Leu-Trp-OH 30 40 >100 50 >100 
Table 2 In vitro inhibition of adamalysin and MMPs 2, 3, 8 and 9 by phosphonate inhibitors. 
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Of course, the most common reagent for the formation of peptide bonds is N,N'-
dicyclohexylcarbodiimide (DCC) and its analogues. In further continuation of their 
earlier report (Scheme 6), Agamennone et al.
21
 synthesised and evaluated a number of 
tripeptide phosphonate inhibitors against MMP-8 and MMP-2, using DCC methodology 
(Scheme 7). Their work relates to synthesis of analogues of phosphotryptophan, 
specifically its derivative L-Pro-L-Leu-L-(P)Trp(OH)2 a left-hand-side phosphonate 
inhibitor of MMP-8.  
 
 
Scheme 7 Reagents and conditions: (i) R-AA-OH, DCC, HOBt, THF, 80-90%; (ii) 10% Pd/C, 
HCO2NH4, CH3OH, 92%; (iii) TMSI, BSA, CH2Cl2, 49-92%; (iv) Ac2O, py, 70-90%; (26c and 26d 
require hydrogenolysis (ii)). 
 
Phosphonopeptide 24 was coupled with a protected amino acid (e.g. leucine) to give 25, 
followed by further coupling with a protected amino acid to give 26a-f. Deprotection of 
26a-f gave 27a-f which was subsequently protected with acetic anhydride to give 28a-f. 
The synthesised analogues were tested for activity against MMP-2 and MMP-8 (Table 
3). The analogues showed varied selectivity for the MMPs tested. One issue the group 
reported is the fact the analogues were accommodated in the right-hand side of the 
MMP-8 active site instead of the left as had been predicted. 
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Phosphonate MMP-2 MMP-8 
No. R Ki (mM) Ki (mM) 
27a L-Pro 1.53 3.94 
27b D-Pro - - 
27c L-Ala 0.4 0.5 
27d D-Ala - 0.41 
27e β-Ala - 0.34 
27f C5H9CO 0.4 1.36 
28a N-Ac-L-Pro 1.76 0.34 
28b N-Ac-D-Pro - - 
28c N-Ac-L-Ala 0.55 0.26 
28d N-Ac-D-Ala 3.77 2.95 
28e N-Ac-β-Ala 0.56 0.49 
Table 3 Inhibition of MMP 2 and 8 by phosphonate inhibitors. 
 
Gavuzzo et al.
22
 have used phosphinic peptidomimetics to obtain transition state 
analogues that are capable of interacting on both sides of the catalytic zinc ion in 
MMPs. The group had taken evidence of complexing the peptidase astacin with a 
phosphinic inhibitor
23
 and substitution at P1’ and P2 positions in phosphinic 
pseudopeptides
24
 to design inhibitors to selectively block particular MMPs. 
The group attempted to synthesise a number of phosphorus containing peptidomimetics 
based on data obtained from the isolation of phosphoramidon, a natural inhibitor of 
thermolysin and other metalloproteinases. The work involves the synthesis of tripeptide 
phosphonates as shown in Scheme 8  
21 
 
 
Scheme 8 Reagents and conditions: (i) DCC, HOBt, THF; (ii) TMSI, BSA, CH2Cl2. 
 
 
This synthesis follows peptide coupling conditions where Cbz-Pro-Leu-OH was 
coupled with the diethyl ester of (S)-phosphotryptophan 29 using DCC and 1-
hydroxybenzotriazole (HOBt) to give 30.  The desired phosphonate 31 was obtained by 
deprotecting 30 using iodotrimethylsilane (TMSI) in the presence of 
bistrimethylsilylacetamide (BSA) to hydrolyse the diethyl phosphonate and also remove 
the carbobenzyloxy (Cbz) group to give 31.  
Habdas et al.
25
 synthesised three new porphyrin-peptidyl-phosphonate derivatives 
(Scheme 9) as potential photosensitisers for the photodynamic therapy (PDT) of 
tumours. The compounds were tested for activity as inhibitors of aminopeptidase N 
(Table 4) and showed moderate inhibition.  
22 
 
 
Scheme 9 Reagents and conditions: (i) Et3N; (ii) DCC, CH2Cl2. 
 
During the synthesis of the compounds they coupled the carboxylic acid of porphyrin 32 
with the ammonium bromide of phosphinic peptide 33a-c to give porphyrin-peptidyl-
phosphonate derivatives 34a-c. 
No. Name Mw IC50 (µM) 
32 TTP-COOH 701 18.5 
34a TTP-Ala-3PyP(OPh) 1094 87.3 
34b TTP-Val-3PyP(OPh) 1122 19.3 
34c TTP-Pro-3PyP(OPh) 1120 32.4 
Table 4 Inhibition of aminopeptidase N by phosphonate derivatives. 
In addition to DCC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) has also 
found wide spread application in the formation of peptide bonds in general, and in the 
23 
 
context of the phosphonopeptide synthesis. The EDCI reagent was used by Ntai et al.
26
 
as part of their investigation to identify the pharmacophore of the angiotensin 
converting enzyme (ACE) in the naturally occurring phosphonotripeptide K-26, a potent 
inhibitor of that enzyme. The group used the protocol to synthesise (Scheme 10) and 
test eight analogues of K-26, in order to gain information into the structure activity 
relationships of K-26.  
 
Scheme 10 Reagents and conditions: (i) P(OEt)3, THF 0 °C to 70 °C; (ii) NH2OH.HCl, py, EtOH, 25 
°C; (iii) Zn/HCOOH, 25 °C; (iv) EDC.HCl, HOBt, 2,4,6-trimethylpyridine, DMF, 25 °C; (v) H2, Pd/C, 25 
°C; (vi) TMSI, thioanisole, MeCN, 0 °C. 
 
Compound 35 was synthesised through an Arbuzov type reaction by reacting 4-
benzyloxyphenylacetyl chloride with triethyl phosphite giving the corresponding α-
ketophosphonate, which was converted to oxime 35 by treatment with hydroxylamine. 
Compound 35 was reduced with zinc and formic acid to give the racemic 1-amino-2-(4-
hydroxyphenyl) ethylphosphonic acid (AHEP) diethyl ester 36. Coupling of the amine 
of 36 with a dipeptide, followed by hydrogenation of the benzyl protecting groups gave 
37.  Removal of the ethyl groups by treatment of TMSI afforded a mixture of the two 
major diastereomers of K-26 (38 and 39), that could be separated by chromatography. 
24 
 
After synthesis of the compounds, measurement of ACE activity was carried out.  The 
IC50 values obtained are shown in the following table (Table 5). 
 
 
No. IC50 (nM) No. IC50 (nM) 
 
 
 
 
38 (K-26) Ac-(L)-Ile-(L)-Tyr-(R)-
AHEP 
14.4 42a Ac-(L)-Ile-(L)-Tyr-(L)-Tyr 2.1 x 10
4
 
39 Ac-(L)-Ile-(L)-Tyr-(S)-AHEP 139 42b Ac-(L)-Ile-(L)-Tyr-(D)-Tyr 2.0 x 10
6
 
40 Ac-(L)-Ile-(L)-Tyr-(R)-AHEP 
(OEt)2 
3.83 x 
10
5
 
  
 
 
 
 
41a (L)-Ile-(L)-Tyr-(S)-AHEP 234.3 43a (L)-Ile-(L)-Tyr-(L)-Tyr 
2.36 x 
10
5
 
41b (L)-Ile-(L)-Tyr-(R)-AHEP 
5.46 x 
10
4
 
43b (L)-Ile-(L)-Tyr-(D)-Ty >10
6
 
 
   
Captopril 7.7   
Table 5 Inhibition of ACE by K-26 analogues. 
 
As can be seen N-acetylation of the natural peptide analogues 43a-b to give 42a-b 
increased the activity 10-fold. The introduction of the phosphonyl substitution 38 gave 
1500-fold more potent activity compared to the natural tripeptide analogue 42a.  
25 
 
Ravashcino et al.
27
 synthesised a number of phosphinopeptides (Scheme 11) for use 
against Trypanosoma cruzi (Chagas’s disease).  
 
Scheme 11 Reagents and conditions: (i) HMDS, 110 °C, 2 h, (ii) RI, CH2Cl2, rt, 16 h; (iii) BnOH, 
DCC, DMAP, THF, rt, 16 h; (iv) TrtN=CH2, BF3.Et2O, toluene, rt, 3 d; (v) TFA (2.5%), CH2Cl2, rt, 30 
min; (vi) N-hydroxysuccinimide, EDC.HCl, DMF, rt, 16 h, (vii) Et3N, DMF, rt, 16 h; (viii) H2, Pd/C, 
MeOH, 1 atm, rt, 1 h. 
 
No. 
amastigotes 
IC50 (µM) 
epimastigotes 
IC50 (µM) 
51a >50 >50 
51b >50 >50 
51c >50 >50 
51d 9.8 >50 
51e 14.2 >50 
51f >50 >50 
51g >50 >50 
Table 6 Effect of phosphinopeptides against Trypanosoma cruzi. 
 
Ammonium hypophosphite 44 was activated using hexamethyldisilazane (HMDS) then 
coupled with various alkyl chains to give 45. Benzylation of the alcohol in 45 was 
carried out to give 46, which was then reacted with the imine to give 47. The trityl 
protecting group in 47 was removed to give 48.  Coupling of 48 to dipeptide 49 afforded 
50, which was subsequently deprotected using hydrogenolysis to give 51 (Scheme 11).  
26 
 
After compounds 51a-g were synthesised they were evaluated for activity against 
amastigotes and epimastigotes (Table 6). 
Pan et al.
28
 synthesised a series of diphenylphosphonates as activity-based probes for 
trypsin-family serine proteases. The work was aimed at synthesising probes that could 
specifically target serine proteases. 
 
 
Scheme 12 Reagents and conditions: (i) AcOH, MW 150 °C, 5-10 min / oil bath 70 °C, 1-3 h; (ii) 
NH2NH2; Boc2O; H2, Pd/C; (iii) NHS-(PEG)4-biotin, Et3N; then TFA; (iv) Cbz-Pro-OH, EDCI, HOBt; 
(v) Cbz-Asn(Trt)-OH, EDCI, HOBt; H2, Pd/C. 
 
The synthesis of the activity based probes (Scheme 12) involves a three component 
reaction, with an amine, aldehyde and triphenylphosphite to give 52. Subsequent 
27 
 
deprotection of 52 using hydrazine to remove the phthalimide group followed by t-
butoxy carbonyl (Boc) protection, and hydrogenation of the Cbz group to give 53. 
Compound 53 was then coupled through varied methods to give 54-56. 
Senten et al.
29
 synthesised dipeptide p-nitroanilides and dipeptide diphenyl 
phosphonates using polymer supported carbodiimide for a solution-phase parallel 
synthesis (Scheme 13).  
 
Scheme 13 Reagents and conditions: (i) Polymer bound carbodiimide, HOBt; (ii) R1aa-pNA 58; (iii) 
Polymer bound polyamine; (iv) R
1
aa
P
(OPh)2 59; (v) TFA, CH2Cl2.  
 
Boc protected amino acids 57 were activated as their 3-hydroxybenzotriazole (HOBt) 
esters using polymer bound carbodiimide followed by reactions with either a p-
nitroanilide (p-NA) of amino acids 58 or an α-amino phosphonate 59 to give 60 and 62.  
The final step involved deprotection of 60 and 62 to give dipeptide p-nitroanilides 61 
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and dipeptide diphenyl phosphonates 63.  The full details for the dipeptides synthesised 
is given in the following tables (Table 7 and Table 8). 
 
 
 
 Pro-p-NA Ala-p-NA 
Raa 
Purity 
(60) 
Purity 
(61) 
 
Yield 
  (%) 
Purity 
(60) 
Purity 
(61) 
Yield  
(%) 
Asn 99 94 98    
Asp 90 95 87    
Gly    97 97 86 
His 40 91 42 97 96 49 
Ile 88 98 10    
Phe 97 99 16 99 95 95 
Pro 96 99 47 98 97 94 
Ser 84 90 84    
Tyr 91 95 18 98 94 75 
Val 88 92 30    
Table 7 Synthesised dipeptide p-nitroanilides. 
 
 Pro
P
(OPh)2 Ala
P
(OPh)2 
Raa 
Purity 
(62) 
Purity 
(63) 
 
Yield 
  (%) 
Purity 
(62) 
Purity 
(63) 
 
Yield 
  (%) 
Ala 58 96 36 76 91 51 
Asn 87 99 59 80 77 23 
Asp 66 98 48 53 91 32 
Gly 64 94 61 78 94 60 
His 31 100 7 30 100 27 
Ile    85 97 21 
Lys 66 100 51    
Phe 83 95 58 89 97 13 
Pro    90 95 55 
Ser 68 84 60 56 83 18 
ThiaPro 75 95 41    
Tyr    90 95 65 
Val 69 90 41 94 95 13 
Table 8 Synthesised dipeptide diphenyl phosphonates. 
 
In addition to carbodiimide reagents such as DCC and EDCI, a number of other peptide 
coupling agents are also used.  
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Scheme 14 Reagents and conditions: (i) nBuLi, THF; (ii) Diethyl chlorophosphate; (iii) TFA, CH2Cl2, 
67%; (iv) H2, Pd(OH)2, EtOH; (v) Boc-(L)-Ala, BOP, Et3N, CH2Cl2, 79%; (vi) HBr/AcOH. 
 
 
Coeffard et al.
30
 report the synthesis of alafosfalin 69 using a methodology they 
developed involving the use of enantioenriched tributylstannylated α-amino alcohols 
and a benzotriazole-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate 
(BOP) coupling protocol. 
The synthesis of alafosfalin 69 (Scheme 14) begins with treating tributylstannylated α-
amino alcohol with butyl lithium and diethyl chlorophosphate to give 65. The alcohol of 
compound was deprotected to give 66.  Compound 66 underwent hydrogenolysis to 
give α-amino phosphonate 67, which was coupled with Boc protected alanine using 
BOP as a coupling agent.  The final step to form alafosfalin 69 involved deprotection of 
68 using hydrogen bromide in acetic acid to remove the ester and amine protecting 
groups. 
In other examples, Joossens et al.
31
 reported the synthesis of diphenyl phosphonate 
inhibitors against the urokinase plasminogen activator (uPA) using O-benzotriazole-1-
yl-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) for peptide coupling. The 
group described a strategy for the synthesis of small libraries of tripeptidyl 
diphenylphosphonate analogues (Scheme 15) for structure-activity relationship studies. 
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Scheme 15 Reagents and conditions: (i) Boc2O, Et3N, dioxane, (ii) Dess-Martin; (iii) benzyl 
carbamate, triphenyl phosphite, Cu(OTf)2, CH2Cl2; (iv) TFA, (v) N,N'-bis(tert-butoxycarbonyl)-1-
guanylpyrazole, MeCN; (vi) H2, Pd/C. 
 
The synthesis involves 2-(4-aminophenyl)ethanol 70 being Boc protected followed by 
oxidation of the alcohol to afford 71. Aldehyde 71 is then involved in a three component 
reaction with benzyl carbamate and triphenyl phosphite to give 72.  Subsequent 
deprotection of 72 using trifluoroacetic acid (TFA) and reacting with N,N'-bis(tert-
butoxycarbonyl)-1-guanylpyrazole gave 73 that required deprotection using 
hydrogenolysis to give 74. 
 
 
Scheme 16 Reagents and conditions: (i) piperidine, DMF, (ii) Fmoc-(D)-Ser(OtBu), TBTU, Et3N, 
DMF; (iii) piperidine, DMF, (iv) R
1
SO2Cl, collidine, CH2Cl2 or R
1
COOH, TBTU, Et3N, DMF; (v) 
AcOH, MeOH, CH2Cl2; (vi) HOBt, resin-bound carbodiimide, CH2Cl2, (vii) resin-bound polyamine; (viii) 
TFA. 
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With compound 74 prepared, the next step was to build up varied chains on a polymer 
support to couple with 74 to achieve final compounds 80 (Scheme 16). Fmoc protected 
resin bound alanine 75 was coupled with serine to give 76. Deprotection of 76 followed 
by addition of various R
1
 groups using sulfonyl chlorides or carboxylic acids afforded 
77a-o.  Cleavage of 77a-o from the resin gave 78a-o, which was then coupled with 74 
to give 79a-o, followed by deprotection using TFA to give 80a-o, with details of R
1
 
groups listed in Figure 4. 
After synthesis, compounds 80a-o were tested for inhibition of uPA and related 
enzymes (Table 9). 
Joosens et al.
32
 also synthesised a series of irreversible diphenyl phosphonate inhibitors 
against urokinase plasminogen activator (uPA), which is important in vascular diseases 
and in cancer.  
 
 
Figure 4 R1 groups of compounds 80a-o. 
 
 
 
 
 
32 
 
No. 
IC50 (nM) 
uPA  
kapp (M
-1
s
-1
) 
uPA 
IC50 (µM)* 
 
tPA plasmin thrombin 
Factor 
Xa 
trypsin 
80a 4.3 ± 0.2 60 ± 2 x 103 
4.6 ± 0.7 
(1000) 
2.0 ± 0.2 
(470) 
20 ± 0.3 
(4700) 
43% @ 
125 
0.3 ± 0.1 
(70) 
80b 2.6 ± 0.3 94 ± 4 x 103 
3.1 ± 0.7 
(1200) 
1.9 ± 0.1 
(740) 
4.9 ± 0.3 
(1900) 
64% @ 
250 
0.16 ± 0.2 
(60) 
80c 3.5 ± 0.7 97 ± 7 x 103 
0.28 ± 
0.02 
(80) 
0.037 ± 0.003 
(11) 
0.77 ± 0.03 
(220) 
33 ± 5 
(9400) 
0.31 ± 0.03 
(90) 
80d 5 ± 1 40 ± 2 x 103 
15 ± 2 
(3000) 
15 ± 1 
(3000) 
22 ± 1 
(5400) 
45% @ 
250 
0.40 ± 0.05 
(80) 
80e 5.8 ± 1.2 46 ± 2 x 103 
4.4 ± 0.5 
(760) 
0.99 ± 0.05 
(155) 
6 ± 1 
(1000) 
96 ± 14 
(16551) 
0.280 ± 0.04 
(50) 
80f 1.5 ± 0.2 80 ± 10 x 103 
3.4 ± 0.1 
(2300) 
1.54 ± 0.17 
(1000) 
4.3 ± 0.2 
(2800) 
68% @ 
250 
0.098 ± 
0.006  (65) 
80g 6.9 ± 0.8 71 ± 0.2 x 103 
13 ± 2 
(1900) 
10 ± 1 
(1400) 
35 ± 4 
(5000) 
~250 
 
280 ± 30 
(40) 
80h 8 ± 1 36 ± 1 x 103 
8.6 ± 0.6 
(1000) 
5 ± 1 
(600) 
6 ± 0.1 
(750) 
62% @ 
250 
0.16 ± 0.03 
(20) 
80i 5.8 ± 0.4 98 ± 6 x 103 
4.3 ± 0.2 
(740) 
1.7 ± 0.3 
(293) 
1.67 ± 0.04 
(288) 
100 ± 18 
(19000) 
0.36 ± 0.04 
(60) 
80j 6.6 ± 0.5 45 ± 1 x 103 
3.7 ± 0.2 
(560) 
0.9 ± 0.1 
(136) 
2.98 ± 0.03 
(451) 
58 ± 7 
(9000) 
0.24 ± 0.02 
(36) 
80k 6.2 ± 0.3 74 ± 4 x 103 
6.6 ± 0.5 
(1100) 
0.9 ± 0.2 
(145) 
7.5 ± 0.4 
(1200) 
53% @ 
250 
0.44 ± 0.06 
(70) 
80l 7 ± 2 70 ± 10 x 103 
16 ± 1 
(2300) 
5.0 ± 0.4 
(700) 
67 ± 12 
(9600) 
53% @ 
250 
0.16 ± 0.03 
(23) 
80m 4.4 ± 0.6 75 ± 10 x 103 
18 ± 3 
(4000) 
8 ± 1 
(1800) 
34 ± 4 
(7700) 
56% @ 
250 
0.16 ± 
0.03 (40) 
80n 5 ± 1 83 ± 11 x 103 
5.5 ± 0.4 
(1100) 
7.2 ± 0.5 
(1400) 
15.9 ± 0.6 
(3200) 
57% @ 
250 
0.14 ± 0.02 
(30) 
*IC50 (µM) or % inhibition at given concentration. Values in bracket are the selectivity index (IC50 / 
IC50 of uPA 
Table 9 Inhibition of uPA and related enzymes by phosphonate inhibitors 
 
The synthesis of the inhibitors (Scheme 17) began with amine protection of various 
alcohols 81 followed by oxidation to give aldehydes 82. Compounds 82 were then 
reacted with benzyl carbamate and triphenyl phosphite to afford 83. The amine 
protecting groups in 83 were deprotected followed by coupling to protected 
guanylpyrazole to give 84. Compound 84 was deprotected using hydrogenolysis 
followed by coupling to protected alanine to give 85. Compound 85 was deprotected 
and coupled to (D)-serine to give 86. The final step required deprotection of the Boc 
groups to give 87, with the details of R
1
 groups used given in Figure 5. 
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Scheme 17 Reagents and conditions: (i) Boc2O, (ii) Dess-Martin; (iii) phthalic anhydride, Et3N, 
toluene, 90 °C, (iv) Swern oxidation; (v) benzyl carbamate, triphenyl phosphite, Cu(OTf)2, CH2Cl2; (vi) 
TFA, (vii) N,N'-bis(tert-butoxycarbonyl)-1-guanylpyrazole, MeCN; (viii) NH2NH2.H2O, THF, (ix) N,N'-
bis(
t
butoxycarbonyl)-1-guanylpyrazole, MeCN; (x) H2/Pd, (xi) Cbz-Ala-OH, TBTU, DMF; (xii) Cbz-(D)-
Ser(O
t
Bu), TBTU, DMF; (xiii) TFA.  
 
 
 
 
Figure 5 R1 groups for compounds 87a-g. 
 
Isomura et al.
33
 synthesised phosphinopeptides to help in their work related to the 
immune response associated with the problems of vancomycin resistance. The work 
involved synthesising a phosphonate peptidomimetic as outlined in the following 
scheme (Scheme 18). 
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Scheme 18 Reagents and conditions: (i) 30% HBr; (ii) Boc2O; (iii) DCC, BnOH; (iv) NaIO4 (v) 1-
adamantine; (vi) aq. HCl; (vii) benzyl D-lactate, BOP, DIPEA; (viii) TFA, CH2Cl2; (ix) Boc-Lys(Ac)-
OH, HBTU, NMM; (x) TFA, CH2Cl2; (xi) Boc-β-Ala-OH, HBTU, NMM; (xii) TFA, CH2Cl2; (xiii) N-
hydroxysuccinimidylhemiglutaryl chloride, DIPEA, CH2Cl2; (xiv) H2, Pd/C, MeOH. 
 
The synthesis begins with the deprotection and protection of the amine in 88 using 30% 
hydrobromic acid to remove Cbz followed by Boc protection of the amine to give 89.  
Subsequent benzylation of the alcohol of 89 followed by treatment with sodium 
periodate then addition of 1-adamantamine gave the corresponding salt 90. Reacting 90 
with benzyl (D)-lactate gave 91. The Boc group in 91 was deprotected with TFA 
followed by coupling with Boc protected lysine with an acetyl on the terminal amine 
chain to give 92. Further deprotection of the Boc in 92 was carried out followed by 
coupling to β-alanine to give 93. Deprotection of the Boc group in 93 followed by 
coupling to N-hydroxysuccinimidylhemiglutaryl chloride gave 94. Compound 94 was 
treated under hydrogenolysis to give the free phosphinic and carboxylic acids 95.  
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Compound 95 was subsequently tested against vancomycin resistant strain VCA33H3 
(Table 10) but showed no activity. 
 
Kcat 
(h
-1
) 
Km 
(mM) 
kcat / Km 
(M
-1
 min
-1
) 
kcat/kuncat 
Ki 
(µM) 
0.120 2.17 0.921 530 160 
 
Table 10 Kinetic data for VCA33H3 that cleaves (D)-Ala-(D)-Lac bond in model peptidoglycan 
substrate. 
 
1.3. Reaction involving Michael addition to acrylates 
The most straight forward and common route to phosphonopeptide in which the amide 
linkage is replaced by a P(O)-CH2 moiety is by Michael addition of a 
phosphinic/phosphinous acid to appropriate acrylates.  
Mucha et al.
34
 used this method in the synthesises of a number of phosphinic tripeptide 
analogues and evaluated their biological activity against cathepsin C (dipeptidyl 
peptidase I), a papain-like cysteine aminopeptidase that is expressed in the lysosomes of 
several tissues and plays an important role in tumorigenesis (Scheme 19). 
 
Scheme 19 Reagents and conditions: (i) HMDS, 100-110 °C, 3 h then H2C=CHCO2Me; (ii) 33% 
HBr/AcOH, rt, 2 h; (iii) CbzNHCH2CO2H, isobutyl chloroformate, Et3N, 0 °C to rt; (iv) 33% HBr/AcOH, 
rt, 2 h; evaporation, 10% HCl and washing with ether; (v) TMSBr 10 eq., 3 d, rt, then H2O, then conc. 
HCl. 
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The synthesis of the phosphorus tripeptides begins with the formation of the phosphinic 
amino acid analogue 96.  Compound 96 was treated with HMDS followed by addition 
of methyl acrylate to give the conjugate addition product 97. Deprotection of the Cbz 
group using hydrogen bromide in acetic acid gave 98, which was then coupled with the 
mixed anhydride of Cbz protected glycine, which had been generated in situ by 
treatment of the acid with isobutyl chloroformate, to give 99. Deprotection of 99 using 
hydrogen bromide and acetic acid followed by treatment with 10% hydrochloric acid 
gave 100. The methyl ester in 100 was hydrolysed with bromotrimethylsilane (TMSBr) 
to give 101. 
No. Ki [mM] No. Ki [mM] 
100a 0.040 101a 0.039 
100b 0.188 101b 0.176 
100c 0.514 101c 0.429 
100d 0.312 101d 0.187 
Table 11 Inhibition of cathepsin C by phosphinic tripeptide analogues.34 
The synthesised compounds were tested for their activity towards inhibition of 
cathepsin C (Table 11). They were shown to be reversible, non-competitive, slow-
binding inhibitors. 
Manzenrieder et al.
35
 have reported their work on the synthesis of phosphino analogues 
of OM-003 an inhibitor of human β-secretase (BACE1). BACE1 is an aspartic protease 
that initiates the processing of amyloid precursor protein (APP) which generates 
amyloid fibrils that are deposited in the cerebrum, a major factor in the pathogenesis of 
Alzheimer’s disease. 
The synthesis of the inhibitors (Scheme 20) begins with activation of amino 
phosphinate 96a using HMDS to form a bis(trimethylsilyl) phosphonite 102 followed 
by treatment with methyl methacrylate to give 103. Treating 103 with hydroiodic acid 
deprotects the Cbz and methyl ester to give 104. The final step of the synthesis involved 
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protection of the amine with FmocCl to give the desired compound 105 as a mixture of 
diastereomers. 
 
 
 
Scheme 20 Reagents and conditions: (i) 5 eq. HMDS, 100-110 °C, 2 h (Ar); (ii) 60 °C, 1.25 eq. methyl 
methacrylate, 85-90 °C, 3h, (Ar) 91%; (iii) 57% aq HI, 2 h; (iv) 40% Na2CO3 (dioxane), 0 °C, 1.2 eq. 
FmocCl, 12 h (74% 2 steps). 
 
Once 105 had been synthesised it was used to make compounds 108a-c (Scheme 21). 
First, a three amino acid sequence H2N-Val-Glu(O-
t
Bu)-Phe-OH was synthesised on a 
resin to give 106. Coupling of polymer supported amino acid 106 with 105 was carried 
out using (pentafluorophenyl) oxytripyrrolidinophosphonium hexafluorophosphate 
(PyPOP), diisopropylethylamine (DIPEA), N-methylpryyolidine (NMP) to give 107.  
After formation of 107, aspartate, leucine and glutamate were sequentially coupled 
followed by cleavage from the resin followed by separation by HPLC to give three 
fractions of the four stereoisomers 108a-d. 
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Scheme 21 Reagents and conditions: (i) 2.5 eq. 105, 2.5 eq. PyPOP, 5 eq. DIPEA, NMP; (ii) wash with 
NMP. 
 
 
No. 
Inhibition 
IC50 (nM) 
Retention time 
(min) 
No. of 
diastereomers 
OM00-3 6 (±0.7) - 1 
108a 12 (±2) 11.4 1 
108b-c 675 (±197) 12.6, 13.1 2 
108d 
2020 
(±673) 
13.7 1 
Table 12 IC50 values (nM) of the isolated diastereomers against BACE1. 
The phosphino peptides were tested for inhibition against BACE1 using OM00-3 (Glu-
Leu-Asp-Leu-Ala-Val-Glu-Phe) as a standard (Table 12). It can be seen from the 
results that only one of the four diastereomers, 108a, was potent.  
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The group had assumed the configuration of the non-fixed stereocentres in 108a were 
(R) and (S), corresponding to (S) and (S) configuration in the native peptide. In order to 
confirm the stereochemistry a method was used to give fixed stereochemistry at the 
isobutyl group (Scheme 22). (S)-1-(2-naphthyl)-ethylamine was condensed with 
isovaleraldehyde to give the imine that was added to hypophosphorus acid to give 
phosphinic acids 109a-b (2:1/SR:SS). 109a-b were then acetylated using acetyl bromide 
(AcBr) to afford 110a-b. Activation of 110b using HMDS followed by reaction with 
methyl methacrylate to give 111.  Treatment of 111 with hydroiodic acid removed the 
chiral auxiliary to give 112. Deprotection of the methyl ester and acetyl group followed 
by N-protection with FmocCl gave 113 an analogue of 105 with fixed stereochemistry. 
Further peptide synthesis was carried out as previously (Scheme 21). After cleavage 
from the solid support, compounds 108a-c were obtained and identified by high-
performance liquid chromatography (HPLC) retention time confirming that the absolute 
configuration of the active stereoisomer 108a is indeed (S) at the stereocenter adjacent 
to the phosphorus atom. 
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Scheme 22 Reagents and conditions: (i) MgSO4, 0 °C, 1 h (Ar), C6H6; (ii) 5 eq. H3PO2, 0 °C, overnight 
(Ar), (THF), (40% 2steps); (iii) 3 eq. Et3N, 0 °C, 2 h (Ar), (THF), 1.5 eq. AcBr, rt, overnight (Ar), (THF) 
(73-94%); (iv) 5 eq. HMDS, 100-110 °C, 2 h (Ar), 60 °C, 1.25 eq. methyl methacrylate, 85-90 °C, 3 h 
(Ar) (85%); (v) 57% aq HI, 100 °C, 2 h (62%); (vi) 8N HCl, 100 °C, 12 h; (vii) sat. Na2CO3, dioxane, 0 
°C, 1.2 eq. FmocCl, 12 h (56% 2 steps). 
Further testing of 108a against other aspartic proteases was carried out (Table 13), 
however no selectivity was found against other proteases. 
 
No. BACE1 BACE2 cathepsin D Pepsin 
108a 12 (±2) 12 (±1) 28 (±8) 8 (±4) 
Table 13 IC50 values (nM) of 108a against BACE1, BACE2, cathepsin D and Pepsin. 
Vassiliou and co-workers have also synthesised a number of phosphinic pseudo-
tripeptides for use as inhibitors of MMPs, which are important in extracellular matrix 
remodelling.
36
  
The work focuses on two O-adamantyl phosphinic esters (Figure 6) that can be 
synthesised from precursor phosphinic acid 115 (Scheme 23) and used in further 
peptide chain extensions.   
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Figure 6 O-adamantyl phosphinic esters 
 
Scheme 23 Reagents and conditions: (i) HMDS, 110 °C, H2C=C(R
3
)CO2C2H5, EtOH, 70 °C; (ii) 
TMSCl, 0 °C, rt, H2C=C(R
3
)CO2C2H5, rt, EtOH. 
 
Key intermediates 115, were prepared by a Michael addition of R
1
-substituted acrylates 
with mono substituted phosphinates 114. Compounds 115 were then used to synthesise 
a series of phosphinic pseudo-tripeptides (Scheme 24). 
Precursor 115 is reacted with silver oxide forming the silver salt, followed by treatment 
with adamantyl bromide to give 116. The methyl ester of 116 was hydrolysed using a 
mixture of sodium hydroxide in MeOH then neutralised with hydrochloric acid to give 
compound 117 selectively without removal of the adamantyl group. Chain extension of 
117 with the amino function of an amino acid (aa) chain, preloaded onto a Rink amide 
resin, using O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU), DIPEA, NMP formed compound 118. Of course, compound 118 could be 
further used in solid-phase syntheses, but in this case, concurrent hydrolysis of the 
adamantyl ester and release from the resin using TFA/CH2Cl2/triisopropylsilane/water 
gave the corresponding phosphinic tripeptides 119a-r with varied R
2
 and R
1
 groups as 
shown (Scheme 24). 
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Scheme 24 Reagents and conditions: (i) AdBr, Ag2O, CHCl3; (ii) 4N NaOH, MeOH; (iii) aq. HCl; (iv) 
H2N-Aa-Rink (R), HBTU, DIPEA, NMP; (v) TFA/CH2Cl2/triisopropylsilane/H2O 5:4:0.5:0.5; (vi) 
HCOO
- 
NH4
+
, 10% Pd/C, MeOH; (vii) FmocCl, 20% Na2CO3, dioxane; (viii) 20% piperidine/NMP; (ix) 
RCO2H, HBTU, DIPEA, NMP; (x) RCOCl, DIPEA, CH2Cl2; (xi) BrCH2COBr, DIPEA, CH2Cl2; (xii) 
aniline derivatives, DIPEA, DMSO. 
 
To facilitate chain extension on both the C- and N-terminus the first step is to remove 
the Cbz protecting group by reduction using Pd/C in methanol with ammonium formate 
as a source of hydrogen.  This is then treated with FmocCl in dioxane using sodium 
carbonate to introduce the Fmoc protecting group to give compound 120 that is more 
suitable for peptide synthesis. Reacting 120 with a Rink amide resin as previously 
discussed allows for the chain extension at the C-terminus giving compound 121. 
Deprotection of the Fmoc group of 121 using piperidine/NMP gives amine 122. The 
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amine can be reacted under three different conditions as shown to give varied 
phosphinic pseudopeptides 123. The last step of the synthesis is the concurrent cleavage 
from the Rink resin and removal of the adamantyl protecting group as previously 
mentioned to give 124a-k. 
 
 
Ki (nM)* 
 
No. 
 
R
1
 
MMP-
11 
mST3 
MMP-
2 
gel-A 
MMP-
9 
gel-B 
MMP-
14 
MT1-
MMP 
MMP-1 
HFC 
MMP-7 
matrilysin 
MMP-8 
HNC 
119a CH2Ph 350 250 280 2030 24% @ 2µM 8% @ 2µM 240 
119b CH2CH2Ph 51 80 60 270 23% @ 2µM 3% @ 2µM 20 
119c 
CH2CH2CH2
Ph 
100 31 23 92 30% @ 2µM 4% @ 2µM 8 
119d CH2OCH2Ph 175 250 44 550 15% @ 2µM 1% @ 2µM 19 
119e CH2SCH2Ph 36 14 6 26 45% @ 2µM 2% @ 2µM <0.5 
119f CH3 2670 
0% @ 
2µM 
0% @ 
2µM 
0% @ 
2µM 
20% @ 2µM 0% @ 2µM 
9% @ 
2µM 
119g CH2CHMe2 22 202 65 192 45% @ 2µM 210 40 
119h CH2CH2Ph 8.8 275 110 660 10% @ 2µM 7% @ 2µM 45 
119i CH2(CH2)2Ph 5 20 10 105 23% @ 2µM 8% @ 2µM 2.5 
119j CH2(CH2)3Ph 33 145 70 580 5% @ 2µM 7% @ 2µM 4.3 
119k CH2OCH2Ph 16 85 55 545 9% @ 2µM 3% @ 2µM 20 
119l 
CH2-S-CH2-
Ph-OMe 
2 6 3 22 13% @ 2µM 
20% @ 
2µM 
0.7 
119m 
2-CH2-
naphthyl 
74 330 675 1350 0% @ 2µM 1800 230 
119n 
2-(CH2)2-
naphthyl 
12 30 55 125 0% @ 2µM 2100 34 
119o (CH2)6-CH3 34 75 30 271 27% @ 2µM 4% @ 2µM 6 
Table 14 Influence of the R1 Substituent (P1’ Position) on MMP inhibition (*Ki (nM) or % inhibition at 
given concentration). 
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After their synthesis the compounds were tested for activity against MMPs (Table 14, 
Table 15, and Table 16). Variations in the substituents used in the R
1
 position were 
carried out to see the effect on potency (Table 14). When the R
1
 substituent is an 
unusual amino acid side chain the compounds are potent inhibitors against five MMPs, 
with the introduction of sulphur into the side chain giving a large increase in potency.  
Use of the naphthyl group increased potency showing the S1’ pocket is large enough to 
accept a bulky group. 
 
 
 
Ki (nM)* 
 
No. 
 
Raa 
MMP-11 
mST3 
MMP-2 
gel-A 
MMP-9 
gel-B 
MMP-14 
MT1-
MMP 
MMP-1 
HFC 
MMP-7 
matrilysin 
MMP-8 
HNC 
119p Ala 
20% @ 
1µM 
31% @ 
2µM 
45% @ 
2µM 
2960 
9% @ 
2µM 
0% @ 
2µM 
240 
119i 
(L)-
Trp 
5 20 10 105 
23% @ 
2µM 
8% @ 
2µM 
2.5 
119q 
(D)-
Trp 
1% @ 
1µM 
6% @ 
2µM 
14% @ 
2µM 
10% @ 
10µM 
0% @ 
2µM 
0% @ 
2µM 
2% @ 
1µM 
119r Dpa 27 260 245 1282 
9% @ 
2µM 
4% @ 
2µM 
25 
Table 15 Influence of the Raa Residue (P2’ Position) on MMP inhibition (*Ki (nM) or % inhibition at 
given concentration). 
 
Modifications to P2’ were carried using of natural and unnatural tryptophan, alanine and 
an aromatic side chain with activities shown (Table 15). Variations in the P2 position 
gave varied results as shown (Table 16).  
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Ki (nM)* 
 
No. 
 
R3 
MMP-
11 
mST3 
MMP-
2 
gel-A 
MMP-
9 
gel-B 
MMP-14 
MT1-
MMP 
MMP-1 
HFC 
MMP-7 
matrilysin 
MMP-
8 
HNC 
124a 
 
20 26 35 90 
43% @ 
2µM 
28% @ 
2µM 
3.5 
124b 
 
5 8 10 40 
43% @ 
2µM 
52% @ 
2µM 
2.5 
124c 
 
15 17 6 73 
49% @ 
2µM 
28% @ 
2µM 
4.5 
124d 
 
3.8 9 6 45 
77% @ 
2µM 
40% @ 
2µM 
4 
124e 
 
10 30 34 63 
72% @ 
2µM 
65% @ 
2µM 
7.5 
124f 
 
1.5 10 8 41 53 605 1.5 
124g 
 
0.9 24 7 32 36 117 5 
124h 
 
4.2 19 13 60 340 370 5 
124i 
 
5 100 110 217 
62% @ 
2µM 
52% @ 
2µM 
17 
124j Cbz-Ala 8 11 10 41 
40% @ 
2µM 
33% @ 
2µM 
5.5 
124k Cbz-Leu 6 40 22 53 
32% @ 
2µM 
45% @ 
2µM 
7 
Table 16 Influence of the R3 Substituent (P2 Position) on MMP inhibition (*Ki (nM) or % inhibition at 
given concentration). 
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Mores et al.
37
 developed a number of phosphinic peptide inhibitors of angiotensin-
converting enzyme 2 (ACE2) and tested them for inhibition.  
 
 
Scheme 25 Reagents and conditions: (i) aq. Na2CO3, CbzCl 1.8 eq., 0 °C to rt, 12 h, 80%; (ii) HMDS 5 
eq., 110 °C, 1 h, Ar, CH2=C(R
2
)CO2Et 1.2 eq., 4 h, then EtOH; 138a-c 52%, 47%, 49%, 141a-c 72%, 
81%, 74% (iii) 1M NaOH in MeOH, rt, 12 h; 139a-c 95%, 96%, 92%, 142a-c 88%, 90%, 95% (iv) H2, 
10% Pd/C, MeOH/H2O 4:1, rt, 2 h; 143a-c 92%, 95%, 94%. 
 
The phosphinic inhibitors are built up through two possible routes (Scheme 25).  
Phosphinic acid 125 is protected to give 126. Compound 126 is activated using HMDS 
then reacted with various acrylates to give 127a-c. The ester in 127a-c is hydrolysed to 
give compounds 128a-c. Phosphinic acids 96a, 96c and 88 are also reacted with 
acrylates to give 129a-c. The esters in 129a-c are hydrolysed as per 128a-c to give 
130a-c. The final step involves deprotection of 130a-c to yield 131a-c.  
Compound 128b (Scheme 26) was deprotected by hydrogenolysis to give 132. 
Compound 132 was then coupled with various protected amino acids followed by 
deprotections and acetylation to give 133a-h. 
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Scheme 26 Reagents and conditions: (i) H2, 10% Pd/C, MeOH/H2O 4:1, rt, 2 h, 95%; (ii) RNH-aa-
CO2Np 1.5 eq., Et3N 2 eq. in DMF, rt, 12 h, 70-80%; (iii) TFA/CH2Cl2, 50%, rt, 1 h, 90-95% or H2, 10% 
Pd/C, MeOH/H2O 4:1, rt, 2 h, 90-95% or HCO2H/CH2Cl2, 5%, rt, 10 min, 95%; (iv) Ac2O 3 eq. in py, rt, 
12 h, 70-75%; (v) TFA/CH2Cl2, 50%, rt, 1 h, 90-95%; aa = a: alanine, b: leucine, c: lysine, d: glutamic 
acid, e: tyrosine, f: phenylalanine, g: valine, h: histidine; (Np = p-nitrophenyl). 
 
 
Scheme 27 Reagents and conditions: (i) BocLeuONp, Et3N, DMF, rt, 12 h / TrtHis(Trt)ONp; (ii) 
TFA/CH2Cl2 50%, rt, 1 h / HCO2H/CH2Cl2 5% 10 min; (iii) Ac2O, Pyridine, rt, 12 h; (iv) TFA/CH2Cl2, 
50% 1 h; (Np = p-nitrophenyl). 
 
Compounds 131a-b (Scheme 27) were coupled with protected amino acids followed by 
deprotection and acetylation to give 134a-b. 
The synthesis of compounds similar to 133a-h was carried out with inclusion of an 
alkyne in order to be able to form oxazole compounds 138a-b (Scheme 28). 
Ammonium phosphinate 44 was activated using HMDS then reacted with an alkyne 
containing acrylate to afford 135. Compound 135 was then reacted with 3,4-dihydro-
2H-pyrrole which was subsequently protected to give 136.  Compound 136 underwent a 
cycloaddition to give 137. The ester in 137 was hydrolysed, then the pyrrole was 
deprotected and the free amine coupled to a protected amino acid followed by N-
acetylation and finally deprotection to give 138a-b.  
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Scheme 28 Reagents and conditions: (i) HMDS 1 eq., 110 °C, 1 h, Ar, CH2=C(CH2C≡CH)CO2Et 0.2 
eq. in CH2Cl2, 0 °C to rt, 12 h, then EtOH, 88%; (ii) TMSCl 4 eq., Et3N, 4 eq. in CH2Cl2, 0 °C to rt, 3 h 
(Ar), 3,4-dihydro-2H-pyrrole 1.1 eq., 0 °C to rt, 1 h, then EtOH; (iii) MgO 3 eq., CbzCl 1.5 eq. in 
H2O/Et2O, 0 °C to rt, 12 h, 54% for two steps; (iv) RCH=NOH 3 eq., py 0.74 eq. in CHCl3, 45 °C, 3 h, 
then 136, Et3N 3 eq., 45 °C, 3 d, repeat 3 times, 80%; (v) 1M NaOH in MeOH, rt, 12 h, 90%; (vi) H2, 
10% Pd/C in MeOH/H2O 4:1, rt, 2 h, 90%; (vii) TrtHis(Trt)ONp 72% or BocLeuONp 75% 1.5 eq.,  Et3N 
2 eq. in DMF, rt, 12 h; (viii) TFA/CH2Cl2, 50%, rt, 1 h, 90% or HCO2H/CH2Cl2 5%, rt, min, 92%; (ix) 
Ac2O 3 eq. in py, rt, 12 h, 70-75%; (x) TFA/CH2Cl2, 50%, rt, 1 h, 90% for 138b; (Np = p-nitrophenyl). 
 
 
Scheme 29 Reagents and conditions: (i) HMDS 1 eq., 110 °C, 1 h (Ar), CH2=C(CH2C≡CH)CO2Et 1.2 
eq., 4 h, then EtOH, 98%; (ii) PhCH=NOH 3 eq., NCS 3 eq., py 0.74 eq. in CHCl3, 45 °C, 3 h, then 151, 
Et3N 3 eq., 45 °C, 3 d, repeat 3 times, 83%; (iii) 1M NaOH in MeOH, rt, 12 h, 92%; (iv) H2, 10% Pd/C in 
MeOH/H2O 4:1, rt, 2 h, 95%; (v) TrtHis(Trt)ONp 1.5 eq., Et3N 2 eq. in DMF, rt, 12 h, 78%; (vi) 
HCO2H/CH2Cl2 5%, rt, 1 h, 93%; (vii) Ac2O 3 eq. in py, rt, 12 h, 75%; (viii) TFA/CH2Cl2, 50%, rt, 1 h, 
90%. Np = p-nitrophenyl. 
Compound 102a (Scheme 29) was taken through a similar synthesis to the one 
described in Scheme 28 to form oxazoles via a different method. Compound 102a was 
reacted with the alkyne containing acrylate to afford 139 which then underwent a 
cycloaddition to form 140. The ester in 140 was hydrolysed, the amine was deprotected 
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and coupled to a protected amino acid, followed by acetylation and deprotection to give 
141. The synthesised compounds were tested as inhibitors of ACE, ACE2 and 
carboxypeptidase A (CPA). (Table 17). 
No. Compound 
 
ACE2 
Ki (nM) 
CPA 
Ki (nM) 
ACE 
Ki (µM) 
128a Cbz-ProΨ(PO2-CH2)Leu-OH  300 - - 
128b Cbz-ProΨ(PO2-CH2)Phe-OH 300 - - 
128c Cbz-ProΨ(PO2-CH2)Ala-OH 3000 - - 
130a Cbz-LeuΨ(PO2-CH2)Phe-OH >10000 - - 
130b Cbz-PheΨ(PO2-CH2)Phe-OH >10000 - - 
130c Cbz-AlaΨ(PO2-CH2)Phe-OH 8000 - - 
131a LeuΨ(PO2-CH2)Phe-OH >10000 - - 
131b PheΨ(PO2-CH2)Phe-OH >10000 - - 
131c AlaΨ(PO2-CH2)Phe-OH >10000 - - 
132 ProΨ(PO2-CH2)Phe-OH >10000 - - 
133a Ac-Ala-ProΨ(PO2-CH2)Phe-OH 7.5 - - 
133b Ac-Leu-ProΨ(PO2-CH2)Phe-OH 0.35 - - 
133bFII Ac-Leu-ProΨ(PO2-CH2)Phe-OH, FII 0.13 0.5 >10 
133c Ac-Lys-ProΨ(PO2-CH2)Phe-OH 6.5 - - 
133d Ac-Glu-ProΨ(PO2-CH2)Phe-OH 7 - - 
133e Ac-Tyr-ProΨ(PO2-CH2)Phe-OH 5.2 - - 
133f Ac-Phe-ProΨ(PO2-CH2)Phe-OH 5.2 - - 
133g Ac-Val-ProΨ(PO2-CH2)Phe-OH 6.6 - - 
133h Ac-His-ProΨ(PO2-CH2)Phe-OH 2.1 - - 
133hFII Ac-His-ProΨ(PO2-CH2)Phe-OH, FII 0.7 60 >10 
134a Ac-His-LeuΨ(PO2-CH2)Phe-OH 920 0.3 - 
134b Ac-Leu-PheΨ(PO2-CH2)Phe-OH 800 175 - 
138aFII Ac-Leu-ProΨ(PO2-CH2)Isoxa(Phe)*-OH 1.25 35 >10 
138bFII Ac-His-ProΨ(PO2-CH2)Isoxa(Phe)*-OH 0.4 1050 >10 
141FII Ac-His-LeuΨ(PO2-CH2)Isoxa(Phe)*-OH 220 >10 µM - 
Table 17 Inhibition of ACE2, CPA and ACE by phosphinic peptide inhibitors (*Isoxa(Phe): 2-(3-
phenyl-isoxazol-5-ylmethyl)-propionic acid). 
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Scheme 30 Reagents and conditions: (i) 20% piperidine/DMF; (ii) FmocGlu(OtBu)-OH, HOBt, 
HBTU, NMM; (iii) 20% piperidine/DMF; (iv) acryloyl chloride, Et3N; (v) bis-(trimethylsiyl)acetamide, 
DCE, 100 °C;  (vi) Pd(PPh3)4, CH3Cl/AcOH/NMM 92.5:2.5:2.5; (vii) 20% piperidine/DMF; (viii) Fmoc-
amino acids, HBTU, NMM; (ix) 20% piperidine/DMF;  (x) TFA/H2O 95:5. 
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Kruger et al.
38
 synthesised phosphinic peptidomimetics for use as inhibitors of the 
Staphylococcus aureus sortase transpeptidase (SrtA) using a solid-supported acrylate. 
The synthesis of 149 (Scheme 30) began with attaching two glutamic acid residues to 
resin 142 to form 143. Compound 143 was deprotected and reacted with acryloyl 
chloride to give 144. Compound 144 was reacted with the activated form of amino 
phosphinic acid 145 to afford 146. Compound 146 was deprotected to give 147. 
Compound 147 then underwent deprotection and coupling reactions with protected 
amino acids to build up the peptide chain forming 148. Compound 148 was finally 
deprotected and cleaved from the resin to give target compound 149.  
Buchardt et al.
39
 reported the synthesis of diastereomerically impure phosphinic 
dipeptide analogues as potential MMP-9 inhibitors. 
 
Scheme 31 Reagents and conditions: (i) CH(OEt)3, rt, 55%; (ii) aq. CH2=O, cat. KOH, 90 °C, 87%; 
(iii) toluene, 100 °C; (iv) 48% aq. HBr, Δ, 73%; (v) CbzCl, K2CO3, H2O, rt, 72%; (vi) HMDS, 110 °C; 
(vii) CH2=CH(
i
Bu)-CO2Et, 90 °C, 96%; (viii) AdBr, Ag2O, CHCl3, Δ, 89%; (ix) NaOH (EtOH), rt; (x) 
H2, Pd/C, FmocOSu, NaHCO3, MeOH/EtOAc/H2O, rt, 65%. 
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The synthesis of phosphinic peptide 156 (Scheme 31) involves multiple steps beginning 
with formation of two components that are reacted to give 154a. Phosphinic acid 150 is 
reacted with trioxymethane to give 151. Diphenylmethanamine 152 is reacted in the 
presence of formaldehyde to give triazine 153. Compounds 151 and 153 are reacted 
together to form 154a followed by protection of the amine to give 154b. Compound 
154b is activated using HMDS then reacted with an acrylate to give 155a. Compound 
155a was then reacted with bromoadamantane to give 155b. The ester of 155b is 
hydrolysed to give 155c. The amine in 155c is deprotected using hydrogenolysis then 
protected with Fmoc to give 156 that is a suitable building block for peptide synthesis. 
Buchardt et al.
40
 also reported a novel methodology for the solid-phase synthesis of 
phosphinic peptides building on from their previous work (Scheme 31). 
 
Scheme 32 Strategy for solid-phase phosphinic peptide synthesis. 
The overall strategy for the building of the phosphinic peptide is described in Scheme 
32. The first step is solid phase peptide synthesis to form peptide 158. Then the amine is 
converted into an acrylate 159, which can react with the phosphinic amino acid 160 to 
give 161. After deprotection of the N-protecting group the peptide is extended at the 
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other end of peptide chain in 162. The actual steps in the synthesis are discussed in the 
following schemes (Scheme 33, Scheme 34): 
 
Scheme 33 Reagents and conditions: (i) CH2=CHCOCl, Et3N, DMAP; (ii) 48% HBr aq.; (iii) 
Protection in basic aq. solution (a: AllocCl, b: CbzCl, c: FmocOSu, d: Boc2O; (iv) BSA (v) NaOH. 
 
Polymer support 157 is converted into acrylate 163. Compound 164 the alanine 
analogue 1-aminoethylphosphinic acid is deprotected with hydrobromic acid and 
protected with various protecting groups under basic conditions to obtain the desired 
phosphinic amino acids 165a-d. As an example compound 165a is reacted with 163 
using BSA as an activator, followed by cleavage from the polymer support to give 166.  
 
Compound 165a was activated with BSA to give 167. Compound 167 underwent a 
Michael addition with 168 to afford 169. Compound 169 was deprotected using 
tetrakis(triphenylphosphine)palladium(0) and N-ethylmorpholinium acetate (NEM) to 
give 170. Compound 170 subsequently underwent further peptide synthesis to give the 
phosphinic undecapeptide that was cleaved from the resin to give 171. 
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Scheme 34 Reagents and conditions: (i) 3 eq. BSA; (ii) 168; (iii) Pd(PPh3)4, NEM, AcOH; (iv) SPPS; 
(v) NaOH. 
 
 
 
 
Scheme 35 Reagents and conditions: (i) iPr2NEt, TMSCl, CH2Cl2; (ii) CH2N2 for 174a 68%, EDCI, 
i
PrOH, CH2Cl2 for 174b 72%; (iii) t-BuOK, I(CH2)3N3, DME, 44% for 175a 88% for 175b. 
 
 
Kende et al.
41
 reported the synthesis of the phe-arg phosphinic acid dipeptide isostere as 
part of the construction of polypeptides by a modular method. 
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Scheme 36 Reagents and conditions: (i) TFA, CH2Cl2; (ii) toluene, reflux; (iii) CH2N2, 61%. 
The first step towards the phosphinic isostere involves synthesis of 175 (Scheme 35). 
Phosphinic acid 114b was activated using trimethylsilylchloride (TMSCl) then reacted 
with di-tert-butyl methylene malonate 172 to afford 173.  Compound 173 was then 
reacted with diazomethane to afford 174a. Compound 174a was reacted with azido 
iodopropane to give 175a. Alternatively, compound 173 was esterified to give 174b and 
then reacted with azido iodopropane to give 175b.  
 
 
Scheme 37 Reagents and conditions: (i) TFA, CH2Cl2; (ii) toluene, reflux; (iii) CDI, (S)-2-
naphthylalanine-N-methylamide, THF; (iv) CH2N2, 46%; (v) Lindlar catalyst, H2, N,N'-bis(tert-
butoxycarbonyl)-1H-pyrazole-1-carboxamidine, EtOH, 63%; (vi) 10% Pd/C, HCO2NH4, MeOH; (vii) 
AcNH-Tyr(
t
Bu)-OH, HOBt, EDCI, NMM, THF, 79%; (viii) TMSBr, CH2Cl2. 
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Compounds 175a or 175b were treated with TFA which converted them to 178 via 
postulated intermediates 176 and 177. Compound 178 was then decarboxylated by 
refluxing in toluene to give 179. Compound 179 was then esterified to give 180 to allow 
for characterisation (Scheme 36).  
Once the group had synthesised 179, they adapted the synthesis to a tetrapeptide 
containing compound 184 (Scheme 37). Enantiopure (S)-114b was reacted as per 
Scheme 35 to afford (S)-175b. Compound (S)-175b was then treated under the 
conditions of Scheme 36 to give (S)-179. Compound (S)-179 was coupled with (S)-2-
naphthylalanine-N-methylamide then methylated to give 181. Compound 181 was 
treated with Lindlar’s catalyst and N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-
carboxamidine to afford 182. Compound 182 was deprotected then coupled with a 
protected tyrosine to give 183. Compound 183 was finally reacted with TMSBr to give 
184. 
The concept of Michael addition was used in an interesting variation by Matziari et al.
42
 
as part of their report on a short route to the synthesis of Fmoc-protected phosphinic 
pseudodipeptide chains as inhibitors of Zinc-metalloproteases. In these examples, 
hypophosphorous acid is first added to an acrylate. The resulting hydrogen phosphite 
then undergoes a phospha-aldol reaction. 
The first step requires the formation of the P-C bond which is achieved according to 
Scheme 38. 
 
 
Scheme 38 Reagents and conditions: (i) HMDS, 110 °C, 2 h (Ar); (ii) 0.2 eq. CH2=C(R
2
)CO2Et, 0 °C 
to rt, 24 h, CH2Cl2, yields 75-90%; (iii) NaOH 2M, MeOH, HCl 6M, yields 90-95%. 
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The first step involves formation of silylated phosphonite 185 via activation of 44 with 
HMDS to give 185. Phosphonite 185 is then reacted with various acrylates to give 186. 
The final step involves removal of the ethyl ester to give 187.   
 
 
Scheme 39 Reagents and conditions: (i) AcCl/AcOH 5/1, 0 °C to rt, 6 h, 43-73%. 
 
Formation of phosphino amino acid 188 is carried out in a one pot coupling of the three 
components (Scheme 39). Compound 187 is reacted with FmocNH2 and the desired 
aldehyde using a mixture of acetyl chloride and acetic acid to catalyse the reaction 
forming 188 that is suitable for solid phase synthesis. The full details of all phosphinic 
amino acids synthesised is in the following table (Table 18). 
No. R
1
 R
2
 Yield (%) 
188a H PhCH2 56 
188b CH3 PhCH2 57 
188c (CH3)2CH PhCH2 55 
188d (CH3)2CHCH2 PhCH2 62 
188e CH3CH2(CH3)CH PhCH2 61 
188f CH3O2CCH2CH2 PhCH2 60 
188g Ph PhCH2 73 
188h PhCH2OCH2 PhCH2 67 
188i 4-imidazole PhCH2 69 
188j CH3 (CH3)2CHCH2 58 
188k Ph CH3 54 
188l (CH3)2CHCH2 H 42 
Table 18 Yields and side-chains of compounds 188a-l. 
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Once compounds 188a-l were formed it was possible to extend the peptide chain 
(Scheme 40).  
 
 
Scheme 40 Reagents and conditions: (i) EDC.HCl 4 eq., HOBt 1 eq.; (ii) DIPEA 1.9 eq., CH2Cl2, rt. 
(iii) Piperidine/DMF 20% rt; (iv) FmocGlu(O
t
Bu)Pfp 3 eq., HOBt 3 eq., DMF, rt; (v) AcOH 6 eq., DIC 6 
eq., HOBt 6 eq., DMF, rt. (vi) TFA/TIS/H2O = 95/2.5/2.5, Yield 85%, purity 89%. 
 
An example of the chain extension is shown in Scheme 40. Compound 188d is coupled 
to the solid supported tryptophan 189. The amine is deprotected followed by coupling to 
another modified amino acid to give 190. To obtain the final compound the Fmoc group 
is removed and replaced with an acetate followed by deprotection of the 
t-
butyl ester and 
cleavage from the polymer support to give 191. 
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1.4. Reactions involving other methods 
 
In addition to the two most widely used reaction types discussed in sections 1.2 and 1.3, 
there are a number of other methods for the synthesis of phosphonopeptides, the scope 
for which are not yet as wide spread as for the other two. In this section, we will discuss 
the most recent of these methods.  
Generally speaking, direct conversion of phosphonates and phosphinic acids to the 
corresponding phosphonamide is energetically disfavoured on the account of the strong 
P-O bond. However, phosphonates and phosphinic acids may be converted to the 
corresponding phosphoryl chlorides, which can then undergo amidolysis. However, the 
conditions used is somewhat harsh and therefore, has limited application. Demange et 
al.
43
 reported the synthesis and evaluation of a number of novel phosphorus containing 
pseudopeptides against human cyclophilin (hCyp-18). hCyp-18 is associated with 
control of CD4
+
 T-cells in HIV-1 making it a useful target for anti-HIV-1 therapy.  
The synthesis of pseudopeptides 201-203 is outlined in Scheme 41. The first step 
involves activation of phosphonate 192 or 193 with phosphorus pentachloride followed 
by reaction with substituted prolines to give 194-196.  The phthalyl protecting groups of 
194-196 were removed followed by coupling to Fmoc protected alanine to give 197-
199. The Fmoc protecting group of compounds 197-199 were removed using 
diisopropylamine followed by protection of the free amine with succinic anhydride or 
acetyl chloride to give 200-202. Compound 202 was subsequently treated to 
hydrogenolysis to give 203. 
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Scheme 41 Reagents and conditions: (i) PCl5, (ii) Pro-R
2
; (iii) N2H4, (iv) FmocAlaOH, DCC, HOBt; 
(v) HN
i
Pr2, (vi) Suc2O or AcCl; (vii) H2, Pd/C, NaHCO3. 
 
The synthesised compounds were derivatives of Suc-Ala-Ala-Pro-Phe-pNA, where one 
alanine residue was replaced by Gly(PO2Et-N) to give Suc-Ala-Gly(PO2Et-N)-Pro-Phe-
pNA. Once synthesised the compounds were evaluated for their inhibition of hCyp-18 
(Table 19). 
Compound Kd ± SD (µM) IC50 ± SD (µM)* 
Suc-Ala-Gly-Pro-Phe-pNA 140 ± 10 1450 ± 60 
Suc-Ala-Glyψ(PO2Et-N)Pro- Phe-pNA 201a 210 ± 100 5400 ± 400 
Suc-Ala-Glyψ(PO2Et-N)Pro-Phe-pNA 201b 20 ± 5 15 ± 1 
Ac-Ala-Glyψ(PO2Et-N)Pro-Phe-ψ(CH2-NH)pNA 202a 1300 ± 200 NI @ 500 µM 
Ac-Ala-Glyψ(PO2Et-N)Pro-Phe-ψ(CH2-NH)pNA 202b 200 ± 15 30% I @ 500 µM 
Ac-Ala-Glyψ(PO2
-
-N)Pro-Phe-pCMA 203 79 ± 4 NI @ 100 µM 
Ac-Ala-Glyψ(COCON)Pro-Phe-pNA 127 ±7 215 ± 40 
Suc-Ala-Ala-Pro-Phe-pNA 135 ± 20 540 ± 70 
Ac-Ala-Ala-Pro-Phe-pNA 145 ± 15 640 ± 120 
Table 19 Inhibition of hCyp-18 by pseudopeptides (*IC50 (µM) or % inhibition at given concentration, 
NI = no inhibition at given concentration). 
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A rare and unusual method for the synthesis of phsophonopeptides was reported by Van 
der Donk et al.
44
 in the synthesis of antibiotic A53868. During the work, the group 
found the reported and revised structures for A53868 (204
45
 and 205
46
) were incorrect 
and the actual structure 206 (Figure 7) obtained is very different from the originally 
reported structures.  
 
Figure 7 Reported structures of A53868 (204, 205) and actual structure (206). 
 
Scheme 42 Reagents and conditions: (i) HP(O)(OBn)2, 1 % [Ni(cod)2], 8% PPhMe2, 4% Ph2P(O)OH, 
THF, 65 °C; (ii) DBU; (iii) Cbz-Gly-Leu, DIC, HOBt; (iv) BBr3. 
 
The group first worked towards synthesis of the originally reported structure 205 
(Scheme 42). Fmoc Protected propargyl amine 207 was treated with dibenzylphosphite 
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to give vinylphosphonate 208 and its isomer 209. Compound 208 was deprotected using 
1,8-diazabicyclo[5.4.0]undec7-ene (DBU) to give 210 which was then coupled to Cbz-
Gly-Leu to give 211.  
Compound 211 was then treated with boron tribromide to remove the benzyl and Cbz 
groups to give 205. Compound 212 was similarly prepared from 209. 
The purified natural product was compared to synthetic compounds 205 and 212 
however neither one was found to correspond to the natural product. Detailed nuclear 
magnetic resonance (NMR) studies were carried out on the natural product which led to 
structures 213 and 214 (Figure 8) being proposed. 
 
Figure 8 Supplementary proposed structures of A53868. 
Compounds 213 and 214 were synthesised and studied to see if either structure matched 
A53868, however neither did. This eventually led the group to propose structure 206, 
whose synthesis is outlined below (Scheme 43). 
Compound 206 was synthesised from fragments 216 and 219.  Dipeptide 216 was 
synthesised by treating 215 with aqueous ammonia in MeOH to give amide 216. 
Formation of α-keto phosphonate 219 was achieved by reacting trimethyl phosphite and 
acetyl chloride to give 219. Coupling 216 and 219 was carried out by an acid catalysed 
condensation to give 220. Compound 220 was transformed to the carboxy(triethyl)silyl 
group followed by hydrolysis to give the free amine, followed by basic hydrolysis of 
one of the esters to give target compound 206. Compound 206 was proved to be 
spectroscopically identical to the natural product, and share identical fragmentation 
patterns in the mass spectrum.  
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Scheme 43 Reagents and conditions: (i) MeOH/NH4OH; (ii) TsOH cat., p-hydroxyanisole, toluene, 
reflux; (iii) Et3SiH, Et3N, PdCl2; (iv) NaHCO3 aq.; (v) 10% NaOH aq. 
Palacios et al.
47
 synthesised phosphonopeptides as part of the preparation of optically 
active oxazoles from phosphorylated 2H-azirines and N-protected amino acids or 
peptides (Scheme 44). 
 
Scheme 44 Synthesis of ketamides. 
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Reacting 3-methyl-2H-azirinyl phosphine oxide (e.g. 221 and 222) with Boc protected 
amino acids (e.g. 223) at low temperature forms ketamides that contain a phosphine 
oxide group 224, 225. Formation of 224 is thought to occur due to the mechanism 
outlined above (Scheme 44). Protonation of the azirine, followed by nucleophilic 
addition of the carboxylate gives 226. Structure 226 can undergo ring expansion to give 
zwitterionic oxazolone 227, which is ring opened to form ketamide 224. This method of 
synthesis could be adopted using azirines derived from phosphonates. The full list of 
compounds synthesised are shown in the following table (Table 20). 
 
No. R R
1
 R
2
 R
3
 Yield (%) 
224aa C6H5 CH3 H H 73 
224ab C6H5 CH3 H CH3 65 
224ac C6H5 CH3 H CH2OH 65 
224ad C6H5 CH3 CH3 H 58 
224ae C6H5 CH3 H CH3 62 
224af C6H5 CH3 CH2OH H 48 
224ag C6H5 CH3 H CH2OH 66 
224ah C6H5 CH3 H CH2C6H5 56 
225ab OC2H5 CH3 H CH3 68 
225ad OC2H5 CH3 CH3 H 71 
225ae OC2H5 CH3 H CH3 66 
225ag OC2H5 CH3 H CH2OH 52 
225bd OC2H5 C2H5 CH3 H 72 
225bg OC2H5 C2H5 H CH2OH 50 
Table 20 Details of R, R1, R2 and R3 for α-ketamides synthesised. 
  
Scheme 45 Reagents and conditions: (i) Ph3P, C2Cl6, Et3N; (ii) TMSCl, PhOH, CH2Cl2. 
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The synthesised α-ketamides were then converted to phosphorylated oxazoles 
containing amino alkyl residues (Scheme 45). Compounds 224 and 225 were treated 
with triphenylphosphine and hexachloroethane to give oxazole phosphine oxides 228 
and 229. The proposed mechanism involves deprotonation of ketamides with 
dichlorotriphenylphosphorane giving enamide intermediate 232. Compound 232 then 
undergoes loss of triphenylphosphine oxide and ring closure to give 228 and 229. 
Deprotection of 228 and 229 was carried out using TMSCl and phenol for oxazole 
phosphine oxides, and hydrochloric acid for oxazole phosphonates deprotection to give 
230 and 231. The full list of compounds synthesised are given below (Table 21). 
 
No. R R
1
 R
2
 R
3
 Yield (%) 
228aa C6H5 CH3 H H 68 
228ab C6H5 CH3 H CH3 70 
228ad C6H5 CH3 CH3 H 72 
228ae C6H5 CH3 H CH3 66 
228ah C6H5 CH3 H CH2C6H5 73 
229ab OC2H5 CH3 H CH3 45 
229ad OC2H5 CH3 CH3 H 56 
229ae OC2H5 CH3 H CH3 50 
229bd OC2H5 C2H5 CH3 H 46 
230aa C6H5 CH3 H H 81 
230ae C6H5 CH3 H CH3 74 
231ad OC2H5 CH3 CH3 H 46 
Table 21 Details of phosphorylated oxazoles synthesised. 
 
Scheme 46 Reagents and conditions: (i) HO2C-Pep-NHBoc 233; (ii) Ph3P, C2Cl6, Et3N. 
 
Where N-protected peptides are used it is possible to use the process of ring opening 
azirines (Scheme 46). Treating 221 and 222 with peptides formed ketamides 233 and 
234, through a mechanism previously discussed (Scheme 44).  Treatment of 233 as per 
228 (Scheme 45), gave 235. The same method is used to convert 234 to 236.  The full 
details of compounds synthesised is described in Table 22. 
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No. R R
1
 Peptide 
Yield 
(%) 
233aa C6H5 CH3 (S)-Gly-Phe 55 
233ab C6H5 CH3 (S)-Ala-Gly-Gly 51 
234ba OC2H5 C2H5 (S)-Gly-Phe 48 
235aa C6H5 CH3 (S)-Gly-Phe 52 
236ba OC2H5 C2H5 (S)-Gly-Phe 50 
Table 22 Details of α-ketamides and phosphorylated oxazoles synthesised. 
 
Sikora et al.
48
 have reported on the synthesis of protected phosphonodipeptides 
containing an N-terminal amino acid using a Staudinger reaction (Scheme 47). 
 
 
Scheme 47 Reagents and conditions: (i) toluene, rt, 1.5 h; (ii) 223 (iii) toluene, 80-85 °C, 3-12 h or rt 
24 h - 3 d. 
 
The synthesis of the phosphonodipeptides began by reacting diethyl 1-
azidoalkylphosphonate 237a-b (formed by reacting hydrazoic acid and diethyl 1-
hydroxyalkylphosphonates) with phosphine 238a-b to give the corresponding 
iminophosphorane 239. Compound 239 was then reacted with protected amino acid 240 
which was converted via intermediate salt 241 into the corresponding 
phosphonodipeptides 242a-c with the details of substituents given in Table 23.  
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No. R
1
 R
2
 R
3
 R
4
 
242a H Bn H Cbz 
242b H (CH2)2SMe H Boc 
242c Me Me H Cbz 
Table 23 Details of R1, R2, R3, and R4 groups for phosphonopeptides synthesised.  
In an interesting variation to the methods discussed in section 1.2, phosphonopeptides 
can be prepared by the addition to an acyl iminium. Xu et al.
49
 reported the synthesis of 
Cbz protected phosphonopeptides and depsiphosphonopeptides. The synthesis involved 
a Mannich-type condensation of benzyl carbamate, aldehydes, and dichlorophosphites 
followed by aminolysis with amino acid ester or alcoholysis with hydroxy acid esters. 
The aim of the work was to develop a general method to synthesise phosphinopeptides 
where the aminoalkylphosphinic acid is in the middle of the peptides. 
The group carried out lots of investigations into conditions finally achieving success 
reacting Cbz-glycinamide, benzaldehyde, phenyldichlorophosphine and ethyl glycine to 
form the phosphonopeptide. The group then extended the method to prepare a series of 
phosphinopeptides with two phosphinotetrapeptides (Scheme 48 and Scheme 49). 
 
Scheme 48 Reagents and conditions: (i) MeCN; ii) AA/Peptide ester 246, DIPEA. 
 
The compounds synthesised according to Scheme 48 are given in Table 24. 
The method resulted in formation of oligomeric phosphinopeptides via a pseudo four 
component condensation; first a Mannich-type three component condensation of amide, 
aldehyde and aryldichlorophosphine, followed by aminolysis with an amino ester or 
peptide ester. The generality of this method allows the linkage of two peptide sequences 
with the Mannich-type reaction as the key step, which led to them naming this a 
Mannich ligation. 
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No. 
Amide 
243 
Aldehyde 
244 
Ar 
245 
Ester 
246 
Yield 
(%) 
247a Cbz-Gly-NH2 PhCHO Ph GlyOEt 67 
247b Cbz-Gly-NH2 PhCHO p-MePh GlyOEt 68 
247c Cbz-Gly-NH2 PhCHO p-ClPh GlyOEt 71 
247d Cbz-Gly-NH2 p-MePhCHO Ph GlyOEt 70 
247e Cbz-Gly-NH2 p-ClPhCHO Ph GlyOEt 65 
247f Cbz-Gly-NH2 
i
PrCHO Ph GlyOEt 69 
247g Cbz-Gly-NH2 
n
PrCHO Ph GlyOEt 69 
247h Cbz-(D)/(L)-Ala-NH2 PhCHO Ph GlyOEt 64 
247i Cbz-β-Ala-NH2 PhCHO Ph GlyOEt 60 
247j Cbz-Gly-NH2 PhCHO Ph (L)-PheOMe 68 
247k Cbz-Gly-NH2 PhCHO Ph (L)-PheOMe trace 
247l Cbz-Gly-NH2 PhCHO Ph β-Ala OEt 69 
247m Cbz-Gly-NH2 PhCHO Ph GlyGlyOEt 51 
247n Cbz-Gly-NH2 PhCHO Ph GlyGlyOEt 28 
247o Cbz-GlyGly-NH2 PhCHO Ph GlyOEt 54 
Table 24 Details of components used in synthesis of phosphonopeptides. 
 
The proposed mechanism for the “Mannich Ligation” is outlined below (Scheme 49).  
The first step involves amide 243 attacking aldehyde 244 forming an N-
acylaminohydrin adduct 248. Compound 248 reacts with aryldichlorophosphine 245 to 
give arylchlorophosphite 249. Compound 249 undergoes elimination to give imine 250 
and arylchlorophosphonous acid 251. Arylchlorophosphonous acid 251 then attacks 250 
to give 252 which undergoes proton transfer to give 253. Compound 253 undergoes 
aminolysis with an amino ester or peptide 246 to afford 254. 
 
 
Scheme 49 Reagents and conditions: (i) ArPCl2 (245); ii) R
3
NH2, DIPEA. 
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A similar method is reported by Belyaev et al.
50
 for the synthesis of diaryl phosphonate 
ester inhibitors of dipeptidyl peptidase IV (DPP IV). 
 
Scheme 50 Reagents and conditions: (i) PCl3; (ii) HCl; (iii) AcOH, 90 °C, 2 h; (iv) HCl/EtOAc (1M); 
(v) H2, Pd/C. 
 
Synthesis of the diaryl phosphonates 260 (Scheme 50) began by reacting phenol 255 
with phosphorus trichloride to give triaryl phosphite 256. Isobutyl chloroformate was 
used to activate N-protected proline which was then coupled to 4-aminobutyraldehyde 
diethyl acetal to give 257a-b. The acetals of 257a-b were hydrolysed with hydrochloric 
acid to give 258a-b. Compounds 258a-b and 256 were then reacted together to form 
259.  The final step involved deprotection of 259 to give 260. 
2,2’-biphenyl derivatives 265 and 266 (Scheme 51) were synthesised using a similar 
strategy to Scheme 50. Compound 261 was reacted with phosphorus trichloride to give 
262 which was then treated with a mixture of acetic acid and triethylamine to give 263.  
Aldehydes 258a-b were then reacted with 263 to give 264a-b. Compounds 264a-b were 
then deprotected to give 265 and 266. After synthesis the diaryl phosphonates and 
biphenyl derivatives were tested as inhibitors of DPP IV (Table 25 and Table 26). 
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Scheme 51 Reagents and conditions: (i) PCl3; (ii) AcOH, Et3N; (iii) 258a-b, AcOH, 90 °C, 2 h; (iv) 
H2, Pd/C, MeOH; (v) HCl/EtOAc (1M). 
 
No. R
1
 
Config 
at Pro
P
 
IC50 (µM) kcalc(M
-1
 s
-1
) 
t1/2 (min) in 
plasma 
260a H R 15 ± 3 (n = 3) 5.1 x 10
1 300 ± 30 
260a H S > 10
4   
260b 4-MeO R,S 22 ± 11 (n = 4) 3.5 x 10
1 470 ± 90 
260c 4-HO R,S 190 ± 80 (n = 3) 4.1 > 200 
260d 3-AcNH R,S 0.8 ± 0.1 (n = 2) 9.6 x 10
2 220 ± 30 
260e 4-AcNH R,S 0.4 ± 0.2 (n = 5) 1.9 x 10
3 320 ± 140 
260f 4-MeSO2NH R,S 0.40 ± 0.02 (n = 2) 1.9 x 10
3 150 ± 30 
260g 3-H2NCONH R,S 2.3 ± 0.3 (n = 2) 3.3 x 10
2 210 ± 80 
260h 4-(N-Bz-Gly-NH) R,S 0.7 ± 0.3 (n = 2) 1.1 x 10
3 93 ± 3 
260i 4-(H-Gly-NH) R,S 0.5 ± 0.1 (n = 2) 1.5 x 10
3 28 ± 3 
260j 4-(H-(S)-Ala-NH) R,S 0.6 ± 0.2 (n = 2) 1.3 x 10
3 8 ± 1 
260k 4-((S)-Pyr-NH) R,S 5.0 ± 0.8 (n = 2) 1.5 x 10
2 170 ± 30 
260l 
4-[(2S)-
MeO2CCH(NHAc)CH2] 
R,S 1.4 ± 0.5 (n = 4) 5.5 x 102 190 ± 150 
260m 4-MeO2C R,S 0.016 ± 0.004 (n = 2) 4.8 x 10
4 19 ± 1 
260n 4-(EtO2CCH2NHCO) R,S 0.023 ± 0.007 (n = 2) 3.3 x 10
4 35 ± 2 
260o 4-[MeO2C(CH2)2NHCO] R,S 0.036 ± 0.006 (n = 4) 2.1 x 10
4 26 ± 1 
260p 4-[CH3(CH2)2NHCO] R,S 0.03 ± 0.01 (n = 2) 2.6 x 10
4 12 ± 1 
265 P(OMe)(OC6H4(2-OH-C6H4)) R,S 47 ± 18 (n = 2) 1.6 x 10
1 140 ± 80 
266 P-2,2’-biphenylyl R,S 31 ± 6 (n = 2) 2.5x 101 6 ± 1 
Table 25 Potency and stability of diaryl phosphonate and biphenyl derivative DPP IV inhibitors. 
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  PEP DPP II MAAP elastase 
No. R
1
 IC50 1 mM IC50 1 mM IC50 1 mM IC50 1 mM 
260a H (R at carbon next to P) 107 71 102 73 100 83 100 82 
260d 3-AcNH 89 50 - - - - - - 
260e 4-AcNH 96 60 100 83 99 96 106 105 
260f 4-MeSO2NH 73 4 - - - - - - 
260h 4-(N-Bz-Gly-NH) 92 32 - - - - - - 
260j 4-(H-(S)-Ala-NH) 88 47 - - - - - - 
260l 4-[(2S)-MeO2CCH(NHAc)CH2] 102 35 - - - - - - 
260m 4-MeO2C 73 4 - - - - - - 
260n 4-(EtO2CCH2NHCO) 85 1 78 66 104 94 102 6 
260o 4-[MeO2C(CH2)2NHCO] 83 0 - - - - - - 
260p 4-[CH3(CH2)2NHCO] 97 5 - - - - - - 
Table 26 Specificity of diaryl phosphonate inhibitors for DPP IV / CD26. 
Nucleophilic displacement has also found an application in the synthesis of 
phosphonopeptides, although its generality is questionable due to the very strict steric 
requirement in these reactions. 
 
Scheme 52 Reagents and conditions: (i) Ag2O, BrCH2CO2Bn, 1,3-dimethylimidazolidin-2-one; 77%; 
(ii) (CF3CO)2O, PPh3, THF; DPP, H2O; 93%; (iii) 20% Pd(OH)2/C, 7 bar H2, MeOH/H2O 5:1; 56%; (iv) 
20% Pd(OH)2/C, 7 bar H2, 
t
BuOH/H2O 4:1; 54% of 271/272/Et3N 2:3:3; (v) ClCH2PO3Bn2, KF/Al2O3, 
K2CO3, Bu4NI, MeCN; 88%; (vi) NaH, 12-crown-4, 1,3-dimethylimidazolidin-2-one/THF, then dibenzyl 
(triflyloxymethyl)phosphonate; 55%; (vii) Pd(OH)2/C, 6.5 bar H2, 
t
BuOH/0.1M Et3NH
+
HCO3
-
 3:1; 40% 
of 277, 14% of 278. 
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Storz et al.
51
 reported the synthesis of β-lactams which involved the use of phosphorus 
containing peptides as part of the multi-step synthesis (Scheme 52). 
β-lactam 267 was N-alkylated using benzyl bromoacetate to give 269. Compound 269 
underwent reductive trifluoroacetylation to give 272. Deprotection of 272 using 
hydrogenolysis gave 273.  Hydrogenolysis of azido lactam 269 gave β–lactam 270 and 
diamino dicarboxylic acid 271 through hydrolysis of 270. β-lactam 267 was also N-
alkylated using dibenzyl (chloromethyl)phosphonate to give 268. Compound 267 was 
N-alkylated using dibenzyl (triflyloxymethyl)phosphonate to give 274. Compound 274 
was subjected to reductive trifluoroacetylation as per 269 to give 275. Hydrogenolysis  
of 275 was carried out to afford 277. 
 
Scheme 53 Reagents and conditions: (i) HMDS, 110 °C, 1–2 h; (ii) CH2Cl2 reflux, 12 h, 58–70% 
yield; (iii) (Me3Si)2NH, CH2Cl2, 0 °C, 1 h; (iv) phthalimidomethyl bromide, CH2Cl2, reflux, 12 h, and 
phosphinate methylation after quenching: CH2N2, 0 °C, toluene/MeOH, 49–57%; (v) H2N–NH2, EtOH, rt, 
18 h, 70–78% yield; (vi) Cbz-Pro-Leu-OH, DCC, HOBT, THF, 0 °C to rt, 15 h, 67–80%; (vii) BTSA, 
CH2Cl2, rt, 1 h; TMSI, CH2Cl2, -20°C to rt, 3 h, 72–83%. 
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In a similar method, Bianchini et al.
52
 designed, modelled, synthesised and biologically 
evaluated three peptidomimetic phosphinates as inhibitors for matrix metalloproteinases 
MMP-2 and MMP-8. The synthesis of the peptidomimetic phosphinates is described in 
Scheme 53. 
The first reaction of the synthesis is as Scheme 38, forming compound 185 from 44, 
which is then reacted with a number of biphenylalkyl iodides to form 278a-c. 
Compounds 278a-c are treated with bis(trimethylsilyl)amine (BTSA) to give 279a-c 
which are immediately treated with phthalimidomethyl bromide followed by 
methylation to give 280a-c. Deprotection of 280a-c using hydrazine afforded 281a-c 
which was then coupled with Cbz-Pro-Leu-OH to give 282a-c. The final step involved 
deprotection of the Cbz group and hydrolysis of the methyl ester of 282 using BTSA 
and TMSI respectively to give compounds 283a-c. 
After their synthesis the peptidomimetics were tested for activity against MMP 2 and 8 
(Table 27).  The compounds were shown to have IC50 values in the micromolar range, 
one of which was a fairly selective MMP-2 inhibitor.  
 
 
No. 
IC50 (µM) 
MMP-2 MMP-8 
283a 1.7 5.1 
283b 1.4 17.6 
283c 48 44.5 
Table 27 Inhibition of MMP 2 and 8 by peptidomimetic phosphinates. 
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1.5. Conclusions 
One of the most popular methods to form phosphonopeptides is to ligate an existing α-
aminophosphonic moiety to the carboxy terminus of a peptide. This method has the dual 
advantage of being both general and reliable. There are already a number of methods for 
the synthesis of α-aminophosphonates (including a few enantioselective ones53,54,55).  In 
addition there are a large number of methods and reagents for the formation of peptide 
bonds. The method has some major drawbacks in that it is best suited to the synthesis of 
phosphonopeptides with a P-residue at the carboxy end. 
Michael addition of a phosphinic/phosphinous acid to an appropriate -substituted 
acrylate is the most common and practical route to phosphonopeptides in which the 
amide linkage is replaced by a P(O)-CH2 moiety.  However, one future direction in this 
arena could be the development of enantioselective addition of phosphinic/phosphinous 
acids to -substituted  acrylates. 
In addition to the two above general routes, a number of other syntheses are reported 
although their scope is yet to be demonstrated. 
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2. Chapter Two: Results and 
Discussion 
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2.1. Introduction and Objectives 
 
The concept of phosphonic and phosphinic acids as structural mimics of carboxylic 
acids has been known for nearly 40 years
56
. The use of these pseudopeptides in which 
one amino acid residue is replaced by its phosphonic analogue (commonly referred to as 
phosphonopeptides) represents one of the most straightforward means of producing 
inhibitors or antagonists to the proteins that bind to that true peptide. Therefore, small 
pseudopeptides containing a phosphonyl moiety in place of the carboxyl moiety have 
found extensive medicinal applications.
57
 In the previous chapter, the synthesis and 
some of the biological properties of these pseudopeptides has been described. 
However, despite the prevalence of phosphonopeptides, no study of the suprastructure 
or conformational preferences of oligomeric α-amino and α-hydroxy 
phosphonic/phosphinic acids has been conducted yet. This is in spite of the fact that the 
incorporation of a tetrahedral phosphonic analogue into a peptide chain would be 
expected to profoundly influence its conformational properties, and thus have a bearing 
on its intended biological activity. One reason for this could be that methods for the 
synthesis of phosphonopeptides are quite limited and heavily focus on those that give 
access to pseudopeptides with the phosphonic residue at either the N or the C terminus 
of the peptide. 
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Figure 9 Comparison of peptide and pseudopeptide structures. 
In this project, the aim was to investigate the synthesis, and study the conformations of 
pseudopeptides containing one or more α-amino or α-hydroxy (phenyl)phosphinic acid 
residues in place of the α-amino carboxylic acid residues (pesudopeptides 285 and 286, 
Figure 9). In addition we also investigated a method for the synthesis of oligomeric α-
hydroxy (phenyl)phosphinates and some conformational preferences of their dimers 
(pseudopeptide 287, Figure 9). The synthesised pseudopeptides can be directly 
compared to generalised peptide structure 284 (Figure 9). 
 
2.1.1. Synthetic strategy 
The syntheses were carried out according to the following routes (Scheme 54), 
(Scheme 55), depending on the position of the phosphinic acid residue within the chain 
and the nature of alcohol R
1
OH:  
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Scheme 54 (i) Hewitt reaction; (ii) phospha-aldol reaction. 
The first step involves conversion of an alcohol (R
1
OH) 288 to the corresponding 
chloroformate 289. To prepare phosphonopeptides with a phosphinic residue at the C 
terminus, the alcohols (R
1
OH) can be a simple alcohol such as methanol, ethanol or 
benzyl alcohol, affording the corresponding phosphinates. The chloroformates are then 
treated under Hewitt reaction conditions (Page 88)
58
 to give the corresponding 
phenylphosphinate 290. Addition of the phenylphosphinate to either aldehydes or 
imines in a phospha-aldol reaction would then afford the corresponding α-hydroxy or α-
amino (phenyl)phosphinate respectively 291. The hydroxyl or amino functions of the α-
hydroxy or α-amino (phenyl)phosphinate product can then be further functionalised 
292, 293 and the pseudopeptide chain can thus be extended from the N-terminus 
(Scheme 54). The hydrolysis or hydrogenolysis of the R
1
O ester would then unmask the 
phosphinic acid. Alternatively, once an α-hydroxy (phenyl)phosphinate is formed, it can 
re-enter the synthetic cycle as an alcohol. Thus, through sequential Hewitt 294 and 
phospha-aldol reactions 295 it is possible to go from monomers to dimers, trimers etc  
(Scheme 54). 
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To prepare phosphonopeptides with a phosphinic residue at the middle of the chain, the 
alcohol can be an α-hydroxy carboxylate 296. As previously formation of chloroformate 
297 followed by the Hewitt reaction affords 298, which can then be used in a phospha-
aldol reaction.  As before, the hydroxyl or amino functions 299 generated after the 
addition to aldehydes and imines can be used to further extend the chain at the N-
terminus 300, 301. Furthermore, however, the carboxyl function in the α-hydroxy acid 
starter unit can undergo the same chain extension at the C-terminus (Scheme 55). 
 
Scheme 55 (i) Hewitt reaction; (ii) phospha-aldol reaction. 
The key advantage of this methodology is that it is general. The R
1
 (Scheme 54) group 
can range from simple (methyl, ethyl, or benzyl) to complex (α-hydroxy carboxylate). 
The phospha-aldol reaction is a very general reaction and a wide range of aldehydes or 
imines can be used to give diversity in the R
2
 group. 
After synthesis of the compounds, it was planned to use X-ray, computational and NMR 
methods to ascertain what structural motifs might be present within the structures 
formed. In order to be able to correlate the results from these pseudopeptides with those 
of true peptides, a brief description of some of the structural motifs observed in peptides 
is provided. 
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2.1.2. Structural motifs observed in peptides59 
Peptides tend to adopt secondary structures that support their ability to recognise and 
interact with other molecules. There are three main motifs in the secondary structure of 
proteins: sheets, turns and helices.  
Sheets: This type of secondary structure contains β-sheets (β-pleated sheets). These are 
formed from beta strands that align side by side and are connected by hydrogen bonds 
to form a twisted, pleated sheet.  
Turns: This is a class of secondary structure that is found within globular proteins that 
allow for the reversal of the direction of the polypeptide chain. Turns are often situated 
on or near to sites of antibody recognition, phosphorylation, and glycosylation, so it is 
likely that they play more than a structural feature. 
Turns can be subdivided into four types: 
Gamma turn: This is a turn that happens due to hydrogen bonding between the C=O of 
one residue and the NH of the i+1 residue, giving a “folding” pattern due to 
intramolecular hydrogen bonding (302, Figure 10). The gamma turn is less common 
when compared with the other types of turn.  
 
302 
Figure 10 Diagram of a gamma turn. 
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Type I turn: This type of turn occurs 2-3 times more frequently than the related type II.  
This turn type has a hydrogen bond between the carbonyl of the first residue and the NH 
of the i+2 residue. In other words, this turn contains a hydrogen bond over three 
residues (303, Figure 11). The mirror image type I’ is rare but is preferred in β-hairpins.  
There are varying preferences for amino acids, with Pro not preferred in the i+2 position 
due to the presence of the secondary amine.  
                 
   303 Type I    304 Type II 
Figure 11 Diagram of type I and II turns. 
Type II turn: This type of turn is similar to type I, with hydrogen bonding over three 
residues (304, Figure 11), however the backbone dihedral angles of the residue are 
different.  The preference for amino acids also varies between the two types of turn. 
Type III turn: This turn type is part of a 3.10 helix, another secondary structural element 
found in proteins (see later).  Only a small proportion of residues are involved in 3.10 
helices, and of those, nearly all the ones in helical segments contain 1-3 hydrogen 
bonds, with the majority less than or equal to 4 residues.  
Helices: While there are a number of turns found in peptides and proteins it is the more 
common helix motif that is key to our investigations. Oligomeric peptides with non-
polar hydrophobic side chains (e.g . polyvaline and polyleucine) are particularly prone 
to forming helical suprastructures. 
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helix 
type 
frequency phi psi n r(Å) p(Å) H-bond 
(CO.HN) 
atoms in 
H-bonded 
loop 
radius (Å) 
(backbone) 
alpha abundant -57.8 -47.0 +3.6 1.5 5.5 i, i+4 13 2.3 
3.10 infrequent -74.0 -4.0 +3.0 2.0 6.0 i, i+3 10 1.9 
pi rare -57.1 -69.7 +4.4 1.1 5.0 i, i+5 16 2.8 
beta 
strand 
abundant -139.0 135 +2.0 3.4 6.8    
Table 28
60
 Parameters for common protein helices. (n = residues per helical turn, r = helical rise per 
residue, and p = helical pitch (Å/turn)). 
 
Helices are a more stable type of secondary structure, with the most common sub type 
being α-helices (4-turn), however there are also 3.10 helices (3-turn) with each amino 
acid having a 120° turn, and π-helices (5-turn) with each amino acid having a 87° turn. 
α-helices are located at the core of a protein, compared with loops that are located in 
outer regions. Within an ideal α-helix there are 3.6 residues per complete turn, with the 
side chains sticking out. An example of an ideal α-helix motif is shown in Figure 12 
and Figure 13. The models show the overall secondary structure obtained when a long 
chain is formed. 
 
Figure 12 View down an idealised polyalanine 3.10 helix and α-helix.  
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Figure 13 Sideway view of an idealised polyalanine 3.10 helix and α-helix 
The structural features of turns and helices are, of course, dependant on the particular 
structural features of the α-amino carboxylic acids that form them. Obviously, α-amino 
and α-hydroxy phosphinic acids, which are constituents of our hybrid pseudopeptides 
have different structural features. These structural features are in turn expected to 
influence the turns and helical features in these pseudopeptides. For example, 
oligomeric α-amino carboxylic acids would contain alternating tetrahedral and trigonal 
carbon atoms in the chain. In contrast, oligomeric α-amino/hydroxy phosphinic acids 
would contain alternating tetrahedral carbon and tetrahedral phosphorus atoms. Clearly, 
there should be an expectation of tighter turns or turns over fewer residues.  
For instance, it was decided to investigate if α-amino and α-hydroxy phosphinic acid 
dimers (308, Figure 14), composed of two residues with four stereocenters, would fold 
in a comparable manner to its tetrameric amino acid analogue (309, Figure 14) since 
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both molecules contain four stereocenters. Obviously, within the same parameters, 
hybrid pseudopeptides containing one α-amino or α-hydroxy phosphinic acid and two α-
amino carboxylic acids (305-307, Figure 14) would also be likely to show folding 
patterns. 
 
Figure 14 Proposed pseudopeptides to be synthesised compared with tetrameric amino acid analogue. 
So the strategy was to synthesise, through the protocols outlined in (Scheme 54, 
Scheme 55) four general types of pseudopeptide with non-polar sidechains, each 
containing at least four stereocenters.  
2.2. An overview of the synthetic methods used 
The transformations outlined in (Scheme 54) and (Scheme 55) rely on two key 
reactions: the Hewitt reaction and the phospha-aldol reaction. The Hewitt reaction 
requires a chloroformate as its starting material, whilst there are a number of methods 
for the phospha-aldol reaction. In this part of the thesis, consideration is given to an 
overview of the three key reactions that are repeatedly used in the construction of the 
phosphonopeptides, chloroformate synthesis, the Hewitt reaction, and the phospha-aldol 
reaction. 
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2.2.1. Chloroformate synthesis 
Transformation of a hydroxyl group to the corresponding chloroformate for use in the 
Hewitt reaction can be carried out using different methods, including the following:  
1. Carbonylation reaction61:  
Although not a direct route to the chloroformate it is possible to carry out 
carbonylation of benzyl alcohols (Scheme 56) with carbonyl sulfide, followed 
by esterification with methyl iodide to give 310 and finally chlorination using 
sulfuryl chloride to give the chloroformate of benzyl alcohol 311.  
 
Scheme 56 Reagents and conditions: (i) DBU, THF, 80 °C, 6 h; (ii) MeI, 20 °C, 16 h; (iii) 
SO2Cl2 0 - 20 °C, 1 h. 
2. Treating the alcohol with phosgene62 and its synthetic equivalents:  
Phosgene (312, Scheme 57) is a highly toxic, colourless, poisonous gas, used in 
World War I as a chemical weapon.  Phosgene 312 can be used in many organic 
chemistry reactions, the most important being synthesis of chloroformates (289 
Scheme 57), carbonates, isocyanates and acid chlorides.   
 
Scheme 57 Conversion of alcohol to chloroformate using phosgene and its equivalents. 
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Due to the toxicity of phosgene 312, substitutes have been created: 
trichloromethyl chloroformate (diphosgene, 313, Scheme 57) and 
bis(trichloromethyl) carbonate (triphosgene, 314, Scheme 57). 
Diphosgene
63
 is a safer phosgene source, a liquid at room temperature that forms 
phosgene on heating or through catalysis. 
Triphosgene
64
 is a non-toxic synthetic equivalent to gaseous phosgene. It is a 
solid that is easy to handle and during the reaction will generate phosgene in 
situ. 
 
It was decided to adopt the method that involves treatment of the alcohol with 
triphosgene in the presence of pyridine in order to form the desired chloroformate 
(Scheme 58).  
 
Scheme 58 Reagents and conditions: (i) Py, (COCl2)3 (314), diethyl ether or CH2Cl2, 0 °C 3 h. 
In the earlier part of the work, formation of the chloroformate was carried out in diethyl 
ether. Pyridine was slowly added to a stirred solution of triphosgene 314 and alcohol 
288 in diethyl ether, maintained at 0 °C under a nitrogen atmosphere. The reaction was 
typically stirred for three hours, after which the reaction was monitored by TLC and if 
necessary, additional reagents were added to the reaction mixture. Once the reaction 
was complete, the mixture was filtered, to remove pyridinium hydrochloride, and was 
then stripped of solvent to give the desired chloroformate 289. Chloroformates were 
then analysed by spectroscopy to confirm their formation, prior to further reaction.  
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However, as confidence in chloroformate formation grew, it became more convenient to 
alter the reaction procedure. Subsequent reactions were carried out in dichloromethane, 
and the resulting solution, containing crude chloroformate was used directly in the next 
step of the Hewitt reaction.  
The mechanism for formation of chloroformates from alcohols is outlined in Scheme 
59. 
 
Scheme 59 Mechanism of chloroformate formation. 
The first step of chloroformate formation involves the lone pair of the alcohol 288 
oxygen carrying out a nucleophilic attack on the carbonyl of triphosgene 314 forming 
intermediate 315. Once intermediate 315 is formed, the base removes a proton from the 
oxonium cation to form 316. After loss of a proton, the tetrahedral intermediate breaks 
down to form a trichloromethyl carbonate 317 whilst generating a molecule of phosgene 
312 and a chloride ion. The chloride ion that was released subsequently attacks the 
carbonyl of the intermediate formed previously, leading to formation of the desired 
chloroformate 289 and elimination of another molecule of phosgene 312 from the 
intermediate. The two molecules of phosgene 312 formed in situ during the reaction will 
then react directly with more of alcohol 288 to produce more chloroformate via 
intermediates 318 and 319. 
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2.2.2. The Hewitt reaction 
Preparation of phosphinate monoesters from phosphinic acid was a problematic reaction 
in organophosphorus synthetic chemistry until our group revisited an unusual reaction 
first reported by Hewitt.
58
 Hewitt had reported that phenylphosphinic acid is 
transformed to its mono ethyl ester in a spontaneous reaction with a concurrent loss of 
CO2 upon treatment with ethyl chloroformate and pyridine in chloroform.  
 
Scheme 60 Reagents and conditions: (i) PhP(OH)2, CH2Cl2,  40 °C.
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Further investigation by our group showed that this was a general reaction and many 
commercially available chloroformates react with phenylphosphinic acid in the presence 
of pyridine, to give the corresponding phenylphosphinate monoester (Scheme 60). In 
addition, a wide range of primary and secondary alcohols can be transformed to their 
corresponding chloroformates and undergo the Hewitt reaction. The conversion is 
exceptionally clean and efficient, affording the desired phenylphosphinic monoester in 
high yields, usually without the need for purification.  Significantly, the Hewitt reaction 
proceeds with retention of configuration if a chiral alcohol is used. However, carbamoyl 
chlorides do not undergo a similar reaction and therefore, the Hewitt reaction is not 
applicable to the synthesis of phosphorus-nitrogen bonds. 
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Scheme 61 Equilibrium between pentavalent and trivalent phosphonic acids and esters. 
Pentavalent tetracoordinated phenylphosphinic acids and esters exist in equilibrium with 
their tautomeric trivalent tricoordinated phenylphosphinous acid/esters (Scheme 61). 
The consequences of this equilibrium are two fold: Firstly, although the phosphorus 
atom in the phenylphosphinate ester is chiral, enantiopure samples racemise very 
quickly through this equilibrium and are unlikely to be separable in an optically active 
form. Secondly, phenylphosphinous acid and its esters can demonstrate nucleophilic 
properties (as the phosphinous acid/ester tautomer) as well as electrophilic properties 
(as the phosphinate tautomer). This “dual” nature of course is also seen in keto-enol 
tautomers; although in this case, refers to the reactivity at the same atom (phosphorus).  
 
Scheme 62 Proposed mechanism of the Hewitt reaction. 
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A mechanism for the Hewitt reaction is proposed (Scheme 62) which has been based on 
investigations by Afarinkia and Yu.
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The reaction proceeds via the formation of a “mixed anhydride” intermediate 327 
(Scheme 62).  The key step in this reaction is the nucleophilic attack of phosphorus on 
oxygen and a concurrent loss of CO2. This highly unusual mechanism is supported by 
the observation that the absolute configuration of the carbon atom in enantiopure 
chloroformates is retained. The phenylphosphinates cannot be separated at this point 
due to 33-45 tautomerism of H-phosphonites which makes separation impossible. 
With the phenylphosphinates synthesised, reactions with aldehydes or imines can take 
place under phospha-aldol conditions to give the corresponding products. 
2.2.3. The phospha-aldol reaction 
The reaction of a phosphorous acid or ester and a carbonyl substrate (typically 
aldehydes or imines) (Scheme 63) is known as a phospha-aldol reaction. The phospha-
aldol reaction is a well known reaction that has been used for the synthesis of α-
functionalised phosphonates since the 1950’s.66 
 
Scheme 63 Generalised phospha-aldol reaction. 
The phospha-aldol reaction has been reported to proceed under numerous conditions,
67
 
with a wide range of carbonyls as well as phosphorous acid/esters.  
It is also possible to control the stereochemistry at the newly created asymmetric carbon 
atom (for a review see: Kee et al.
68
). This can be achieved by using a chiral aldehyde or 
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imine as a starting material,
69,70,71
 use of a chiral phosphorus reagent as a starting 
material,
72,73,74
 use of a chiral base,
75,76
 or indeed, one of many metal catalysts 
containing chiral ligands.
77,78,79,80,81,82
  
During the present work, KF was used as a means of activation of the carbonyl of the 
aldehyde during the phospha-aldol reaction for some reactions. This solvent free method 
used with liquid aldehydes, gives clean high yielding products, compared with 
thermally mediated phospha-aldol reactions.  
The most common types of the reaction are those with pentavalent tetracoordinated 
phosphinate mono or diesters (also known as hydrogen phosphites). However trivalent 
tricoordinated phosphorous triesters (also known as triphosphites) also undergo an 
efficient reaction (Abramov reaction).
66,83,84
  There are examples of the Kabachnik-
Fields reaction; a three component carbonyl, amine and hydrophosphoryl coupling 
using catalysts to give α–amino phosphonates,85,86  and enantiomerically pure α–amino 
phosphonates.
87,88
 
Although the outcomes of the two types of phospha-aldol reaction are similar, they 
proceed by different pathways. As was discussed earlier (Scheme 60), pentavalent 
tetracoordinated phosphonite monoacids are not nucleophilic at all. They are in fact 
more susceptible to be electrophiles. However, because of the equilibrium between the 
pentavalent tetracoordinated phosphorous acid and its trivalent tricoordinated tautomer, 
there is always a small concentration of the latter in any reaction mixture. In this 
nucleophilic form, phosphorous species react with electrophilic carbonyls. The rate of 
the addition can be enhanced by addition of a base, which may drive the phosphorous 
tautomerism towards the anionic species, or a Lewis acid which activates the carbonyl 
function.  
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Trivalent tricoordinated phosphorous trialkyl esters are already in a nucleophilic form 
and readily attack carbonyls, however the addition is reversible. These reactions can be 
promoted thermally or by addition of protic and Lewis acids, which activate the 
carbonyl function and facilitate the loss of an alkyl group. 
In between these two types are the phosphorous silyl esters. Like their trialkyl ester 
analogues, phosphorous silyl esters are already in a nucleophilic form and react readily 
with carbonyl functions. However, unlike their trialkyl ester analogues, the adduct 
breaks down very easily, driven by concurrent migration of the silyl group to the 
oxygen of the carbonyl (or the nitrogen of imine). Earlier computational investigations 
have suggested that the addition may be a concerted process, but even so, the overall 
reaction is facile. 
2.2.3.1. The silyl mediated phospha-aldol reaction 
One of the most significant advances in the phospha-aldol reaction in recent years has 
been the development of the “in situ” method for the preparation of silyl esters of 
phosphorous acids.
89
 The in situ method circumvents problems with handling of the 
hydrolytically sensitive phosphorous silyl esters. During the in situ method, a solution 
of phenylphosphinate is treated sequentially with dry triethylamine and TMSCl, which 
generates in situ the phenylphosphinous tautomer. This will in turn react with the 
aldehyde or imine under very mild conditions. 
The mechanisms through which the reactions take place are outlined in Scheme 64. As 
outlined in Scheme 61, pentavalent tetracoordinated phenylphosphinic acids and esters 
290 exist in equilibrium with their tautomeric, trivalent tricoordinated 
phenylphosphinous acid/esters 324. Whilst the trivalent tricoordinated tautomer is 
nucleophilic, the equilibrium is overwhelmingly in favour of the non-nucleophilic 
pentavalent tetracoordinated tautomer. The lack of reactivity of phosphorous acids 
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towards aldehydes and imines can be attributed to the status of this equilibrium. 
Treatment with dry triethylamine and TMSCl converts the phosphorous acid to its silyl 
ester. Due to the strong Si-O bond, the phosphorous silyl esters are locked in the 
nucleophilic trivalent tricoordinated form 324. At the same time as the 290 tautomer is 
converted to 324, the equilibrium drives forward, eventually resulting in complete 
conversion of the equilibrium mixture to 331. 
 
Scheme 64 Reagents and conditions: (i) Et3N, TMSCl. 
Once the molecule is locked in the nucleophilic form addition of the aldehyde or imine 
can take place according to the mechanism shown in Scheme 65. 
Silyl-mediated phospha-aldol reactions initially afford the O-silylated α-hydroxy or N-
silylated α-amino phenylphosphinates. As the N-Si bond is labile and easily susceptible 
to hydrolysis, they were not usually observed. Since the O-Si bond is more robust, after 
aqueous workup or during chromatographic purification on silica gel, partial cleavage of 
the silyl ethers is observed. In order to ensure that this did not cause a problem with 
purification, crude reaction mixtures were treated with tetrabutylammonium fluoride 
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(TBAF) to remove the silyl ether. Silicon carbon bonds are polar, leaving the TMS 
protecting group open to nucleophilic attack. A source of fluoride acts as a strongly 
electronegative nucleophile that can form a strong bond to silicon.  Silicon can form a 
strong bond with fluorine with a value of 522.7 kJ mol
-1
 that facilitates the deprotection. 
TBAF is supplied as a 1.0M solution in THF; therefore the deprotection is carried out in 
a THF/diethyl ether mixture. 
 
Scheme 65 Phospha-aldol reaction of phosphonite and aldehyde or imine to form phosphinate 
monomer. 
 
2.3. Synthesis of α-hydroxy and α-amino phenylphosphinate      
monomers 
In line with the general synthetic strategy outlined in Scheme 54, the first task was to 
prepare α-hydroxy and α-amino phenylphosphinate monomers (Figure 15). 
 
 
Figure 15 (i) Hewitt reaction; (ii) phospha-aldol reaction (332/334). 
Ethyl and benzyl chloroformates were reacted with phenylphosphinic acid under Hewitt 
reaction conditions. The reactions proceed cleanly and efficiently to afford 95% and 
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92% yield of 320 and 321 respectively (Scheme 66). Both compounds were sufficiently 
pure after work up to be used directly in the next step of the synthesis.  
 
Scheme 66 Reagents and conditions: (i) Py, PhP(OH)2, CH2Cl2, 40 °C, 30 min.  
As mentioned in Section 2.2.3 alkyl phenylphosphinates react with aldehydes under a 
variety of conditions, including in the presence of KF, to afford the corresponding α-
hydroxy phenylphosphinates. Indeed, both benzyl and ethyl phenylphosphinate react 
with a number of aldehydes efficiently and cleanly (Scheme 67).  
 
Scheme 67 Reagents and conditions: (i) RCHO, KF, overnight, then CH2Cl2, stirring 30 min.  
During the phospha-aldol reaction, two new stereogenic centers are created, one at the 
phosphorus and the other at the hydroxyl carbon adjacent to it. Therefore, we can expect 
a mixture of two diastereomers. The reactions afford equal mixtures of diastereomers 
(Table 29), except in the reaction of 3-methylbut-2-enal with ethyl phenylphosphinate, 
where there is a modest selectivity, which can be detected in the 
31
P and 
1
H NMR of the 
crude product, which shows a 3:2 ratio in favour of the (SP,RC/RP,SC) diastereomer. It is 
believed that the (SP,RC) and (RP,SC) enantiomeric pair are preferentially formed over 
the (SP,SC) and (RP,RC) enantiomeric pair, due to optimal π-stacking, when the phenyl 
ring is orientated above the alkene (Scheme 68).  
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Scheme 68 Orientations for reaction of phosphonite and aldehyde during phospha-aldol reaction. 
From the reaction of benzyl phenylphosphinate two diastereomeric products (each as a 
pair of enantiomers) were obtained. However, it was not possible to isolate either of the 
diastereomers in pure form by fractional crystallisation. In contrast, from the reaction of 
ethyl phenylphosphinate, two diastereomers were obtained, one of which was an oil and 
the other one crystalline. Therefore it was possible to conveniently carry out a 
separation of the diastereomers by crystallisation. In the first instance, the solid 
diastereomer was separated from the crude product mixture and washed using diethyl 
ether. Recrystallisation using ethyl acetate (EtOAc) then gave colourless crystals of a 
single diastereomer as confirmed by 
31
P and 
1
H NMR.  The absolute configuration of 
the two enantiomers in the crystalline diastereomer was confirmed by X-ray 
crystallography as (SP,RC/RP,SC)
90
. 
No. R
1
 R 
Yield (%) State Separable 
337 CH2CH3 CH(CH3)2 Quant. Oil Mix No 
338 CH2CH3 C6H5 Quant. Crystal Mix No 
339 CH2CH3 CH2CH(CH3)2 Quant. Oil Mix No 
340 CH2CH3 CH=C(CH3)2 Quant. Oil / Crystal Yes 
341 CH2(C6H5) CH=C(CH3)2 97 Crystal Mix No 
Table 29 α-hydroxy monomer compounds synthesised. 
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Although it was possible to obtain one of the two diastereomers in pure form, it was not 
possible to get a sufficiently large quantity of the other diastereomer. Even very slow, 
careful crystallisation always left some of the (SP,RC/RP,SC) diastereomer in the 
supernatant solution, which meant a diastereomerically mixed residue. Not only was 
crystallisation not suitable for the separation of diastereomers, but chromatography also 
proved to be ineffective. In most cases the two diastereomers had very similar retention 
factors (Rf) on silica gel and were either wholly inseparable by column chromatography 
or could only afford a very small quantity of the pure diastereomer.  
Brief investigations were carried out to see if the diastereomers could be separated 
chromatographically after derivatisation. Various attempts at O-alkylating the leucine 
analogue 340 were carried out, but were unsuccessful despite many variations in 
reaction conditions.  
 
Scheme 69 Reagents and conditions: (i) Ac2O, cat. H2SO4, CH2Cl2. 
 
Acetylation of valine analogue 337 was successful giving 342 (Scheme 69) although the 
diastereomers were still inseparable. 
 
Scheme 70 Reagents and conditions: (i) Ac2O, cat. H2SO4, CH2Cl2. 
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Interestingly though, when (1-hydroxy-3-methylbut-2-enyl) phenylphosphinic acid 
ethyl ester 340a was treated under similar reaction conditions, the expected product was 
not obtained (Scheme 70). The reaction was monitored by TLC and the starting material 
was completely consumed, however after work-up and NMR analysis it was clear that 
the desired product had not been formed.  
The structure was assigned based on NMR and mass spectroscopy as 344. 
31
P NMR 
showed a signal at 31.6 ppm, 
1
H NMR showed three signals for the two sets of olefinic 
protons 5.23, 5.84, 7.09 ppm, 
13
C NMR showed signals at 120, 124, 150 ppm. While 
these characteristics signals do not confirm the compound structure, a similar compound 
was previously synthesised and characterised by our group showing similar spectral 
properties (Figure 16).   
 
Figure 16 NMR characteristics of compound 345. 
The assignment for 344 is consistent with the corresponding values observed in 
compound 345 which was previously synthesised in our group.
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We also attempted the preparation of a single enantiomer of diastereomerically pure 
340a or b through an enzyme mediated acylation reaction (Scheme 71).  
 
Scheme 71 Reagents and conditions: (i) vinyl acetate, Cal B, mol. sieves, diisopropyl ether, 60 °C, 2 d. 
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Literature procedures using enzymes to selectively protect the hydroxyl group of 
compounds were carried out.
92,93
 Candida antarctica lipase B (Cal B / Novozyme 435) 
and vinyl acetate in isopropyl ether were heated to 60 °C in the presence of molecular 
sieves to selectively acetylate one isomer of 340a-b as in the literature but after two 
days no reaction had taken place, the starting material was recovered.  
At this point it was decided to continue the synthetic strategies outlined in Scheme 54 
and Scheme 55 using the crystalline diastereomer as a monomer unit for chain 
extension.  
 
Scheme 72 Reagents and conditions: (i) Pd/C (10% wt), H2, EtOAc, 100%. 
The next step of the synthesis involves hydrogenation of the double bond (Scheme 72).  
Ethyl 1-hydroxy-3-methylbut-2-enyl(phenyl)phosphinate 340a underwent 
hydrogenation at standard pressure and temperature using Pd/C as the catalyst with 
EtOAc as solvent. The hydrogenated product 347 serves as the phosphono leucine 
monomer unit, which is analogous to leucine, but contains two stereocenters per residue 
unlike the single stereocenter in each leucine residue.  It should be noted that 347 could 
not be prepared in a diastereomerically pure form by treatment of 320 with 
isovaleraldehyde as shown in Scheme 67. The reaction affords a mixture of 
diastereomers that are not separable. 
As well as synthesising alcohol monomers concurrent synthesis of a number of amino 
monomers was carried out. This allowed for variation in the pseudopeptides formed, 
due to flexibility in the structure by inclusion of the amine functionality that can be 
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derivatised, whilst still providing a hydrogen donor for use in secondary structural 
properties.  
To this end the synthesis of two different types of amine monomers were synthesised 
using imines prepared according to Scheme 73.  
 
Scheme 73 Reagents and conditions: (i) toluene, 120 °C, overnight. 
 
Formation of the imines were carried out by refluxing isovaleraldehyde and the 
corresponding amine in toluene overnight, using Dean-Stark apparatus to collect the 
water generated during the reaction (Scheme 73). Imines 348 and 349 were not purified, 
but reacted directly with phosphite 320 under phospha-aldol conditions to give amine 
monomers 350 and 351 (Table 30). 
 
No. R
1
 R State Yield (%) Separable 
350 CH2(C6H4-pOMe) CH2CH(CH3)2 Oil / Oil Quant. No 
351 CH2(C6H5) CH(CH3)2 Oil / Crystal 95 Yes 
Table 30 Amine monomers synthesised. 
As shown in Table 30, amine monomers were successfully synthesised, however 
isolation of all of the diastereomers proved difficult apart from with valine analogue 
351. As the initial work focused on synthesis using leucine analogues the use of the 
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valine analogue was put on hold until further work with the leucine analogue was 
carried out. 
In view of the problem with the isolation of pure diastereomers from the aldol reaction 
with benzyl imines, an alternative strategy was envisaged for the formation of the α-
amino phenylphosphinate monomer. This was the transformation of the compound 347, 
either directly or via its tosyl or mesyl derivative, to its azide derivative, followed by 
reduction of the azide function to amine. 
 
Scheme 74 Reagents and conditions: (i) TsCl, Py, 0 °C to rt; (ii) NaN3, DMF, 60 °C; (iii) Pd/C 5%, H2, 
EtOAc. 
 
Alcohol 347 was transformed into the corresponding p-toluenesulfonyl (tosyl) 
derivative 352 by reacting with tosyl chloride in pyridine (Scheme 74). Introduction of 
a tosyl group produces a good leaving group that can be reacted with nucleophiles and 
easily be displaced. Compound 352 was reacted with sodium azide in DMF to give 
azide 353.  The last step involved reduction of the azide to give amine compound 354a 
as a yellow oil. This reduction was carried out with hydrogen using Pd/C as the catalyst 
and EtOAc as the solvent. 
Whilst the classical azide formation method was suitable, a shorter method
94
 was 
adopted and is described in Scheme 75: 
 
 
Scheme 75 Reagents and conditions: (i) PPh3, NaN3, CCl4, 60 °C; (ii) Pd/C 5%, H2, EtOAc. 
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Compound 347 was reacted with triphenylphosphine and sodium azide in carbon 
tetrachloride, to give after column chromatography compound 353 as previously 
discussed (Scheme 74).  
 
Scheme 76 Mechanism for transformation of alcohol to azide. 
The mechanism for the conversion of hydroxyl 347 to azide 353 goes via an SN2 
mechanism shown in Scheme 76. The first part of the reaction involves the formation of 
the chlorotriphenylphosphonium ion, which occurs when triphenylphosphine and 
carbon tetrachloride react with each other. The lone pair of the hydroxyl group attacks 
the phosphorus atom of the chlorotriphenylphosphonium ion forming intermediate 355, 
which is attacked by sodium azide to form the corresponding azide product with 
inversion of configuration at the stereocenter. Therefore, the reaction presumably 
afforded compound 353 with (RP,RC) relative configuration. 
 
 
Scheme 77 Reagents and conditions: (i) PPh3, NaN3, CCl4, 60 °C; (ii) Pd/C 5%, H2, EtOAc. 
In an attempt to investigate if the amine with RP,SC relative configuration can be 
obtained, the same reaction was carried out using the sample of alcohol 340a-b enriched 
with the non-crystalline diastereomer (RP,RC relative configuration) (Scheme 77). 
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However, both azides 356a-b and amines 354a-b were obtained as an inseparable 
diastereomeric mixture. 
2.3.1. Unexpected reactions when forming the azide 
Further probing of the reaction between triphenylphosphine, sodium azide and carbon 
tetrachloride for formation of the azide with compound 340a was carried out in an 
attempt to save one step by reducing the double bond and the azide in one reaction. 
Triphenylphosphine and sodium azide were added in a large excess to 340a in carbon 
tetrachloride and heated to 80 °C for 3 hours, varying the original conditions 
significantly. It had been anticipated that the reaction could be accelerated and also 
reduce the synthesis by one step.  
After heating for three hours the starting material had been consumed and a product 
with similar Rf to azide 353 had been formed. However after purification of the 
compound the 
1
H NMR was not in agreement with the azide product but instead a new 
product had been formed.  
 
The compound formed during this reaction is identical to compound 344 formed when 
reacting the alcohol with acetic anhydride in the presence of acid (Scheme 70). 
 
 
Scheme 78 Reagents and conditions: (i) PPh3, NaN3, CCl4, 80 °C, 3 h. 
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After formation of product 344 through the reaction described in Scheme 78 the next 
step was to test the reaction with a mixture of diastereomers 340a-b (Oil/Crystal 3:1) to 
see the outcome of the reaction. The reaction removes one stereocenter therefore it was 
expected reacting the oil diastereomer would form product 344 as with the reaction of 
crystal diastereomer 340a (Scheme 70).  
2.4. Synthesis of α-hydroxy phenylphosphinate dimers 
Once a reliable method for the large scale preparation of a single diastereomeric α-
hydroxy phenylphosphinic analogue of leucine was in place, it was decided to first 
investigate the preparation of dimeric phenylphosphinates. This required development 
of an iterative process in which an α-hydroxy phenylphosphinic moiety acts as the 
starter alcohol unit for the subsequent Hewitt and phospha-aldol reactions.  
2.4.1. Forming the chloroformate of the monomer & the Hewitt 
reaction 
Formation of dimers requires conversion of the hydroxyl group of compound 347 to the 
chloroformate 358 (Scheme 79) as previously shown in Scheme 58 followed by Hewitt 
reaction conditions as detailed in Scheme 60 to give the corresponding 
phenylphosphinate 359-360 (Scheme 79).  
Initially, synthesis of phenylphosphinate 359-360 was carried out in two steps (Scheme 
79), with characterisation of intermediate chloroformate 358 to ensure its efficient and 
successful formation. However, once confidence in the reliability of the reaction 
increased, further syntheses of phosphite 359-360 were carried out in a modified “one 
pot” synthesis (Scheme 79). The mechanisms for formation are the same as the general 
mechanisms outlined in Scheme 59 and Scheme 62. 
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Scheme 79 Reagents and conditions: (i) Py, (COCl2)3, CH2Cl2, 0 °C, 3 h; (ii) PhP(OH)2, CH2Cl2, 40 
°C, 1 h. 
In the “one-pot” method, the complete formation of the intermediate chloroformate was 
monitored by TLC and confirmed by 
31
P NMR. In the event of the reaction not having 
been completed, additional reagents were added and the monitoring of the reaction was 
continued. Once the chloroformate had been completely formed, the reagents for the 
Hewitt reaction were added carefully and the reaction was heated at reflux for one hour 
whilst being checked periodically by TLC.  
 
Scheme 80 Equilibrium between H-phosphonite tautomers. 
The product of the reaction is a diastereomeric mixture of (SP,RC,RP) and (SP,RC,SP) 
relative configurations.  Separation of these diastereomers proved to be impractical as 
the two are interconvertible due to 33-45 tautomerism of H-phosphonites (Scheme 
80).  Thus the two diastereomers 359-360 are in equilibrium with the 
phenylphosphinous mono ester tautomer 361 which nevertheless exists in only minute 
amounts.  In the 
31
P NMR two pairs (i.e. four signals) were observed, each as a doublet 
due to P-P coupling (Figure 17). This observation is consistent with two diastereomers 
being present in equal ratios. Each diastereomer has two doublets, one signal for each 
phosphorus atom that is in turn split by the other phosphorus atom.   
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Figure 17 31P NMR of compound 359-360 
Due to the impracticality to separate the two diastereomers it was decided to use the 
crude phosphinate product for the next step of the synthesis directly, without further 
purification.  
2.4.2. Silyl mediated phospha-aldol reaction of diphosphinate 
The next step in the dimer synthesis involves a phospha-aldol reaction with various 
aldehydes as shown in Scheme 81. 
 
Scheme 81 Reagents and conditions: (i) Et3N 15 min, TMSCl 15 min, RCHO 0 °C to rt; (ii) aq. work 
up. 
 
107 
 
The addition of an aldehyde to phosphonite 359-360 creates two additional 
stereocenters in the products, leading to the formation of four diastereomers. Since each 
of the diastereomers contains two phosphorus atoms in different magnetic 
environments, they each appear with a different signal and couple to each other. 
Therefore, in the absence of any selectivity, a total of 16 peaks in the 
31
P NMR would 
be repeated. 
The silylated phosphorus esters were formed by addition of TMSCl to a solution of 
triethylamine and compound 359-360 in dichloromethane at 0 °C. After 15 minutes the 
aldehydes were added and the mixture was stirred at room temperature overnight. The 
reaction was monitored by withdrawing a small sample which was then evaporated, and 
analysed by NMR.  
After confirmation that the reaction was complete, the mixture was concentrated and 
subjected to an aqueous work up and additional analysis by NMR. Typically at this 
stage, the 
31
P NMR showed a change from 16 peaks to 32 peaks, 16 peaks 
corresponding to the four silylated products 362-364, with an additional 16 peaks 
corresponding to the hydrolysed alcohol products 365-367. As the silyl group had been 
partially removed during work up it was deemed necessary to carry out a complete 
removal of the silyl group using TBAF so that the separation of products would be 
simplified.   
After treatment with TBAF, column chromatography was carried out to separate out the 
four diastereomers. The clean separation of all four of the diastereomers by column 
chromatography was not always possible. However, in most cases, it was possible to 
obtain sufficient quantities of pure diastereomers for further analysis.  
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2.4.2.1. Dimer (365) formed using benzaldehyde  
The first dimer to be synthesised was 365, with the relevant chemical properties 
described in Table 31. 
 
Diastereomeric ratio: 7:3:1:1 
No. Rf Stereochemistry State X-ray 
31
P Peaks 
365a 0.62 SRRR Crystal Yes 40.65, 43.15 
365b 0.59 SRRS Crystal Yes* 39.8, 40.65 
365c 0.30 SRSS 
Oil Mix. No 
37.84, 40.82, 
38.51, 40.38 365d 0.30 SRSR 
Table 31 Chemical properties of dimer 365 (*crystals previously isolated and characterised). 
2.4.2.2. Dimer (366) formed using isovaleraldehyde  
After the reaction with benzaldehyde the next aldehyde chosen was isovaleraldehyde. 
The reaction was carried out as shown in Scheme 81 using isovaleraldehyde. The NMR 
spectra showed the same patterns as seen when reacting with benzaldehyde. The 
chemical properties for dimer 366 are described in Table 32. 
 
Diastereomeric ratio: 2.5:2:1:1 
No. Rf Stereochemistry State X-ray 
31
P Peaks 
366a 0.7 SRRR Oil No 40.25, 46.05 
366b 0.4 SRRS Crystal Yes 41.0, 42.1 
366c 0.25 SRSS Solid No 38.8, 41.8 
366d 0.24 SRSR Crystal Yes 38.2, 41.0 
Table 32 Chemical properties of dimer 366. 
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2.4.2.3. Dimer (367) formed using isobutyraldehyde  
The addition of isobutryaldehyde was carried out as shown in the previous aldehyde 
additions to give dimer 367, with the chemical properties described in Table 33. 
 
Diastereomeric ratio: 2.4:2.3:1:1 
No. Rf Stereochemistry State X-ray 
31
P Peaks 
367a 0.6 SRRR Crystal Yes 41.26, 45.23 
367b 0.55 SRRS Crystal Yes 41.57, 42.55 
367c 0.35 SRSS Crystal Yes* 
39.06, 41.81, 39.53, 41.81 
367d 0.34 SRSR Crystal Yes* 
Table 33 Chemical properties of dimer 367 (*crystals previously isolated and characterised). 
 
Detailed analysis of the solution structures of diastereomers in the same series were 
carried out through NMR spectroscopy, including 
1
H{
31
P} spectroscopy, NOESY 
(Nuclear Overhauser Enhancement Spectroscopy), and HOESY (Heteronuclear 
Overhauser Enhancement Spectroscopy) between phosphorus and hydrogen nuclei. 
During the analysis of the 
1
H NMR spectra it was clear that the first two diastereomers 
in the isovaleraldehyde series had a different conformation to the latter two. On 
comparison of the 
31
P-coupled and 
31
P-decoupled 
1
H spectra (
1
H{
31
P}) it could be seen 
that in the first two diastereomers the hydroxyl hydrogen was coupled to a hydrogen 
nucleus (Hβ) and both phosphorus nuclei. HOESY between the phosphorus and 
hydrogen nuclei (Figure 18) showed that the hydroxyl hydrogen is coupled slightly 
more strongly to the phosphorus nucleus bonded further away from it (Pα) than to the 
phosphorus nucleus bonded closest to it (Pβ). The same studies were carried out on the 
other two diastereomers in the series and the results showed that the hydroxyl hydrogen 
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is coupled to a hydrogen nucleus (Hβ) and the phosphorus nucleus bonded closest to it 
only (Pβ). Based on the observations it could be suggested that the coupling between the 
hydroxyl and Pα in the first two diastereomers cannot be through-bond but must be 
through-space, the most likely way this could take place would be through 
intramolecular hydrogen bonding.  To confirm the coupling did not arise due to 
intermolecular hydrogen bonding successive ten-fold dilutions were carried out that did 
not affect the spectra, thus proving the theory. The same observations were shown when 
reacting with the other aldehydes in the series. 
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Figure 18 2D NMR spectra of compound 367a. 
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2.4.3. Computational Studies of α-hydroxy phenylphosphinate dimers1 
To examine the propensity of compounds 366a-d to form intramolecular hydrogen 
bonds from a theoretical perspective, a randomized (Monte Carlo) search of their 
conformational preferences was carried out.
95
 The results of these computations are 
shown in Table 34. Starting from four different starting conformations, 1296 random 
conformations were analysed. In each case, the lowest energy conformations were 
visually inspected. In two cases, diastereomers (SP,RC,RP,RC) and (SP,RC,RP,SC), the 
lowest energy conformations as well as a number of other low energy conformations 
were found to contain an intramolecular hydrogen bond between the hydrogen atom of 
the terminal hydroxyl group and the oxo atom (P=O) furthest away from it (Figure 19).  
 
 
Figure 19 H-bonding interaction in two diastereomers. 
In both cases, the conformations without this hydrogen bond were, as expected, higher 
in energy by at least 4 Kcal/mol. In the other two cases, diastereomers (SP,RC,SP,SC) and 
(SP,RC,SP,RC), the lowest energy conformations as well as other low energy 
conformations were found to contain no intramolecular hydrogen bond. In fact, no 
hydrogen bonded conformations were found within 10 Kcal/mol of the lowest energy 
conformation.  
 
 
 
                                                 
1 This work was carried out by Dr. K. Afarinkia using Gaussian 03 and is presented here in order to provide a more 
comprehensive analysis. 
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Relative 
Configuration 
Lowest energy  
in H-bonded 
conformations 
(Kcal/mol) 
Lowest energy  
in non H-bonded 
conformations 
(Kcal/mol) 
Number of 
intramolecularly 
H-bonded 
conformations 
(SP,RC,RP,RC)  124.134 129.155 22 
(SP,RC,RP,SC) 
366b 
124.141 128.206 13 
(SP,RC,SP,SC)  N/A 125.968 0 
(SP,RC,SP,RC) 
366d 
N/A 126.652 0 
(RP,RC,RP,RC)  123.963 128.416 33 
(RP,RC,RP,SC)  122.504 127.459 4 
(RP,RC,SP,SC)  N/A 127.657 0 
(RP,RC,SP,RC)  N/A 125.991 0 
a
 From a random 1296 
Table 34 Computed enthalpies of formation for all diastereomers of compound 366. 
In order to better correlate the configuration of the molecule with its likelihood to form 
intramolecular hydrogen bonding, a randomized search of the conformational 
preferences of the four diastereomers of dimeric compound 366 that would have arisen 
had we started the synthesis from 341b was carried out. Again, computational data 
suggest that two of these diastereomers, with (RP,RC,RP,RC) and (RP,RC,RP,SC) 
configuration, are likely to form intramolecular hydrogen bonds whereas the other two 
with (RP,RC,SP,RC) and (RP,RC,SP,SC) configuration, are unlikely to form intramolecular 
hydrogen bonds. A similar trend was observed for diastereomers 365a-d (Table 35) and 
367a-d (Table 36). This leads to an understanding that the propensity of dimeric α-
hydroxyphenylphosphinates to form intramolecular hydrogen bonds directly correlates 
to the relative configurations at the carbon and phosphorus atoms. 
 
Table 35 Computed enthalpies of formation for all diastereomers of compound 365. 
Relative 
Configuration 
Lowest energy  
in H-bonded 
conformations 
(Kcal/mol) 
Lowest energy  
in non H-bonded 
conformations 
(Kcal/mol) 
Number of 
intramolecularly 
H-bonded 
conformations 
(SP,RC,RP,RC) 
365a 
158.210 160.882 10 
(SP,RC,RP,SC) 
365b 
159.534 161.609 11 
(SP,RC,SP,SC)  N/A 160.692 0 
(SP,RC,SP,RC)  N/A 161.486 0 
(RP,RC,RP,RC)  156.955 160.573 16 
(RP,RC,RP,SC)  158.400 161.573 1 
(RP,RC,SP,SC)  N/A 160.780 0 
(RP,RC,SP,RC)  N/A 161.641 0 
a
 From a random 1152 
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Relative 
Configuration 
Lowest energy  
in H-bonded 
conformations 
(Kcal/mol) 
Lowest energy  
in non H-bonded 
conformations 
(Kcal/mol) 
Number of 
intramolecularly 
H-bonded 
conformations 
(SP,RC,RP,RC)  124.352 127.892 25 
(SP,RC,RP,SC)  123.948 127.181 4 
(SP,RC,SP,SC)  
(367c) 
N/A 126.598 0 
(SP,RC,SP,RC)  
(367d) 
N/A 125.913 0 
(RP,RC,RP,RC)  124.377 127.255 5 
(RP,RC,RP,SC)  122.352 126.975 12 
(RP,RC,SP,SC)  N/A 126.917 0 
(RP,RC,SP,RC)  N/A 125.365 0 
a
 From a random 1152 
Table 36 Computed enthalpies of formation for all diastereomers of compound 367. 
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2.4.4. X-ray analysis of α-hydroxy phenylphosphinate dimers 
While the computational studies gave sufficient data that appeared to confirm the 
evidence obtained by NMR, it was decided to confirm the relative configurations of H-
bonded and non H-bonded diastereomers. To achieve this aim, it was necessary to move 
towards determination of the structure of the molecules in the solid state by X-ray 
crystallography.  
 
In the benzaldehyde series the first two diastereomers were both crystalline. The final 
two diastereomers were isolated as an oil mixture, therefore X-ray analysis was not 
possible. Based on the X-ray crystal structure 365a had (SP,RC,RP,RC) relative 
configuration (Figure 20). The alignment of the atoms was not suitable for 
intramolecular hydrogen bonding to be possible, despite the solution studies and 
computational studies to back the theory up. It could be possible that the influence of 
the phenyl groups had an effect during crystallisation such that the orientation of the 
atoms would not permit hydrogen bonding. 
 
Figure 20 X-ray crystal structure of 365a. 
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In the isovaleraldehyde series the first compound is an oil and the third one could not be 
crystallised. The remaining two diastereomers were crystalline and the X-ray crystal 
structures were obtained. Based on the results of the X-ray crystal structures 366b had 
(SP,RC,RP,SC) relative configuration (Figure 21) and the alignment of the atoms 
suggested intramolecular hydrogen bonding between the hydrogen of the hydroxyl and 
the oxygen of the phosphonyloxy (P=O) functionality.  
 
 
Figure 21 X-ray crystal structure of 366b. 
 
It was also possible to see that 366d had (SP,RC,SP,RC) relative configuration (Figure 
22) and the alignment of the atoms precluded any intramolecular hydrogen bonding.  
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Figure 22 X-ray crystal structure of 366d. 
 
At this point some evidence was present to confirm the theories shown by solution and 
computational studies, however all of the information from one series of compounds 
had not been confirmed until looking at the other series of compounds formed from the 
reaction with isobutyraldehyde, dimer 367. 
 
In the isobutyraldehyde series all four diastereomers were crystalline. Based on the X-
ray crystal structure 367a had (SP,RC,RP,RC) relative configuration (Figure 23), with the 
alignment of the atoms suggesting intramolecular hydrogen bonding between the 
hydrogen of the hydroxyl and the oxygen of the phosphonyloxy (P=O) functionality. 
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Figure 23 X-ray crystal structure of 367a. 
 
Based on the X-ray crystal structure 367b had (SP,RC,RP,SC) relative configuration 
(Figure 24), with the alignment of the atoms suggesting intramolecular hydrogen 
bonding between the hydrogen of the hydroxyl and the oxygen of the phosphonyloxy 
(P=O) functionality.  
 
 
Figure 24 X-ray crystal structure of 367b. 
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2.5. Synthesis of α-hydroxy phenylphosphinate trimers 
It can clearly be seen that applying the Hewitt reaction followed by the phospha-aldol 
reaction sequentially could be carried out ad infinitum. In order to demonstrate the 
theory is applicable to synthesising longer oligomeric chains of α-hydroxy 
phenylphosphinate residues, chain elongation was carried out with one of the dimer α-
hydroxy phenylphosphinates obtained in sufficient quantity.  
Compound 366b was treated with triphosgene and pyridine in dichloromethane as 
shown in Scheme 82, to afford the corresponding chloroformate 368. Once the 
chloroformate was formed it was treated under Hewitt reaction conditions to afford 369. 
As with the synthesis of the dimer molecules the phosphite formed is a mixture of 
diastereomers that are tautomers, so isolation of the individual diastereomers was not 
possible at this stage.  
 
Scheme 82 Reagents and conditions: (i) Py, (COCl2)3, CH2Cl2, 0 °C, 3 h; (ii) PhP(OH)2, CH2Cl2, 40 
°C, 1 h. 
 
After phosphite 369a-b was formed it could be used in the phospha-aldol reaction to 
form the trimer molecule (Scheme 83). The synthesis is carried out in the same manner 
as formation of the dimer molecules. The phosphite is first silylated to form the reactive 
intermediate, followed by treatment with isovaleraldehyde resulting in the formation of 
four diastereomeric trimer compounds 370a-d (Scheme 83). 
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After the addition of the aldehyde and work up of the reaction the silyl protected 
alcohols were evident again as a mixture of four diastereomers 370a-d. Separation was 
carried out and one of the diastereomers 370b was isolated in pure form as an oil. The 
isolated diastereomer still had the TMS protecting group attached therefore deprotection 
had to be carried out to achieve the desired compound.  
 
Scheme 83 Reagents and conditions: (i) Et3N 15min, TMSCl 15min, isovaleraldehyde 0 °C to rt. 
The first method attempted to deprotect the silyl group of the trimer (Scheme 84) was to 
treat it with camphorsulfonic acid, a weak acid, unfortunately this method for 
deprotection failed. To overcome this problem the trimer was immobilised on silica gel, 
left for 24 hours followed by extraction of the compound from the silica gel which gave 
the desired deprotected trimer compound 371b.  
 
 
Scheme 84 Reagents and conditions: (i) camphorsulfonic acid; (ii) Silica (SiO2), 24 h. 
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2.6. Summary  
A method for the synthesis of dimeric α-hydroxy phenylphosphinates has been 
developed and is has been proven by X-ray, NMR and computational studies that 
depending on the relative configuration at the carbon and phosphorus atoms, the 
structures may fold over to form intramolecularly hydrogen bonded structures (Figure 
25).  
 
Figure 25 Structural conformations of dimer diastereomers. 
We have shown through the synthesis of that this methodology can be applied to longer 
chained oligomers (Scheme 85) by sequential chain extension through repeated 
chloroformate formation followed by Hewitt reaction and phospha-aldol reaction. 
 
Scheme 85 (i) chloroformate formation; (ii) Hewitt reaction; (iii) phospha-aldol reaction 
122 
 
2.7. Synthesis of α-amino/ α-hydroxy phenylphosphinates   
As part of an investigation into dimeric α-hydroxy phenylphosphinates (Section 2.4), 
we demonstrated that depending on the relative configuration of phosphorus and carbon 
atoms, these dimers fold over to give an eight-atom parsing intramolecular hydrogen 
bonding between the oxygen atom of the phosphonyl group (P=O) and hydrogen atom 
of the hydroxyl group (OH).  
 
Scheme 86 Comparison of α-hydroxy, functionalised α-hydroxy and α-amino phenylphosphinates. 
Although this was a fascinating observation, dimeric phenylphosphinate esters do not 
provide us with any further opportunity to investigate folding patterns by intramolecular 
H-bonding in more complex systems. Further substitution of the OH in these 
compounds also removes the hydrogen and the potential for H-bonding. Therefore, we 
decided to investigate the preparation of α-amino / α-hydroxy dimeric 
phenylphosphinates (Scheme 86). In these molecules there will still be a potential for 
intramolecular H-bonding with the remaining NH whilst other H-bond acceptor donors 
can be incorporated into the R group. 
 
2.7.1. Via phospha-aldol reaction with imines  
It was first decided to carry out the synthesis of the α-amino phenylphosphinates 
following a similar procedure to formation of the α-hydroxy phenylphosphinate dimers 
(365-367). The reaction involves transformation to the silyl protected intermediate, 
123 
 
followed by the phospha-aldol reaction with an imine instead of the aldehyde.  The 
reaction mechanism is as shown in Scheme 63. 
The general scheme for synthesis of the α-amino phenylphosphinate dimers is shown 
below (Scheme 87): 
 
 
Scheme 87 Reagents and conditions: (i) Et3N 15 min, TMSCl 15 min, R
1
N=CHR 0 °C to rt, (ii) aq. 
work-up. 
 
The method for synthesis of α-amino phenylphosphinates involves reacting phosphite 
359-360 with the desired imine. Formation of the imines was carried out according to 
Scheme 73 to give 379 and 348 (Figure 26).   
 
 
 
Figure 26 Imines synthesised for reaction with 359-360. 
 
Imines 379 and 348 were not purified, but reacted directly with phosphite 359-360 in 
the next step of the synthesis (Scheme 87). As in the synthesis of α-hydroxy 
phenylphosphinate dimers the reaction afforded four diastereomeric products 380a-d 
and 381a-d (Figure 27). 
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Figure 27 Protected α-amino phenylphosphinates synthesised. 
Unfortunately separation of all of diastereomers 380a-d was not possible. 
Diastereomers 381a-d were part of a complex reaction mixture from which no single 
diastereomeric compound could be isolated was not possible at this stage.  In an attempt 
to overcome this problem it was decided to remove the protecting group to give the free 
amine compound 382a-d. Unfortunately removal of the protecting group with DDQ and 
hydogenolysis (Scheme 88) did not completely remove the protecting group. Attempts 
to separate 381a-d from 382a-d as the reaction mixture was too complex to isolate a 
single diastereomeric compound. 
 
 
Scheme 88 Reagents and conditions: (i) DDQ, CH2Cl2; (ii) Pd/C, H2, EtOAc. 
At this point further efforts towards the synthesis of α-amino phenylphosphinates using 
the phospha-aldol method were halted in favour of derivatisation of α-hydroxy 
phenylphosphinates. 
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2.7.2. Conversion of the hydroxyl group to azide 
Since direct access to the diastereomerically pure α-amino phenylphosphinate through a 
phospha-aldol reaction to imines had proved to be problematic, it was decided to use an 
alternative approach. We had previously shown successfully, that the α-hydroxy 
phenylphosphinate monomer 347 could be converted to the corresponding α-amino 
phenylphosphinate 354a via an azide displacement of the alcohol function, followed by 
reduction of the azide function (Scheme 74 and Scheme 75). Therefore, this approach 
was adopted for diastereomerically pure α-hydroxy phenylphosphinate dimers. 
 
The first step was to devise a method for conversion of the alcohol to an azide which 
could then be reduced to the corresponding amine. The first attempt was to convert the 
single diastereomeric compound 366b to its corresponding tosyl derivative prior to 
reaction with sodium azide. This approach had previously been successfully applied to 
the synthesis of α-amino phenylphosphinate monomer 354a (Scheme 74). 
 
No. Starting Material Reagents Outcome 
383b 366b TsCl, pyridine No reaction 
383b 366b TsCl, Et3N No reaction 
383b 366b MsCl, pyridine, CH2Cl2 No reaction 
383b 366b MsCl, Et3N, CH2Cl2 No reaction 
383a 366a Excess MsCl, Et3N, CH2Cl2 Reaction 
Table 37 Conditions for leaving group formation. 
 
This reaction did not proceed despite multiple attempts using excess of tosyl chloride 
and different bases. Attempts to synthesise the mesylate of 383a were however 
successful. It was found that using a large excess of methanesulfonyl chloride and 
triethylamine, afforded the desired mesylate that could be purified by flash 
chromatography. The conditions used to form the mesylate are outlined in Table 37. 
However, when mesylate 383a was treated with sodium azide the displacement reaction 
did not proceed (Scheme 89). 
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Scheme 89 Reagents and conditions: (i) NaN3, DMF, 60 °C, overnight. 
After failure to form azide 384a from mesylate 383a it was decided to convert alcohol 
366a to azide 384a directly using Mitsunobu reaction (Scheme 90). Attempts for this 
reaction are shown in Table 38. This approach had previously been successfully applied 
to the synthesis of α-amino phenylphosphinate monomer 354a (Scheme 75). 
No. Reagents Outcome 
366a 1 eq. NaN3, 1eq. PPh3, DEAD, DMF No reaction 
366a 1 eq. NaN3, 2 eq. PPh3, DMF, CCl4 No reaction 
366a 1 eq. NaN3, 5 eq. PPh3, DMF, CCl4 Reaction 
Table 38 Conditions used for azide formation. (Structure of 366a shown in Scheme 90). 
 
Initial attempts at the formation of azide 384a from alcohol 366a were unsuccessful, 
therefore an analogous method using sodium azide and triphenylphosphine and carbon 
tetrachloride in DMF was attempted as shown in Table 38. This resulted in a clean 
conversion (TLC) to a new product which was isolated by column chromatography. 
After isolation of the product, NMR analysis clearly demonstrated that this was not the 
expected azide 384a. In the 
1
H NMR spectrum of the product the signals of the CH3 and 
CH2 of the ethyl ester were absent. The mass spectrum also did not show a molecular 
ion peak consistent with formation of the azide.  
 
 
Scheme 90 Reagents and conditions: see Table 39. 
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After further spectroscopic analysis, including 2D NMR experiments, and full 
characterisation of the compound it was proposed that the product of the reaction was a 
1,4,2,5-dioxadiphosphinane-2,5-dioxide ring, a cyclised version of starting alcohol 366a 
(Scheme 90). The structure of compound 385 was subsequently confirmed by X-ray 
crystallography (Figure 28). X-ray crystallography also confirmed that the 
configuration of the carbon atom attached to the alcohol had been inverted during the 
reaction. The compound has a boat configuration, with one of the phenyls and two 
i
butyl groups in the pseudo equatorial position.   
 
 
Figure 28 X-ray crystal structure of 385 
The mechanism below (Scheme 91) was proposed to explain how cyclisation of the 
alcohol could have taken place. Whilst it is a somewhat unusual mechanism, there are 
similar reactions involving cyclisation through the oxo oxygen atom of a phosphonyl 
moiety reported in the literature.
96,97,98
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Scheme 91 Mechanism of cyclisation. 
Interestingly, although 1,4,2,5-dioxadiphosphinane-2,5-dioxide ring has been previously 
synthesized and analysed by X-ray crystallography
99
, this was the first ever example 
that could be applied to the synthesis of non-symmetric analogues. Therefore, we 
decided to briefly investigate the reaction. In an attempt to confirm the mechanism of 
the cyclisation, we varied the reaction conditions and reagents to investigate their role 
(Table 39). 
Reagents Outcome 
 
NaN3, PPh3, CCl4, DMF Cyclisation 
NaN3, PPh3, DMF No reaction 
PPh3, CCl4 Cyclisation 
CCl4 No reaction 
PPh3, DMF No reaction 
Table 39 Varied reaction conditions for cyclisation (equivalents, time, and temperature 
are constant). 
 
It could be seen from the investigations outlined in (Table 39) that the cyclisation 
reaction did not require sodium azide or DMF but it did require triphenylphosphine and 
carbon tetrachloride as predicted by the proposed mechanism. 
Rather unexpectedly, we found that when diastereomer 366b was subjected to the same 
reaction conditions that caused the transformation of 366a to 385, the analogous 
reaction did not proceed. Instead we obtained chloride 387 with inversion of 
stereochemistry (Scheme 92). The reason for this difference is not very clear but 
presumably is related to steric condition in the intermediates for the intramolecular 
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cyclisation in 366b. The generality of the cyclisation is currently under further 
investigation.  
 
Scheme 92 Reagents and conditions: (i) 10 eq. PPh3, CCl4, 60 °C, 3 h. 
2.8. Coupling amino acids to the phenylphosphinate analogue of 
leucine  
2.8.1. Couplings to -hydroxy phenylphosphinates 
After success with the preparation of dimeric phenylphosphinates, it was decided to 
investigate the preparation of pseudopeptides with a phenylphosphinate at the C 
terminus. As outlined before (Figure 14), it was envisaged that at least two amino acid 
residues would need to be coupled before any folding patterns could be observed. This 
could be achieved either via stepwise coupling of two leucine residues (as shown in 
Scheme 93 and Scheme 94), or via coupling of a di-leucine at the free hydroxyl or of 
phenylphospholeucine (as shown in Scheme 95).  
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Scheme 93 Reagents and conditions: (i) DCC, DMAP, CH2Cl2, Boc-(L)-Leu-OH; (ii) TFA, CH2Cl2, 0 
°C. 
Compound 347 was coupled to Boc-(L)-Leu-OH using DCC and DMAP as coupling 
reagents (Scheme 93). The coupling gave 388 in quantitative yield as shown by NMR 
analysis; however the isolated yield was only 70%. This could be associated with 
problematic column chromatography of a polar, acid sensitive 388. The coupling 
afforded two diastereomeric products as expected from the reaction of an enantiomer 
mixture of the starting alcohol 347 with an enantiopure reactant. The two diastereomers 
formed from the coupling could not be separated as they showed as a single spot on 
TLC. The mixture of diastereomers was solid and recrystallisation to isolate single 
diastereomers was attempted, however separation of diastereomers by this method was 
unsuccessful. The next step was to remove the Boc group hoping that the diastereomers 
of the free amine may be separable. The Boc protecting group is acid labile, therefore 
treatment of 388 with neat trifluoroacetic acid removed the protecting group to give the 
free amine 389 as expected. The products isolated were again a mixture of 
diastereomers that unfortunately could not be separated by column chromatography or 
crystallisation (Scheme 93). 
Despite the inability to separate the diastereomers from each other, it was decided to 
continue the chain extension to add another leucine residue to 389 using the same 
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method previously discussed (Scheme 93) for formation of 388 to form 390.  The 
reaction proceeded with a good yield giving four diastereomeric products.  
Unfortunately as with the first coupling reaction no single diastereomer could be 
isolated.  Again in an attempt to isolate a single diastereomer the Boc protecting group 
was removed.  This reaction was carried out under the same conditions as the 
deprotection of 388 to give 391. The reaction proceeded with quantitative yield but after 
work up and purification no single isomer could be obtained from the mixture of 
diastereomers. 
The coupling of 347 with Boc-(D)-Leu-OH was also attempted (Scheme 94) to afford 
392 followed by deprotection of the Boc group to give 393. As before coupling of 393 
was carried out to give 394 followed by deprotection to give 395. As previously the 
diastereomers were not separable by purification. 
 
Scheme 94 Reagents and conditions: (i) DCC, DMAP, CH2Cl2, Boc-(D)-Leu-OH; (ii) TFA, CH2Cl2, 0 
°C. 
Due to problems with separation it was decided to couple diamino acids 400 and 402 
(Scheme 95) to monomer 347 (Scheme 96, Scheme 97). The reaction was carried out 
using peptide conditions.  
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The synthesis of the diamino acids 400 and 402 is outlined in Scheme 95. 
 
Scheme 95 Reagents and conditions: (i) Cs2CO3, DMF, 60 °C, 1 h; then BnBr (0 °C for addition) 60 
°C, 3 h; (ii) TFA, CH2Cl2, 0 °C; (iii) DCC, DMAP, CH2Cl2, Boc-(L)-Leu-OH; (iv) DCC, DMAP, CH2Cl2, 
Boc-(D)-Leu-OH; (v) Pd/C 5%, H2, EtOAc. 
 
After formation of diamino acids 400 and 402, coupling was attempted to alcohol 347 
using peptide coupling conditions (Scheme 96 and Scheme 97), however the couplings 
did not proceed. 
 
Scheme 96 Reagents and conditions: (i) HBTU, Et3N, 400, THF; (ii) DCC, DMAP, 400, CH2Cl2. 
 
 
Scheme 97 Reagents and conditions: (i) HBTU, Et3N, 402, THF; (ii) DCC, DMAP, 402, CH2Cl2. 
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2.8.2. Coupling to α-amino phenylphosphinates 
Although the attempted syntheses were mostly successful, any further progress was 
hampered by the fact that equal mixtures of diastereomers had been obtained. Because 
of this, NMR and other analysis of the mixtures were complex and unreliable. 
Therefore, it was decided to investigate coupling to α-amino phenylphosphinates, rather 
than α-hydroxy phenylphosphinates, in the hope that separation of the diastereomers, 
and hence the analysis of any supramolecular structures would become possible. 
 
 
 
Scheme 98 Reagents and conditions: (i) HBTU, Et3N, THF, Boc-(L)-Leu-OH; (ii) HBTU, Et3N, THF, 
Boc-(D)-Leu-OH. 
 
Using similar methods used in the couplings to α-hydroxy phenylphosphinates, α-
aminophenylphosphinate 354a was coupled to Boc-(L)-Leu-OH and Boc-(D)-Leu-OH 
using HBTU and triethylamine as the coupling reagents (Scheme 98). The reaction 
proceeded with good yield to afford 405 and 406 both as a mixture of diastereomers. In 
spite of attempts of separation, compounds 405 and 406 were not isolated as single 
diastereomers. For the synthesis of “trimers” we decided to directly couple diamino 
acids Boc-(L)-Leu-(L)-Leu-OH 400 and Boc-(D)-Leu-(L)-Leu-OH 402, previously 
synthesised as outlined in Scheme 95, to the α-amino phenylphosphinate 354a. 
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Scheme 99 Reagents and conditions: (i) HBTU, Et3N, THF, 400; (ii) TFA, CH2Cl2, 0 °C. 
 
α-Amino phenylphosphinate 354a was coupled to 400 using HBTU and triethylamine 
(Scheme 99) following the same procedure as described earlier (Scheme 98). The 
reaction gave two diastereomers one of which, 407a, was isolated in pure form (20% 
yield). However the other diastereomer 407b could not be separated in pure form and 
was always obtained as a mixture with the other diastereomer. Product 407a was 
subsequently deprotected using TFA to give 408a. Unfortunately product 408a was 
obtained as an oil therefore crystallographic studies to determine the relative 
configuration of the molecule were not possible. 
Careful analysis of the NMR spectra of 408a however did not show any evidence to 
suggest any intramolecular hydrogen bonding in this molecule. 
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Scheme 100 Reagents and conditions: (i) HBTU, Et3N, THF, 402; (ii) TFA, CH2Cl2, 0 °C. 
 
α-Amino phenylphosphinate 354a was also coupled to 402 (Scheme 100) using the 
same procedure as described in Scheme 99. The reaction gave two diastereomers 409a-
b that could not be separated. The products 409a-b were deprotected using TFA as 
before to give a crystalline mixture of diastereomers 410a-b.  Even though the 
diastereomers were not separable, the quality of the crystals were sufficiently high to 
encourage us to obtain X-ray crystallography, which is currently pending.  
2.9. Coupling to leucine dimer analogue 
 
As separation of diastereomerically pure compounds of Leu-Leu-Leu(P) was proving 
very difficult and the investigation into the secondary structures were unrewarding, it 
was decided to change track slightly and investigate Leu-Leu(P)-Leu(P) trimers. Our 
success with Leu(P)-Leu(P), both for the separation of diastereomers as well as 
observation of folding patterns encouraged this exercise. 
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Compounds 366a and 366b were chosen to be coupled with protected amino acids.   
 
 
Scheme 101 Reagents and conditions: (i) DCC, DMAP, CH2Cl2, Boc-(L)-Leu-OH; (ii) DCC, DMAP, 
CH2Cl2, Boc-(D)-Leu-OH. 
 
Compounds 366a and 366b were reacted with Boc-(L)-Leu-OH and Boc-(D)-Leu-OH 
using the conditions shown in Scheme 101 and Scheme 102, however the coupling 
reaction did not proceed recovering only the starting materials. 
 
Scheme 102 Reagents and conditions: (i) DCC, DMAP, CH2Cl2, Boc-(L)-Leu-OH; (ii) DCC, DMAP, 
CH2Cl2, Boc-(D)-Leu-OH. 
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2.10. Formation of α-hydroxy carboxylic acids 
As discussed earlier (Scheme 55), to prepare phosphonopeptides with a phosphinic 
residue at the middle of the chain, it is possible to start from an α-hydroxy carboxylate 
296, convert it to the chloroformate 297, then via the Hewitt reaction to the 
corresponding phenylphosphinate ester 298, which can then be used in a phospha-aldol 
reaction to give 299 (Scheme 103).  
 
Scheme 103 Reagents and conditions: (i) Hewitt reaction; (ii) phospha-aldol reaction. 
In view of our existing experience with leucine analogues, it was decided that the R
1
 
group should be an isobutyl group (Scheme 103), meaning that the synthesis could start 
from 2-hydroxy-4-methylpentanoic acid (hydroxy leucine). 
 
2.10.1. Preparation of 2-hydroxy-4-methylpentanoic acid 
 
Scheme 104 Reagents and conditions: (i) 0.5M H2SO4, NaNO2, 0 °C to rt. 
Conversion of (L)-leucine 415 to (S)-2-hydroxy-4-methylpentanoic acid 416 was 
achieved using a diazotization reaction (Scheme 104). Diazotization involves a double 
inversion at the carbon stereocenter. The mechanism for the conversion is shown in 
Scheme 105. 
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Scheme 105 Mechanism of conversion of amine to alcohol via diazotization. 
 
The enantiopurity of the alcohol was recorded using a polarimeter, obtaining a specific 
rotation of -27.4°, in agreement with -27.6° reported in the literature for the enantiopure 
compound.
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The resulting α-hydroxy carboxylic acid was converted to its methyl (417) and ethyl 
(418) esters through an acid catalysed esterification (Scheme 106). 
 
Scheme 106 Reagents and conditions: (i) AcCl, ROH, 0 °C. 
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The selective formation of the benzyl ester 419 (without affecting the formation of a 
benzyl ether) can be achieved through use of a base such as cesium carbonate and 
benzyl bromide (Scheme 107).  
 
Scheme 107 Reagents and conditions: (i) Cs2CO3, DMF, 60 °C, 1 h; (ii) BnBr (0 °C for addition) 60 
°C, 3 h. 
The next part of the synthesis requires formation of the phenyl phosphinate, which can 
be carried out over two steps, first forming the chloroformate then using Hewitt reaction 
conditions to form the corresponding phenyl phosphinate. 
 
2.10.1.1. Reactions of phosphites derived from the methyl and ethyl 
esters 
 
 
Scheme 108 Reagents and conditions: (i) Py, (COCl2)3, CH2Cl2, 0 °C 3 h; (ii) PhP(OH)2,  
CH2Cl2, 40 °C, 1 h. 
 
Compounds 417 and 418 were reacted to form the corresponding chloroformates 420 
and 421 (Scheme 108) followed by Hewitt reaction conditions to give the 
corresponding phenyl phosphinates 422 and 423 (Scheme 108). 
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Scheme 109 Reagents and conditions: (i) Et3N 15 min, TMSCl 15 min, isovaleraldehyde 0 °C to rt; (ii) 
TBAF, THF/Et2O, 1 h. 
Phosphites 422 and 423 were reacted with isovaleraldehyde to form 424 and 425 
(Scheme 109). As was seen before, during the aqueous work up partial deprotection had 
taken place, therefore complete deprotection had to be carried out using TBAF to give 
426 and 427. Unfortunately, separation of the individual diastereomers in either of the 
ethyl or methyl series was not possible. 
 
Scheme 110 Reagents and conditions: (i) Boc-(L)-Leu-OH, DCC, DMAP, CH2Cl2. 
The coupling of methyl ester 426 to Boc-(L)-Leu-OH and of the ethyl ester 427 to both 
Boc-(L)-Leu-OH and Boc-(D)-Leu-OH were attempted but for reasons which were not 
clear, were unsuccessful (Scheme 110 and Scheme 111).  
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Scheme 111 Reagents and conditions: (i) Boc-(L)-Leu-OH, DCC, DMAP, CH2Cl2; (ii) Boc-(L)-Leu-
OH, HBTU, Et3N, THF; (iii) Boc-(D)-Leu-OH, DCC, DMAP, CH2Cl2; (iv) Boc-(D)-Leu-OH, HBTU, 
Et3N, THF. 
 
Similarly, conversion of the alcohol function in 427 to the azide function using methods 
previously employed, were unsuccessful (for comparison see Scheme 75 and Scheme 
91). 
Therefore, the next step of the synthesis was to carry out the phospha-aldol reaction of 
phosphite 423 with imine 379, to give protected amine 431 directly (Scheme 112). 
 
Scheme 112 Reagents and conditions: (i) Et3N 15 min, TMSCl 15 min, imine 0 °C to rt. 
The diastereomers of compound 431 could not be separated, however, the N-benzyl 
group was successfully removed under catalytic hydrogenation conditions (Scheme 
113).  Unfortunately though, free amine 432 was obtained with substantial quantities of 
a by-product 433 (Scheme 113) and therefore, this was not deemed a viable synthetic 
method. 
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Scheme 113 Reagents and conditions: (i) Pd/C 5%, H2, EtOAc. 
The 
31
P NMR of the crude reaction mixture showed that the four signals corresponding 
to the protected product 431 had disappeared, but eight new signals were present: four 
corresponding to the desired amine 432 with similar chemical shifts to the 
corresponding alcohol 427, as well as four new signals at considerably different 
chemical shifts. Characterisation by NMR showed that the ethyl ester of the carboxylic 
acid had been removed and a secondary amide had been formed. Based on these 
observations, it was concluded that compound 432 had undergone an intramolecular 
cyclisation forming compound 433. 
 
Scheme 114 Mechanism of cyclisation of 432. 
The mechanism proposed for the cyclisation reaction is shown in Scheme 114. It is 
thought that once the amine is formed under hydrogenation conditions the lone pair of 
the nitrogen attacks the carbonyl of the ester and cyclisation occurs. 
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2.10.2. Modifications to the free carboxylic acid 
 
In spite of numerous attempts to derivatise and purify the compounds mentioned, the 
results were not promising.  To try and overcome this obstacle it was decided to attempt 
the synthesis on the free carboxylic acid. 
 
Scheme 115 Reagents and conditions: (i) Py, (COCl2)3, CH2Cl2, 0 °C 3 h; (ii) PhP(OH)2, CH2Cl2, 40 
°C, 1 h. 
 
Compound 416 was successfully transformed to its phenylphosphinate derivative 434 
through the reaction described in Scheme 115. 
 
Scheme 116 Reagents and conditions: (i) Et3N 15 min, TMSCl 15 min, isovaleraldehyde 0 °C to rt; (ii) 
TBAF, THF/Et2O; (iii) TBDMSCl, imidazole, CH2Cl2. 
 
Compound 434 was then reacted with isovaleraldehyde under silyl mediated phospha-
aldol conditions to form compound 435, which would then be desilylated to give 
compound 436 (Scheme 116). Compound 436 was part of a complex reaction mixture 
from which no single diastereomeric compound could be isolated was not possible at 
this stage. In an attempt to aid separation, compound 436 was converted to 437, 
however the diastereomers were still inseparable. 
 
144 
 
 
Scheme 117 Reagents and conditions: (i) Et3N 15min, TMSCl 15min, 379 0 °C to rt; (ii) 396, DCC, 
DMAP, CH2Cl2. 
 
Compound 434 was also reacted with imine 379 to give the corresponding protected 
amine product 438 (Scheme 117). Separation did not give single diastereomers so a 
coupling to the carboxylic acid end was attempted using H2N-(L)-Leu-OBn 398 to give 
439. Further modifications including deprotection of the amine are pending. 
2.11. Towards the synthesis of a long chain leucine analogue 
pseudopeptide 
At this stage, it was decided to consider a different approach to achieving our objective 
of demonstrating secondary structure motifs from hybrids of α-amino carboxylates and 
α-amino/α-hydroxy phenylphosphinates. Instead of building larger peptides starting 
from smaller, diastereomerically pure α-amino/α-hydroxy phenylphosphinates, longer 
chain units would be attacked at either end of a diastereomerically mixed α-amino/α-
hydroxy phenylphosphinate unit. Obviously, a mixture of peptides would be obtained 
but the idea was that these larger peptides might be more easily separable because the 
ones with the “correct” stereochemistry would fold and hence would have different 
properties that would enable separation.  
To form this structure two tetra leucine molecules would be attached at the either end of 
α-amino phenylphosphinate/hydroxyleucine dimer 436. This would give decamer 440 
(Figure 29) which is likely to form an -helical structure. 
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Figure 29 Proposed decamer to be synthesised. 
Pseudopeptide 440 can be divided into three parts that for synthesis (Scheme 118). Two 
components can be synthesised in the same manner, building up the tetramer of leucine 
then deprotecting either the C or N terminus followed by coupling to the central 
component. The remaining central component is α-hydroxy 
phenylphosphinate/hydroxyleucine dimer 436 (Scheme 116) which was previously 
synthesised. 
  
Scheme 118 Retrosynthetic analysis of decamer 440. 
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2.11.1. Synthesis of tetramer of leucine 
The first component to be synthesised is the tetramer of leucine as this requires the most 
steps when carrying out a stepwise elongation of the peptide chain.  
 
 
Scheme 119 Reagents and conditions: (i) TFA, CH2Cl2, 0 °C 30 min; (ii) Boc-(L)-Leu-OH, DCC, 
DMAP, CH2Cl2. 
 
Starting from the previously synthesised diamino acid 399 (Scheme 95), three steps are 
carried out involving deprotection to give 443, coupling to give 444 and a further 
deprotection using the same conditions as described previously to give the triamino acid 
445 with the free N-terminus. 
 
Scheme 120 Reagents and conditions: (i) Boc-(L)-Leu-OH, DCC, DMAP, CH2Cl2; (ii) TFA, CH2Cl2, 
0 °C 30 min. 
 
Continuing the synthesis from triamino acid 445, two steps are carried out; a coupling 
reaction to give 446 followed by deprotection to give the benzyl ester of tetra leucine, 
compound 447 (Scheme 120). 
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2.11.2. Coupling of protected hydroxy carboxylic acid to leucine 
tetramer 
To allow for synthesis of the centre phosphorus unit the molecule requires a hydroxyl 
group to be inserted. Following on from the earlier synthesis of 419 (Scheme 107), it is 
possible to use NaH, a strong base, to initiate benzylation of the alcohol instead of the 
carboxylic acid.  
 
Scheme 121 Reagents and conditions: (i) NaH, DMF 60 °C 1 h; (ii) BnBr (0 °C for addition) 60 °C 3 
h. 
The synthesis of the benzyl protected alcohol 448 that will be coupled to the tetramer of 
leucine is discussed in Scheme 121. The reaction converted diacid 416 to compound 
448. 
 
Scheme 122 Reagents and conditions: (i) 448, DCC, DMAP, CH2Cl2. 
 
Coupling of compound 448 to compound 447 was carried out using the same conditions 
for the stepwise chain extension (Scheme 122). The reaction afforded the desired 
dibenzyl protected pentamer product 449. 
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2.11.3. Deprotection of “pentamer” of leucine 
 
Scheme 123 Reagents and conditions: (i) Pd/C 5%, H2, EtOAc. 
 
The last step before addition of the phenyl phosphinate requires deprotection, which can 
be carried out by catalytic hydrogenation. Compound 449 was treated under 
hydrogenation conditions to form the fully deprotected “pentamer” 450 (Scheme 123).  
Unfortunately hydrogenation did not remove both of the protecting groups as planned; 
instead only one benzyl groups was removed, confirmed by mass spectroscopy. As both 
ends of “pentamer” could not be deprotected, the use of this “pentamer” had to be 
stopped and an alternate one synthesised. 
2.11.4. Alternative method for tetramer synthesis 
Whilst the stepwise elongation of the amino acid chain was suitable at first, the 
problems with deprotection required modifications to the synthesis. As all of tetramer 
446 was used for the formation of “pentamer” 449 it was not possible to carry out a 
transesterification, therefore it was necessary to begin the synthesis again. This time it 
was decided to divide the tetramer component synthesis into two parts to reduce the 
number of steps. 
The synthesis of the first part is discussed in Scheme 124. 
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Scheme 124 Reagents and conditions: (i) EtOH, DCC, DMAP; (ii) TFA, CH2Cl2, 0 °C 30 min; (iii) 
Boc-(L)-Leu-OH, DCC, DMAP, CH2Cl2. 
 
The synthesis began by protecting the carboxylic acid of Boc-(L)-Leu-OH 396 as an 
ethyl ester to give 451. Deprotection of the Boc group of 451 gave 452 which was then 
coupled with Boc-(L)-Leu-OH 396 to give 454, forming the first component. 
The second part (400) to be combined with 454 to form the tetramer was already 
discussed in Scheme 95.  
  
 
Scheme 125 Reagents and conditions: (i) DCC, DMAP, CH2Cl2; (ii) HBTU, Et3N, THF. 
Tetramer 455 (Scheme 125) is formed by coupling 400 and 454 using peptide coupling 
conditions to give the desired tetramer. 
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Scheme 126 Reagents and conditions: (i) TFA, CH2Cl2, 0 °C 30 min; (ii) 448, DCC, DMAP, CH2Cl2. 
The method for forming compound 457 is outlined in Scheme 126. As previously, 
formation of “pentamer” 457 requires removal of the Boc protecting group from 455, 
followed by coupling with 448. Due to time constraints the final step is pending, but 
once complete can be used to form the decamer compound. 
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2.12. Inhibition of cathepsin C 
 
Dipeptidyl Peptidase I (DPP-I aka cathepsin C) is a cysteine dipeptidyl aminopeptidase 
that is expressed in the lysosomes of several tissues, the highest level being in the lung, 
macrophages, neutrophils, CD8
+
 T cells and mast cells. The classification of DPP-I as 
part of the lysosomal papain-type cysteine proteinase family (which also includes 
cathepsins B, H, K, L, O, and S) is based on its localization in the cell, acidic pH 
optimum for enzyme activity, and conserved amino acid sequence with respect to the 
NH2-terminal and COOH-terminal regions that form the substrate-binding pocket of the 
enzyme.  
 
Figure 30 The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the 
inhibitor Gly-Phe-CHN2.
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DPP-I is an oligomeric protein (Figure 30) with exclusive exopeptidase activity, which 
is different from the other cathepsins (B, H, K, L, O, and S) that are monomeric proteins 
with endopeptidase activity. As well as this significant difference, the overall amino 
acid sequence homology of DPP-I shows relatively little similarity with the other 
members of this group of proteinases. It is the only cysteine proteinase that has so far 
been shown to exist in polymorphonuclear leukocytes (PMNL).
101
  PMNL are a 
category of granulocytes specifically neutrophil granulocytes.  These are white blood 
cells that have a lobed nucleus and granules in their cytoplasm. 
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Cathepsin C is thought to play an important role in intracellular protein degradation.  
The enzyme is responsible for the cleavage of two residues from the N- termini of 
proteins. It has a broad specificity and will continue cleaving residues until it finds a 
stop sequence, usually arginine or lysine in the N-terminal position (P2), proline on 
either side of the scissile bond ( P1 / P1’) or isoleucine (P1). The pro form contains the 
pro peptide and a catalytic region, which can be further processed into heavy/light 
chains that are linked by a disulfide bond.  
It has been shown that cathepsin C activates several chymotrypsin-like serine proteases 
by removing an amino-terminal dipeptide. In addition, cathepsin C is involved in the 
similar cleavages in several other proteases allowing for their full activation. These 
include cathepsin G1 (CG), proteinase-3 (Pr-3), neutrophil elastase (NE), granzymes A, 
B, C and mast cell chymase and tryptase.  
It is thought that serine proteases, and especially neutrophil elastase play a key role in 
inflammatory disease. This can be shown by the early onset of emphysema in patients 
deficient in plasma α1AT, the main neutrophil elastase inhibitor in the lung.  Similarly 
with cystic fibrosis, an excess of NE leads to inflammation and tissue destruction. 
Disturbance of the normal balance of enzymatic activity, which is in part affected by 
cathepsin C, may lead to many other pathological conditions, such as rheumatoid 
arthritis and osteoarthritis, cancer, neurological disorders, osteoporosis and lysosomal 
storage diseases.  
For example, it has been shown that in vitro, NE affects the levels of TNFα 102,103 and 
TGFα, and stimulates mucus secretion102. NE may potentiate the oncogenicity of PML-
RARα in acute promyelocytic leukaemia and in various other cancers.104; reviewed in 105) 
Another serine protease, mast cell tryptase, is thought to participate to asthma 
pathophysiology through its effect on bronchodilating peptides and protease activated 
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receptor-2 (PAR-2).
106,107
 CG and Pr-3 have distinct in vitro effects on cell signalling 
and cytokine and chemokine processing. CG modulates chemokine and reactive oxygen 
species release in murine PMN
108
, and activates PAR-4.
109
  
Clearly then, inhibition of cathepsin C will result in a reduced activity within several 
clinically important serine protease targets, and could possibly have greater efficacy that 
simply blocking individual serine proteases. This is of specific importance in complex 
inflammatory diseases such as chronic obstructive pulmonary disease (COPD).  
However, of the selective and potent cathepsin C inhibitors that have been found, most 
have a poor metabolic stability and are cytotoxic. A brief summary of the known 
inhibitors of cathepsin C are given below (Figure 31, Table 40 and Table 41). These 
include irreversible inhibitors (Figure 31), non-phosphorus containing pseudopeptides 
(Table 40) and phosphorus containing reversible inhibitors (Table 41). In particular, 
one of the potent, reversible inhibitors of DPPI is Leu-Leu-OMe 458. Based on this 
observation, we reasoned that Leu(P)-Leu-OMe (compound 426) and analogue 431 
should also be a potent reversible inhibitor.  
 
154 
 
 
Figure 31 Various inhibitors of cathepsin C currently known.  The activity ranges from >10 to 0.001 
M with Gly-4-(I)Phe-DMK.
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Inhibitor KM mM Inhibitor KM mM 
Gly-ΔE-Phe-Gly-Phe-pNA 3.2 Gly-Gly-ΔE-Phe-Phe-pNA 4.3 
Gly-ΔZ-Phe-Gly-Phe-pNA  7.8 Gly-Gly-ΔZ-Phe-Phe-pNA  7.8 
Gly-Phe-Gly-Phe-pNA 22.5 Gly-Gly-Phe-Phe-pNA Insoluble 
Gly-Phe-pNA 0.23   
Table 40 Various inhibitors of cathepsin C synthesised by Kafarski group.110 
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R Ki mM R Ki mM 
CH2CH(CH3)2 0.040 CH2CH(CH3)2 0.039 
Ph 0.188 Ph 0.176 
CH2Ph 0.514 CH2Ph 0.429 
CH2CH2Ph 0.312 CH2CH2Ph 0.187 
Table 41 Various cathepsin C inhibitors of synthesised by Kafarski group.
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Scheme 127 Reagents and conditions: (i) AcCl, MeOH, 0 °C; (ii) Boc-(L)-Leu-OH, DCC, DMAP, 
CH2Cl2; (iii) TFA, CH2Cl2, 0 °C 30 min.  
 
The synthesis of the target compound began with L-leucine, which was transformed into 
its methyl ester by treatment with acetyl chloride in methanol to give 460. Coupling of 
460 with Boc-(L)-Leu-OH using DCC and DMAP as coupling reagents gave the 
corresponding diamino acid 461. The final step towards the target compound involved 
deprotection of the amino acid using TFA to give the corresponding amine product 458. 
Both compounds 426 and 431 were tested in an enzyme hydrolysis assay. Action of the 
enzyme on Ala-Ala-pNA releases para-nitroaniline. The rate of the enzyme reaction 
was measured as the increase in the absorption of the reaction mixture at = 405 nm. 
Action of the enzyme on Ala-Ala-pNA both in the presence of the test compounds and 
reference (blank) were measure but no difference was found. Therefore, we concluded 
that neither 426 nor 431 are inhibitors of cathepsin C.  
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3. Chapter Three: Experimental 
Section 
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3.1. General methods and instrumentation 
Commercially available reagents were used as received without additional purification. 
All solvents were of reagent grade. Petroleum ether refers to the fraction of petroleum 
spirit boiling in the range of 60 to 80 °C. Where stated, mixtures of solvents are referred 
to as percentage volume to volume (v/v) ratios. 
Products were typically purified by column chromatography using Merck 9385 silica 
gel 60 (40-63 μm). Analytical thin layer chromatography (TLC) was conducted on 
Merck silica gel 60 F254 glass backed plates. Visualisation of the reaction components 
was accomplished by illumination under short wavelength (254 nm) ultraviolet light or 
using basic potassium permanganate (KMnO4) stain. 
Microanalyses were performed at the London Metropolitan University. All melting 
point (mp) values were determined on a Gallenkemp melting point apparatus and are 
stated uncorrected.  
Routine infrared (IR) spectra were recorded on a Perkin-Elmer FTIR spectrometer using 
sodium chloride plates or made using KBr discs. Spectra are reported in wavenumbers 
(cm
-1
) with the following abbreviations; strong (s), medium (m), weak (w) and broad 
(br). 
Proton Nuclear Magnetic Resonance (
1
H NMR) spectra were recorded using Bruker 
AMX400 (400 MHz) and JEOL ECA-600 (600 MHz) spectrometers as stated. Chemical 
shifts are reported in parts per million (, ppm) with internal reference to tetramethyl 
silane. Coupling constants (J) are expressed in Hertz (Hz) and spectra are reported with 
the following abbreviations; singlet (s), doublet (d), triplet (t), quartet (q), quintet 
(quint.), multiplet (m) and broad (br). 
Carbon Nuclear Magnetic Resonance (
13
C NMR) were performed on the same 
instruments operating at 101 and 150 MHz respectively. Phosphorus Nuclear Magnetic 
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Resonance (
31
P NMR) were performed on the same instruments operating at 162 and 
243 MHz respectively. Deuterated chloroform-d (CDCl3) was used as the NMR solvent 
unless otherwise stated. 
1
H-
1
H connectivities were determined using DQF COSY; 
1
H-
13
C 
1
JCH connectivities by 
HMQC and 
2
JCH and 
3
JCH using HMBC; 
1
H-
31
P 
2
JPH, 
3
JPH and 
4
JPH connectivities were 
determined using HOESY experiments. 
Routine mass spectra were run on a Micromass Quattro Ultima spectrometer in the 
electrospray ionisation (ESI), positive (+ve) or negative (-ve) mode as stated. High 
resolution mass spectrometry was performed at the National Mass Spectrometry Centre 
Swansea using MAT95 or MAT900 in the electrospray ionisation (ESI) mode.  
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3.2. Synthetic procedures 
Ethyl phenylphosphinate 320 
 
Pyridine (12.8 ml, 158 mmol) was slowly added to a vigorously stirred solution of ethyl 
chloroformate (16 ml, 100 mmol) and compound 322 (22.4 g 157 mmol) in chloroform 
(350 ml) at room temperature. (Caution! Exothermic Reaction; Rapid Effervescence.)  
Once the effervescence had stopped, the solution was stirred in a 40 
o
C water bath for 
15 min.  The solution was poured into 0.1M HCl (aq) (60 ml) and the organic layer was 
extracted.  The organic extracts were washed with water (60 ml) and then dried over 
Na2SO4.  The solvent was removed in vacuo to give the title compound as a colourless 
oil (30 g, quantitative yield). 
νmax/cm
-1
 1000-1300 CO, 1653-2102 P=O, 2843-3600 CH  
P (162 MHz, CDCl3) 24.54 
H (400 MHz, CDCl3) 1.33 (3H, t, J 7.1, OCH2CH3), 4.04-4.20 (2H, m, OCH2CH3), 
7.44-7.49 (2H, m, Ar H). 7.54 (1H, d, JP 563.0, PH), 7.53-7.58 (1H, m, Ar H), 7.71-7.78 
(2H, m, Ar H). 
C (101 MHz, CDCl3) 16.74 (d, JP 6.5, OCH2CH3), 62.67 (d, JP 6.4, OCH2CH3), 129.20 
(d, JP 13.9, Ar CH), 131.33 (d, JP 11.9, Ar CH), 131.52 (d, JP 123.1, Ar CH), 133.59 (d, 
JP 3.0, Ar CH). 
LRMS m/z (ESI) 363.1 [M2+H]
+
, 193 [M+Na]
+
, 171 [M+H]
+
. 
HRMS (ESI) calcd. for C8H11O2PNa 193.0394, found 193.0391 [M+Na]
+
. 
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Benzyl phenylphosphinate 321  
 
Pyridine (5.6 ml, 70 mmol) was slowly added to a vigorously stirred solution of benzyl 
chloroformate (8.3 ml, 58 mmol) and compound 322 (10 g, 7 mmol) in dichloromethane 
(150 ml) at room temperature. (Caution! Exothermic process; Rapid Effervescence). 
Once the effervescence had stopped, the solution was left stirring in a water bath at 40 
o
C for 15 min.  The solution was poured into 0.1M HCl (aq) (60 ml) and the organic 
layer was extracted.  The organic extracts were washed with water (80 ml), and then 
dried over Na2SO4.  The solvent was removed in vacuo to give the title compound (12 g, 
quant. yield) as a colourless oil. 
νmax/cm
-1
 1035-2526 P=O, 2833-3305 CH 
P (162 MHz, CDCl3) 24.99 
H (400 MHz, CDCl3) 5.12 (1H, q, J 12.0, OCH2Ar), 5.13 (1H, q, J 12.0, OCH2Ar), 
7.28-7.48 (5H, m, Ar H), 7.50-7.52 (2H, m, Ar H), 7.58-7.61 (1H, m, Ar H), 7.65 (1H, 
d, JP  566.0, PH), 7.77-7.83 (2H, m, Ar H). 
C (101 MHz, CDCl3) 65.55 (OCH2Ar), 128.16 (d, JP 135.2, Ar C), 128.20 (d, JP 140.0, 
Ar C), 129.07 (d, JP 17.4, Ar CH), 129.19 (d, JP 18.0, Ar CH), 131.13 (d, JP 12.1, Ar 
CH), 131.45 (d, JP 12.0, Ar CH), 133.22 (d, JP 2.9, Ar CH), 133.70 (d, JP 3.0, Ar CH). 
LRMS m/z (ESI) 487.1 [M2+Na]
+
,  339.1 [M+Na]
+
, 233 [M+H]
+
.  
HRMS (ESI) calcd. for C13H13O2PNa 255.0550, found 255.0550 [M+Na]
+
. 
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Ethyl (1-hydroxy-2-methylpropyl)(phenyl)phosphinate 337
111
 
 
Compound 320 (20 g, 118 mmol) was mixed with isobutyraldehyde (11.8 ml, 129 
mmol).  KF (60 g, 689 mmol) was added and the mixture was left to stir overnight.  
dichloromethane (80 ml) was added and the reaction was allowed to stir for 30 min.  KF 
was filtered off through celite and the solvent was removed in vacuo. The residue was 
subjected to column chromatography (EtOAc : Pet. Ether 3:1 - 1:1) to give the title 
compound as a colourless oil (28.6 g, 118 mmol, quant. yield), a mixture of two 
diastereomers. 
νmax/cm
-1 
3263, 2856-2963, 1714, 1592, 1468, 1438, 1390, 1366, 1338, 1236, 1190, 
1118, 1097, 1020. 
P (162 MHz, CDCl3) 40.22, 40.24. 
H (400 MHz, CDCl3) 1.00 (3H, d, J 6.7, CH3), 1.01 (3H, d, J 6.7, CH3), 1.03 (3H, d, J 
6.6, CH3), 1.06 (3H, d, J 6.7, CH3), 1.32 (3H, t, J 7.1, OCH2CH3), 1.33 (3H, t, J 7.1, 
OCH2CH3), 1.90-1.98 (1H, m, CHMe2), 2.00-2.12 (1H, m, CHMe), 3.75 (1H, dd, J 3.7, 
4.7, PCH), 3.77 (1H, dd, J 4.6, 5.8, PCH), 3.87-4.03 (2H, m, OCH2CH3), 4.08-4.21 (2H, 
m, OCH2CH3), 7.46-7.51 (4H, m, Ar H), 7.55-7.60 (2H, m, Ar H), 7.81-7.87 (4H, m, Ar 
H).  
C (101 MHz, CDCl3) 16.53 (d, JP 6.0, OCH2CH3), 16.60 (d, JP 6.0, OCH2CH3), 17.32 
(d, JP 6.0, CH3),  17.97 (d, JP 7.3, CH3),  20.17 (d, JP 8.2, CH3),  20.28 (d, JP 10.2, CH3),  
29.40 (d, JP 3.9, CHMe2), 29.59 (d, JP 3.0, CHMe2), 61.15 (d, JP 7.2, OCH2CH3), 61.28 
(d, JP 7.0, OCH2CH3), 74.44 (d, JP 113.8, PCH), 75.13 (d, JP 110.1, PCH), 128.47 (d, JP 
12.1, Ar CH), 128.52 (d, JP 12.1, Ar CH), 128.71 (d, JP 118.6, Ar C), 129.36 (d, JP 
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118.9, Ar C), 132.26 (d, JP 9.5, Ar CH), 132.41 (d, JP 9.5, Ar CH), 132.54 (d, JP 2.7, 2 x 
Ar CH).  
LRMS m/z (ESI) 265.2 [M+Na]
+
, 243.2 [M+H]
+
.  
HRMS (ESI) calcd. for C12H20O3P 243.1145, found 243.1142 [M+H]
+
. 
Ethyl (hydroxy(phenyl)methyl)(phenyl)phosphinate 338  
 
Compound 320 (10 g, 60 mmol) was mixed with benzaldehyde (6 ml, 60 mmol).  KF 
(20 g) was added and the mixture was left to stir overnight.  dichloromethane (80ml) 
was added and the reaction was allowed to stir for 30 min.  KF was filtered off using 
celite and the solvent was removed in vacuo to give the title compound as a white solid, 
a mixture of diastereomers. (16 g, 97% crude yield). Recrystallisation of the solid 
diastereomers using EtOAc afforded two products.  
Diastereomer 1 (338a) (1.0 g, 6% yield):  
mp 119-121 
o
C. 
νmax/cm
-1
 1000-1491 P=O, 2800-3058 CH, 3264 OH 
P (243 MHz, CDCl3) 39.34 
H (600 MHz, CDCl3) 1.32 (3H, t, J 7.1, CH3), 3.95-4.01 (1H, m, OCH2), 4.11-4.17 
(1H, m, OCH2CH3), 4.28 (1H, br s, OH), 5.17 (1H, d, J 11.0, PCH), 7.20-7.22 (5H, m, 
Ar H), 7.30-7.32 (2H, m, Ar H), 7.42-7.44 (2H, m, Ar H), 7.46-7.49 (1H, m, Ar H). 
C (151 MHz, CDCl3) 16.62 (d, JP 6.0, OCH2CH3), 61.95 (d, JP 7.2, OCH2CH3), 73.34 
(d, JP 110.7, PCH), 127.04 (d, JP 122.83, Ar C), 127.05 (d, JP 5.0, Ar CH), 127.86 (d, JP 
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3.3, Ar CH), 128.03 (d, JP 2.7, Ar CH), 128.13 (d, JP 12.4, Ar CH), 132.61 (d, JP 2.8, Ar 
CH), 132.97 (d, JP 9.2, Ar CH), 136.38 (d, JP 1.1, Ar C). 
LRMS m/z (ESI) 277.0 [M+H]
+
.  
Diastereomer 2 (338b) (1.2 g, 7% yield):  
mp 101-104 
o
C. 
νmax/cm
-1
 1000-1500 P=O, 2850-3059 CH, 3263 OH 
P (243 MHz, CDCl3) 37.98. 
H (600 MHz, CDCl3) 1.26 (3H, t, J 7.1, CH3), 4.03-4.09 (1H, m, OCH2), 4.11-4.16 
(1H, m, OCH2CH3), 4.3 (1H, br s, OH), 5.10 (1H, d, J 7.5, PCH), 7.20-7.23 (5H, m, Ar 
H), 7.29-7.31 (2H, m, Ar H), 7.51-7.53 (2H, m, Ar H), 7.62-7.63 (1H, m, Ar H). 
C (151 MHz, CDCl3) 16.58 (d, JP 5.8, OCH2CH3), 61.78 (d, JP 6.9, OCH2CH3), 73.68 
(d, JP 110.2, PCH), 127.38 (d, JP 5.2, Ar CH), 127.80 (d, JP 3.2, Ar CH), 127.98 (d, JP 
2.7, Ar CH), 128.11 (d, JP 124.2, Ar C), 128.32 (d, JP 12.4, Ar CH), 132.59 (d, JP 2.9, 
Ar CH), 133.00 (d, JP 9.2, Ar CH), 136.17 (d, JP 1.6, Ar C). 
LRMS m/z (ESI) 277.0 [M+H]
+
.  
Ethyl (1-hydroxy-3-methylbut-2-en-1-yl)(phenyl)phosphinate 340 
 
Compound 320 (15 g, 88 mmol) was mixed with 3-methyl-2-butenal (8.5 ml, 88 mmol). 
KF (30 g) was added and the mixture was stirred until it was completely solid.  
dichloromethane (80 ml) was added and the reaction was allowed to stir for 30 min.  KF 
was filtered off through celite and the solvent was removed in vacuo.  Recrystallisation 
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using EtOAc gave the title compound as colourless crystals (First crop 6.0 g, 27%).  
Diastereomer 1 (340a) (Crystalline): 
mp 113-115 °C. 
Found: C, 61.40; H, 7.60; C13H19O3P requires C, 61.41; H, 7.53;  
νmax/cm
-1
 3273 (OH), 2950-2848 (CH), 1440, 1226, 1211, 1163, 1121, 1051 (P=O) 
P (162 MHz, CDCl3) 38.77 
H (400 MHz, CDCl3) 1.35 (3H, t, J 7.0, OCH2CH3), 1.47 (3H, d, J 4.0, CH3), 1.69 (3H, 
d, J 4, CH3), 3.90-3.93 (1H, t, JP 6.0, OH), 4.00-4.11 (1H, m, OCH2CH3), 4.17-4.26 
(1H, m, OCH2CH3), 4.73 (1H, ddd, J 4.0, 6.0, JP 10.0, PCH), 5.13-5.16 (1H, m, 
CH=CMe2), 7.44-7.58 (3H, m, Ar H), 7.75-7.80 (2H, m, Ar H). 
C (101 MHz, CDCl3) 17.0 (d, JP 5.0, OCH2CH3), 18.9 (d, JP 3.0, CH3), 26.3 (d, JP 3.0, 
CH3), 62.04 (d, Jp 7.0, OCH2CH3), 68.8 (d, JP 116.0, PCH), 120.13 (=CMe2), 128.9 (d, 
Jp 121.0, Ar C), 128.7 (d, JP 12.0, Ar CH), 132.8 (d, JP 3.0, Ar CH), 133.1 (d, JP 10.0, 
Ar CH), 139.1 (d, JP 13.0, CH=CMe2), 139.43 (=CMe2). 
LRMS m/z (ESI) 254 [M+H]
+
.  
HRMS (ESI) calcd. for C13H19O3PNa 277.0964, found 277.0968 [M+Na]
+
. 
Diastereomer 2 (340b) (Oil): 
νmax/cm
-1
 3275 (OH), 2954-2854 (CH), 1450, 1377, 1226, 1214, 1160, 1055 (P=O) 
P (162 MHz, CDCl3) 38.25 
H (400 MHz, CDCl3) 1.35 (3H, t, J 6.5, OCH2CH3), 1.50 (3H, d, J 4.0, CH3), 1.76 (3H, 
d, J 4.0, CH3), 3.23 (1H, br s, OH), 4.03-4.13 (1H, m, OCH2CH3), 4.16-4.25 (1H, m, 
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OCH2CH3), 4.72 (1H, dd, J 3.5, JP 9.60, PCH), 5.24-5.28 (1H, m, CH=CMe2), 7.47-
7.50 (2H, m, Ar H), 7.55-7.57 (1H, m, Ar H), 7.80-7.85 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.59 (d, JP 5.8, OCH2CH3), 18.54 (d, JP 1.6, CH3), 26.01 (d, JP 
2.1, CH3), 61.66 (d, JP 7.1, OCH2CH3), 68.42 (d, JP 115.3, PCH), 119.04 (=CMe2), 
128.74 (d, JP 121.7, Ar C), 128.32 (d, JP 12.0, Ar CH), 128.39 (d, JP 12.0, Ar CH), 
132.43 (d, JP 9.3, Ar CH), 139.69 (d, JP 11.3, CH=CMe2), 139.81 (=CMe2). 
LRMS m/z (ESI) 254 [M+H]
+
.  
HRMS (ESI) calcd. for C13H19O3PNa 277.0964, found 277.0966 [M+Na]
+
. 
Benzyl (1-hydroxy-3-methylbut-2-en-1-yl)(phenyl)phosphinate 341 
 
Compound 320 (12.85 g, 55 mmol) was mixed with 3-methyl-2-butenal (5.4 ml, 56 
mmol).  KF (24 g) was added and the mixture was left to stir overnight.  
dichloromethane (80 ml) was added and the reaction was allowed to stir for 30 min.  KF 
was filtered off through celite and the solvent was removed in vacuo.  The product was 
a mixture of two diastereomers, both solids.  Recrystallisation using diethyl ether gave 
the title compound as white crystals.  
Diastereomer 1 (341a) (2.33 g, 13% yield): 
mp 120-125 
o
C. 
νmax/cm
-1
 1025-1669 P=O, 2853-2924 CH, 3233 OH 
P (162 MHz, CDCl3) 38.86 
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H (400 MHz, CDCl3) 1.50 (3H, d, J 4.0, CH3), 1.75 (3H, d, J 4.0, CH3), 2.96 (1H, dd, J 
4.7, 6.0, OH), 4.77 (1H, dt, J 4.0, JP 9.5, PCH), 5.00 (1H, dd, J 6.7, 11.8, OCH2Ph), 
5.20 (1H, dd, J 6.7, 11.8, OCH2Ph), 5.25-5.29 (1H, m, CH=CMe2), 5.25-5.29 (1H, m, 
OCH2Ph), 7.33-7.39 (5H, m, Ar H), 7.46-7.51 (2H, m, Ar H), 7.57-7.61 (1H, m, Ar H), 
7.82-7.87 (2H, m, Ar H). 
C (101 MHz, CDCl3) 18.97 (d, JP 1.7, CH3), 26.31 (d, JP 2.1, CH3), 67.17 (d, JP 7.0, 
CH2Ar), 69.03 (d, JP 115.0, PCH), 120.01 (d, JP 2.6, Ar C), 128.74 (d, JP 12.7, Ar CH), 
128.46 (d, JP 39.7, Ar CH), 128.58 (d, JP 120.8, Ar C), 128.80 (d, JP 23.2, Ar CH), 
128.87 (d, JP 10.5, Ar CH), 132.97 (d, JP 2.6, Ar CH), 133.11 (d, JP 9.3, Ar CH). 
LRMS m/z (ESI) 339.1 [M+Na]
+
.  
HRMS (ESI) calcd. for C18H21O3PNa 339.1126, found 339.1116 [M+Na]
+
. 
Diastereomer 2 (341b) (1.8 g, 10% yield): 
mp 105-110 
o
C. 
νmax/cm
-1
 1083-1668 P=O, 2853-2922 CH, 3283 OH 
P (162 MHz, CDCl3) 39.53 
H (400 MHz, CDCl3) 1.47 (3H, d, J 4.0, CH3), 1.70 (3H, d, J 4.0, CH3), 2.83 (1H, dd, J 
5.5, 6.1, OH), 4.78 (1H, dt, J 4.0, JP 9.6, PCH), 5.00 (1H, dd, J 6.8, 11.8, OCH2Ph), 
5.14-5.18 (1H, m CH=CMe2), 5.22 (1H, dd, J 6.7, 11.8, OCH2Ph), 7.32-7.40 (5H, m, Ar 
H), 7.45-7.50 (2H, m, Ar H), 7.56-7.60 (1H, m, Ar H), 7.78-7.83 (2H, m, Ar H). 
C (101 MHz, CDCl3) 19.00 (d, JP 1.6, CH3), 26.42 (d, JP 2.0, CH3), 67.09 (d, JP 6.7, 
CH2Ar), 68.95 (d, JP 115.0, PCH), 119.22 (d, JP 2.8, Ar C), 128.47 (d, JP 41.7, Ar CH), 
128.74 (d, JP 8.0, Ar CH), 128.83 (d, JP 121.7, Ar C), 128.86 (d, JP 14.1, Ar CH), 
128.94 (d, JP 1.9, Ar CH), 132.87 (d, JP 8.4, Ar CH), 133.03 (d, JP 2.8, Ar CH). 
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LRMS m/z (ESI) 339.1 [M+Na]
+
.  
HRMS (ESI) calcd. for C18H21O3PNa 339.1126, found 339.1123 [M+Na]
+
. 
1-(ethoxy(phenyl)phosphoryl)-2-methylpropyl acetate 342
111
 
 
Acetic anhydride (0.44 ml, 5 mmol), was added to a stirred solution of compound 337 
(1.01 g, 4 mmol) in dichloromethane (20 ml) maintained at 0
 
°C.  The solution was 
allowed to stir for 1 h and monitored by TLC. On completion of the reaction the solvent 
was removed in vacuo.  The reaction mixture diluted with dichloromethane, poured into 
water (50 ml) and the organic layer was extracted with dichloromethane (2 x 25 ml).  
The combined organic extracts were washed with saturated NaHCO3, followed by brine 
and then dried over Na2SO4 and stripped of solvent in vacuo. The residue was subjected 
to chromatography (EtOAc : Pet. Ether 5:1 - 2:1) to give the title compound (1.18 g, 4 
mmol, quant. yield) a mixture of diastereomers as a colourless oil. 
νmax/cm
-1 
3264, 2865-2962, 1747, 1592, 1468, 1439, 1390, 136,7 1191, 1119, 1025. 
P (162 MHz, CDCl3) 40.30, 40.32. 
H (400 MHz, CDCl3) 1.00 (6H, d, J 6.7, CH3), 1.02 (3H, d, J 6.2, CH3), 1.06 (3H, d, J 
6.7, CH3), 1.32 (3H, t, J 7.1, OCH2CH3), 1.33 (3H, t, J 7.1, OCH2CH3), 1.45 (6H, s, 
COCH3), 1.87-1.99 (1H, m, CHMe2), 2.02-2.14 (1H, m, CHMe2), 3.74-3.78 (2H, m, 2 x 
PCH), 3.89-4.03 (2H, m, OCH2CH3), 4.10-4.21 (2H, m, OCH2CH3), 7.46-7.51 (4H, m, 
Ar H), 7.55-7.59 (2H, m, Ar H), 7.82-7.86 (4H, m, Ar H).  
C (101 MHz, CDCl3) 16.53 (d, JP 5.9, OCH2CH3), 16.56 (d, JP 5.8, OCH2CH3), 17.32 
(d, JP 5.9, CH3), 17.96 (d, JP 7.4, CH3), 20.17 (d, JP 9.9, CH3), 20.27 (d, JP 10.3, CH3), 
29.40 (d, JP 4.0, CH3), 29.59 (d, JP 2.9, CH3), 61.19 (d, JP 7.2, OCH2CH3), 61.31 (d, JP 
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7.0, OCH2CH3), 74.99 (d, JP 113.7, PCH), 75.68 (d, JP 110.0, PCH), 128.48 (d, JP 12.1, 
Ar CH), 128.59 (d, JP 12.1, Ar CH), 129.28 (d, JP 119.1, Ar C), 129.32 (d, JP 119.1, Ar 
C), 132.26 (d, JP 9.5, Ar CH), 132.39 (d, JP 9.7, Ar CH), 132.46 (d, JP 3.0, Ar CH), 
132.55 (d, JP 2.7, Ar CH), 149.93 (CCO2), 150.04 (CCO2). 
LRMS m/z (ESI) 285.3 [M+H]+, 243.2 [M-Ac+H]+.  
 (Z)-ethyl (3-methylbuta-1,3-dien-1-yl)(phenyl)phosphinate 344 
 
Acetic anhydride (0.4 ml, 4 mmol ) followed by sulphuric acid ( 0.02 ml, 0.4 mmol ) 
were added to a stirred solution of compound 340a (1.012 g, 4 mmol ) in 
dichloromethane (150 ml) maintained at 0 ºC.  On completion of the reaction the 
reaction mixture was poured into saturated NaHCO3 (50 ml) and the organic layer was 
separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  The combined 
organic extracts were washed with brine and then dried over Na2SO4, stripped of solvent 
in vacuo. The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to 
give the title compound (0.9 g, 3.8 mmol, 95% yield) as a colourless oil. 
νmax/cm
-1
 2860-2957 1641 1553 1432 1388 1369 1277 1198 1133 1119 
P (162 MHz, CDCl3) 31.49 
H (400 MHz, CDCl3) 1.27 (3H, t, J 7.1, OCH2CH3), 1.79 (3H, s, CH3), 3.87-3.97 (1H, 
m, OCH2CH3), 3.98-4.10 (1H, m, OCH2CH3), 5.23 (2H, s, CH2), 5.84 (1H, dd, J 17.2, 
JP 20.6, CH= CHMe2), 7.09  (1H, dd, J 17.3, JP 20.2, CH=CHMe2), 7.38-7.43 (2H, m, 
Ar H), 7.45-7.50 (1H, m, Ar H), 7.71-7.77 (2H, m, Ar H). 
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C (101 MHz, CDCl3) 16.55 (d, JP 6.6, OCH2CH3), 17.84 (CH3), 60.75 (d, JP 5.7, 
OCH2CH3), 118.30 (d, JP 139.4, C=), 123.67 (CH2), 127.81 (d, JP 120.2, Ar C), 128.56 
(d, JP 12.9, Ar CH), 131.46 (d, JP 10.0, Ar CH), 132.12 (d, JP 2.8, Ar CH), 150.18 (d, JP 
5.3, =C). 
LRMS m/z (ESI) 237.2 [M+H]
+
 
Ethyl (1-hydroxy-3-methylbutyl)(phenyl)phosphinate 347  
 
A mixture of compound 340a (10.28 g, 40 mmol) and 10% Pd/C (2 g, 20% wt) in 
EtOAc (200 ml) was stirred under a hydrogen atmosphere overnight.  The catalyst was 
filtered off using celite and the solvent was removed in vacuo to give the title compound 
as a white solid (10.36 g, 40 mmol, quant. yield).   
mp 96-98 °C. 
Found: C, 60.98; H, 8.10. C13H21O3P requires C, 60.93; H, 8.26.  
νmax/cm
-1
 3259 (OH), 3062-2869 (CH), 1592, 1469, 1439, 1389, 1210 (P=O) 
P (162 MHz, CDCl3) 40.49. 
H (400 MHz, CDCl3) 0.88 (3H, d, J 6.6, CH3), 0.93 (3H, d, J 6.7, CH3), 1.35 (3H, t, J 
7.1, OCH2CH3), 1.40-1.45 (1H, m, CH2CHMe2),  1.44-1.60 (1H, m, CH2CHMe2), 1.85-
1.93 (1H, m, CHMe2), 2.49 (1H, m, OH), 3.98-4.08 (2H, m, PCH and OCH2CH3), 4.08-
4.26 (1H, m, OCH2CH3), 7.43-7.73 (3H, m, Ar H), 7.75-7.85 (2H, m, Ar H). 
C (101 MHz, CDCl3) 15.6 (d, JP 5.0, OCH2CH3), 20.0 (CH3), 22.1 (CHMe2), 22.53 
(CH3), 38.4 (CH2), 60.4 (d, JP 7.0, OCH2CH3), 67.3 (d, JP 114.0, PCH), 127.3 (d, JP 
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119.0, Ar C), 127.5 (d, JP 12.0, Ar CH), 131.6 (d, JP 9.0, Ar CH), 132.8 (d, JP 3.0, Ar 
CH). 
LRMS m/z (ESI) 257 [M+H]
+
.  
HRMS (ESI) calcd. for C13H21O3PNa 279.1121, found 279.1125 [M+Na]
+
. 
 (4-Methoxy-benzyl)-[3-methyl-but-ylidene]-amine 348 
 
Isovaleraldehyde (6.4 ml, 60 mmol), and p-methoxy benzylamine (7.8 ml, 60 mmol), 
were added to toluene (100 ml) and heated under reflux overnight, using Dean-Stark 
apparatus.  Once the reaction was complete the solvent was removed in vacuo to give 
the title compound (12 g, quant. yield) as a yellow oil which was used immediately in 
the next step without further purification. 
H (400 MHz, CDCl3) 0.94 (3H, d, J 7.0, CH3), 0.98 (3H, d, J 7.0, CH3), 1.84 (1H, m, 
CHMe2), 2.45 (2H, m, CH2
i
Pr), 3.85 (3H, s, COCH3), 4.59 (2H, s, CH2Ph), 5.15 (1H, m, 
CH), 6.7-7.25 (5H, m, (MeO)Ar H). 
C (101 MHz, CDCl3) 22.88 (CH3), 22.95 (CH3), 26.75 (CHMe2), 44.90 (CH2), 50.24 
(CH2Ar), 57.32 (OCH3), 11456-13288 (Ar CH), 155.42 (Ar C), 160.54 (=CH). 
LRMS m/z (ESI) 206.2 [M+H]
+
.
 
 (E)-N-(2-methylpropylidene)-1-phenylmethanamine 349 
 
Benzylamine (5.0 g, 47 mmol), and isovaleraldehyde (3.9 g, 48 mmol), were added to 
toluene (100ml) and the resulting solution was heated under reflux overnight, while 
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water was removed by a using Dean-Stark apparatus.  Once the reaction was complete 
the solvent was removed in vacuo to give the title compound as a yellow oil. (7.0 g, 43 
mmol, 92% yield) which was used immediately in the next step without further 
purification. 
H (400 MHz, CDCl3) 1.06 (6H, d, J 7.0, CH3), 2.50 (1H, m, CHMe2), 4.55 (2H, s, 
CH2Ph), 7.21-7.37 (5H, m, Ar H), 7.43 (1H, d, J 5, CHCHMe2). 
C (101 MHz, CDCl3) 21.7 (CH3), 24.6 (CHMe2), 36.5 (CHMe2), 67.0 (CH2Ph), 129.10 
(Ar CH), 130.21 (Ar CH), 130.80 (Ar CH), 130.92 (Ar CH), 141.65 (Ar CH), 173.40 
(=CH);   
LRMS m/z (ESI) 162 [M+H]
+
. 
 [1-(4-Methoxy-benzylamino)-3-methyl-butyl]-phenyl-phosphinic acid ethyl ester 
350 
  
Triethylamine (7.7 ml, 55 mmol) was added to a stirred solution of compound 320 (8.5 
g, 50 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (6.95 ml, 55 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. Imine 
348 (10.8 g, 53 mmol) was added and the reaction mixture was left to warm up to room 
temperature overnight under a dry nitrogen atmosphere.   Once the reaction was 
complete the reaction mixture was poured into water (50 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
The residue was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 2:1) to give a 
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diastereomeric mixture of the title compound (18.8 g, 50 mmol, quant. yield), as a 
colourless oil. 
νmax/cm
-1 
2868-2957 1611 1514 1465 1438 1249 1178 1120 1022  
P (162 MHz, CDCl3) 44.05, 44.29  
H (400 MHz, CDCl3) 0.63 (3H, d, J 6.5, CH3), 0.75 (3H, d, J 6.5, CH3), 0.80 (3H, d, J 
6.7, CH3), 0.87 (3H, d, J 6.6, CH3), 1.31 (3H, t, J 5.4, OCH2CH3), 1.33 (3H, t, J 5.4, 
OCH2CH3), 1.36-1.44 (2H, m, CH2
i
Pr), 1.56-1.62 (2H, m, CH2
 i
Pr), 1.71-1.84 (2H, m, 
2x CHMe2), 2.99-3.06 (2H, m, 2x NHCH), 3.69 (2H, d, J 1.6, CH2Ar), 3.76 (3H, s, 
COCH3), 3.78 (3H, s, COCH3), 3.88 (2H, d, J 12.0, CH2Ar), 3.86-3.93 (2H, m, 
OCH2CH3), 4.06-4.17 (2H, m, OCH2CH3), 6.76 (2H, d, J 8.5, (MeO)Ar H), 6.82 (2H, d, 
J 8.4, (MeO)Ar H), 7.04 (2H, d, J 7.4, (MeO)Ar H), 7.22 (2H, d, J 8.4, (MeO)Ar H), 
7.45-7.49 (4H, m, Ar H), 7.53-7.57 (2H, m, Ar H), 7.78-7.85 (4H, m, Ar H).  
C (101 MHz, CDCl3) 16.70 (d, JP 6.3, OCH2CH3), 16.78 (d, JP 6.1, OCH3), 21.28 
(CH3), 21.61 (CH3), 23.48 (CH3), 23.50 (CH3), 24.43 (d, JP 11.6, CHMe2), 24.62 (d, JP 
10.7, CHMe2) 38.20 (CH2), 38.51 (CH2), 51.72 (CH2NAr), 51.75 (CH2NAr), 53.74 (d, 
JP 37.2, NHCH), 54.46 (d, JP 32.6, NHCH), 55.38 (OCH3), 55.40 (OCH3), 60.94 (d, JP 
7.3, OCH2CH3), 60.98 (d, JP 7.3, OCH2CH3), 113.75 (2x MeOAr CH), 113.80 (2x 
MeOAr CH), 128.28 (d, JP 13.3, Ar CH), 128.56 (d, JP 11.9, Ar CH), 128.65 (d, JP 11.8, 
Ar CH), 129.70 (2x MeOAr CH), 129.88 (2x MeOAr CH), 130.87 (d, JP 111.5, Ar C), 
130.89 (d, JP 111.2, Ar C), 132.35 (d, JP 2.8, Ar CH), 132.40 (d, JP 2.8, Ar CH), 132.49 
(d, JP 9.3, Ar CH), 132.71 (d, JP 9.3, Ar CH), 158.81 (MeOAr C), 158.86 (MeOAr C). 
LRMS m/z (ESI) 376.3 [M+H]
+
. 
HRMS calcd. for C21H31O3NP 376.2036, found 376.2029 [MH
+
]. 
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(1-Benzylamino-2-methyl-propyl)-phenyl-phosphinic acid ethyl ester 351 
 
Triethylamine (18 ml, 130 mmol) was added to a stirred solution of compound 320 (20 
g, 118 mmol) in dichloromethane (200 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (16.5 ml, 130 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. Imine 
349 (19 g, 118 mmol) was added and the stirred reaction mixture was left to warm up to 
room temperature overnight under a dry nitrogen atmosphere. Once the reaction was 
complete the reaction mixture was poured into water (50 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over MgSO4 and stripped of solvent in vacuo to 
give the crude title compound (37.08 g, 112 mmol, 95% crude yield).  Recrystallisation 
using EtOAc gave colourless crystals.  
Diastereomer 1 (351a) (Crystal) (7 g, 18% yield). 
mp 100-103 °C. 
νmax/cm
-1 
3281 3058 2861-2972 1603 1590 1496 1461 1451 1435 1389 1374 1364 1216 
1165 1116 1093 1070 1024 
P (243 MHz, CDCl3) 45.12 
H (600 MHz, CDCl3) 0.91 (3H, d, J 6.8, CH3), 0.94 (3H, d, J 6.8, CH3), 1.32 (3H, t, J 
7.0, OCH2CH3), 1.82-1.89 (2H, m, CHMe2 + NH), 2.84 (1H, dd, J 3.1, 9.9, NHCH), 
3.79-3.86 (1H, m OCH2CH3), 3.90 (2H, dd, J 12.8, 43.6, CH2Ar), 4.09-4.16 (1H, m, 
OCH2CH3), 7.21-7.25 (1H, m, Ar H), 7.27-7.29 (4H, m, Ar H), 7.45-7.48 (2H, m, Ar 
H), 7.53-7.56 (1H, m, Ar H), 7.78-7.82 (2H, m, Ar H). 
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C (151 MHz, CDCl3) 16.83 (d, JP 6.3, OCH2CH3), 17.35 (d, JP 2.8, CH3) 21.49 (d, JP 
14.1, CH3), 28.46 (d, JP 8.3, CHMe2) 53.88 (d, JP 3.9, CH2Ar), 60.52 (d, JP 7.5, 
OCH2CH3) 61.73 (d, JP 100.2, PCH), 127.10 (Ar CH), 128.30 (Ar CH), 128.65 (d, JP 
11.9, Ar CH), 128.67 (Ar CH), 131.2 (d, JP 111.0, Ar C), 132.22 (d, JP 2.9, Ar CH), 
132.33 (d, JP 9.6, Ar CH), 140.46 (Ar C). 
LRMS m/z (ESI) 332.17 [M+H]
+
.  
HRMS (ESI) calcd. for C19H27O2NP 332.1774, found 332.1779 [M+H]
+
. 
Diastereomer 2 (351b) (Oil) (10 g, 30% yield): 
νmax/cm
-1 
3316 3282 3054 2872-2959 1603 1495 1454 1436 1389 1374 1322 1281 1228 
1192 1127 1047 1024 
P (243 MHz, CDCl3) 42.15 
H (600 MHz, CDCl3) 0.93 (3H, d, J 6.9, CH3), 0.98 (3H, d, J 6.8, CH3), 1.21 (3H, t, J 
7.1, OCH2CH3), 2.18-2.28 (2H, m, CHMe2), 2.75-2.79 (1H, m, PCH), 3.70-3.78 (1H, m 
OCH2CH3), 3.84 (2H, dd, J 10.3, 28.8, CH2Ar), 3.96-4.09 (1H, m, OCH2CH3), 6.94-
6.96 (1H, m, Ar H), 7.10-7.12 (2H, m, Ar H), 7.21-7.23 (2H, m, Ar H), 7.38-7.42 (2H, 
m, Ar H), 7.45-7.50 (1H, m, Ar H), 7.71-7.79 (2H, m, Ar H). 
C (151 MHz, CDCl3) 16.55 (d, JP 6.2, OCH2CH3), 18.15 (d, JP 3.8, CH3) 21.35 (d, JP 
11.4, CH3), 28.36 (d, JP 8.1, CHMe2), 53.63 (d, JP 5.7 CH2Ar), 60.57 (d, JP 7.6, CH2), 
60.89 (d, JP 108.3, PCH), 126.92 (Ar CH), 128.10 (Ar CH), 128.34 (Ar CH), 128.46 (d, 
JP 11.8, Ar CH), 131.09 (d, JP 111.6, Ar C), 132.05 (d, JP 2.7, Ar CH), 132.42 (d, JP 9.5, 
Ar CH), 139.87 (Ar C). 
LRMS m/z (ESI) 332.17 [M+H]
+
.  
HRMS (ESI) calcd. for C19H27O2NP 332.1774, found 332.1779 [M+H]
+
. 
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Toluene-4-sulfonic acid 1-(ethoxy-phenyl-phosphinoyl)-3-methyl-butyl ester 352 
 
TsCl (9.54 g, 50.05 mmol) was added to a stirred solution of compound 347 (3.66 g, 
14.3 mmol) in pyridine (60 ml) maintained at 0 °C.  Once addition was complete the 
reaction was left to stir for 4 h and monitored by TLC.  Once the reaction was complete 
the solvent was removed in vacuo and the residue was diluted with dichloromethane and 
poured into water (50 ml) and the organic layer was extracted.  The aqueous phase was 
washed with dichloromethane (2 x 25 ml).  The combined organic extracts were dried 
over Na2SO4 and stripped of solvent in vacuo. The residue was subjected to 
chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title compound (3.79 g, 9.25 
mmol, 65% yield) as a colourless oil. 
νmax/cm
-1
 3473 2871-2958 1596 1439 1362 1230 1189 1174 1121 1095 1022 
P (243 MHz, CDCl3) 35.10 
H (600 MHz, CDCl3) 0.85 (3H, d, J 6.2, CH3), 0.87 (3H, d, J 6.2, CH3), 1.28 (3H, t, J 
7.1, OCH2CH3), 1.61-1.81 (3H, m, CH2
i
Pr + CHMe2), 2.41(3H, s, ArCH3), 3.94-4.04 
(1H, m, OCH2CH3), 4.04-4.13 (1H, m, OCH2CH3), 4.95-4.99 (1H, m, PCH), 7.22-7.24 
(2H, m, MeAr H), 7.38-7.43 (2H, m, MeAr H), 7.53-7.57 (1H, m, Ar H), 7.62-7.68 (4H, 
m, Ar H). 
C (151 MHz, CDCl3) 16.43 (d, JP 5.9, OCH2CH3), 21.38 (CH3), 21.62 (CH3), 23.05 
(ArCH3), 24.11 (d, JP 9.3, CHMe2), 61.80 (d, JP 6.6, OCH2CH3), 77.31 (d, JP 117.7, 
PCH), 127.65 (d, JP 128.4, Ar C), 127.80 (MeAr CH), 128.58 (d, JP 12.8, Ar CH), 
129.53 (MeAr CH), 132.67 (d, JP 9.7, Ar CH), 132.91 (d, JP 2.8, Ar CH), 133.89 (MeAr 
C), 144.63 (MeAr C). 
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LRMS m/z (ESI) 411.2 [M+H]
+
.  
HRMS (ESI) calcd. for C20H27O5PS 411.1390, found 411.1391 [M+H]
+
. 
(1-Azido-3-methyl-butyl)-phenyl-phosphinic acid ethyl ester 353 
 
Triphenylphosphine (3.82 g, 15 mmol) followed by sodium azide (1.14 g, 17 mmol) 
were added to a stirred solution of compound 347 (3.73 g, 15 mmol) in CCl4 (50 ml) 
followed by heating at 60 °C for 3 h.  Once the reaction was complete the solvent was 
removed in vacuo and the residue was diluted with dichloromethane and poured into 
water (10 ml) and the organic layer was separated.  The aqueous phase was washed with 
dichloromethane (2 x 20 ml).  The combined organic extracts were dried over Na2SO4 
and stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc 
: Pet. Ether 6:1 - 3:1) to give the title compound (3.94 g, 14.03 mmol, 96% yield) as a 
colourless oil. 
νmax/cm
-1 
3462 2871-2958 2101 1592 1468 1438 1389 1369 1289 1247 1224 1121 1022 
P (162 MHz, CDCl3) 39.29. 
H (400 MHz, CDCl3) 0.94 (6H, d, J 6.6, CH3), 1.31-1.37 (1H, m, CH2
i
Pr), 1.40 (3H, t, 
J 7.1, OCH2CH3), 1.54-1.62 (1H, m, CH2
i
Pr), 1.77-1.87 (1H, m, CHMe2), 3.68-3.75 
(1H, dt, J 2.9, 9.5, PCH), 4.0-4.10 (1H, m, OCH2CH3), 4.17-4.27 (1H, m, OCH2CH3), 
7.52-7.57 (2H, m, Ar H), 7.62-7.66 (2H, m, Ar H), 7.84-7.89 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.57 (d, JP 6.0, OCH2CH3), 20.83 (CH3), 22.53 (CH3), 23.18 
(CH3), 25.04 (d, JP 13.0, CHMe2), 36.09 (CH2
i
Pr), 58.11 (d, JP 110, CH), 61.71 (d, JP 
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6.7, OCH2CH3), 127.49 (d, JP 124.0, Ar C), 128.76 (d, JP 12.0, 2 x Ar CH), 132.66 (d, 
JP 10.0, 2 x Ar CH), 133.06 (d, JP 3.0, Ar CH). 
LRMS m/z (ESI) 304.2 [M+Na]
+
, 282.2 [M+H]
+
.  
HRMS (ESI) calcd. for C13H21O2N3P 282.1366, found 282.1362 [M+H]
+
. 
1-Amino-3-methyl-butyl)-phenyl-phosphinic acid ethyl ester 354a
112
 
 
A mixture of compound 353 (3.94 g, 14 mmol) and 5% Pd/C (0.79 g, 20 % wt) in 
EtOAc was stirred under a hydrogen atmosphere overnight.   The catalyst was filtered 
through celite and the solvent was removed in vacuo to give the title compound (3.58 g, 
14 mmol, quant. yield) as a yellow oil. 
νmax/cm
-1 
3375 2868-2955 1672 1592 1549 1467 1438 1387 1367 1259 1201 1121 1023  
P (162 MHz, CDCl3) 44.05 
H (400 MHz, CDCl3) 0.80 (3H, d, J 6.6, CH3), 0.87 (3H, d, J 6.7, CHMe2), 1.26 (3H, t , 
J 7.1, OCH2CH3), 1.28-1.35 (2H, m, NH2), 1.45-1.53 (1H, m, CH2
i
Pr), 1.77-1.87 (1H, 
m, CHMe2), 3.07 (1H, ddd, J 3.4, 8.0, JP 11.3, PCH) 3.80-3.90 (1H, m, OCH2CH3), 
4.02-4.11 (1H, m, OCH2CH3), 7.41-7.47 (2H, m, Ar H), 7.49-7.54 (1H, m, Ar H), 7.72-
7.77 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.56 (d, JP 6.0, OCH2CH3), 20.93 (CH3), 23.62 (CH3), 24.13 (d, 
JP 12.0, CHMe2), 38.68 (CH2
i
Pr), 48.98 (d, JP 106.0, PCH), 61.08 (d, JP 7.4, 
OCH2CH3), 128.77 (d, JP 116.0, Ar C), 128.63 (d, JP 12.0, 2 x Ar CH), 132.43 (d, JP 
2.0, Ar CH), 132.55 (d, JP 9.0, Ar CH). 
LRMS m/z (ESI) 278.3 [M+Na]
+
, 256.3 [M+H]
+
. 
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HRMS (ESI) calcd. for C13H23O2N1P 256.1461, found 256.1464 [M+H]
+
. 
Ethyl (3-methyl-1-((phenylhydrophosphoryl)oxy)butyl)(phenyl)phosphinate 359-
360 
 
Triphosgene (3.47 g, 12 mmol), followed by pyridine (2.85 ml, 35 mmol) were added to 
a stirred solution of compound 347 (9 g, 35 mmol) in dichloromethane (150 ml) 
maintained at 0 °C and under a dry nitrogen atmosphere.  The mixture was left stirring 
for 3 h at 0 °C. Pyridine (3.21 ml, 40 mmol) was slowly added to the stirred solution of 
the chloroformate and phenylphosphinic acid (5.63 g, 40 mmol).  (Caution! Exothermic 
reaction; Rapid Effervescence).  Once the effervescence had stopped the stirred solution 
was left to warm up to room temperature under a dry nitrogen atmosphere.  The solution 
was poured into 0.1M hydrochloric acid (50 ml) and the organic layer was separated.  
The organic extracts were washed with water (50 ml) and dried using Na2SO4. The 
combined organic extracts were stripped of solvent in vacuo to give the title compound 
as a colourless oil (14 g, quant. yield). 
νmax/cm
-1
 3400 (OH), 2840-2951 (CH), 1448, 1405, 1113 (P=O), 1017 (P=O) 
P (162 MHz, CDCl3) 28.25 (d, J 8.8), 36.9 (d, J 8.8). 
H (400 MHz, CDCl3) 0.45 (3H, d, J  6.6, CH3), 0.51 (3H, d, J  6.4, CH3), 1.00 (3H, t, J 
7.1, OCH2CH3), 1.25-1.34 (1H, m, CHMe2), 1.35-1.51 (2H, m, CH2
i
Pr), 3.67-3.77 (1H, 
m, OCH2CH3), 3.79-3.90 (1H, m, OCH2CH3), 4.51-4.60 (1H, m, PCH), 7.06-7.46 (10H, 
m, Ar H), 7.32 (1H, d, J 575.0, PH).  
C (101 MHz, CDCl3) 16.78 (d, JP 5.7, OCH2CH3), 21.19 (CH3), 23.76 (CH3), 24.17 (d, 
JP 13.6, CHMe2), 39.72 (d, JP 3.6, CH2), 62.04 (d, JP 7.3, OCH2CH3), 68.01 (d, JP 
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116.6, PCH), 127.81 (d, JP 119.5, Ar C), 128.80 (d, JP 1.8, Ar CH), 128.95 (d, JP 3.6, Ar 
CH), 130.82 (d, JP 12.0, Ar CH), 132.04 (d, JP 133.4, Ar C), 132.61 (d, JP 9.4, Ar CH), 
132.91 (d, JP 2.8, Ar CH), 133.03 (d, JP 2.6, Ar CH). 
LRMS m/z (ESI) 403.1 [M+Na]
+
.  
HRMS (ESI) calcd. for C19H26O4P2Na 403.1204, found 403.1220 [M+Na]
+
. 
Ethyl (1-(((hydroxy(phenyl)methyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphinate 365 
  
Triethylamine (6.7 ml, 48 mmol) was added to a stirred solution of compound 359-360 
(10.2 g, 40 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (6.1 ml, 48 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. 
Benzaldehyde (4.9 ml, 48 mmol) was added and the reaction mixture was left to warm 
up to room temperature overnight under a dry nitrogen atmosphere.  Once the reaction 
was complete the reaction mixture was poured into water (50 ml) and the organic layer 
was separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo to 
give compound 362 (22 g, 40 mmol, quant. yield) as a yellow oil.  TBAF (20 ml of a 
1M solution in THF) was added to a stirred solution of this crude product in THF (20 
ml). After 5 min, the reaction mixture was poured into water (60 ml) and was extracted 
with dichloromethane (3 x 60 ml). The combined organic extracts were dried over 
Na2SO4 and stripped of solvent in vacuo to give the title compound as a mixture of 
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diastereomers.  The residue was subjected to chromatography (EtOAc : pet. ether 2:1, 
then 1:1,  then neat EtOAc) the appropriate fractions were combined, stripped of solvent 
and crystallised, if appropriate, to afford:  
Compound 365a colourless crystals, (Rf(tlc) 0.62 in ether), 3.0 g (16% over three steps); 
mp 150-155 °C. 
Found: C, 64.08; H, 6.57. C26H32O5P2 requires C, 64.19; H, 6.63.  
νmax/cm
-1
 3265 OH, 2854, 2923 CH, 1592, 1485, 1463, 1448, 1439, 1371, 1249, 1231, 
1188, 1173, 1123 (P=O), 1056. 
P (162 MHz, CDCl3) 40.65 (d, J 14.0), 43.15 (d, J 14.0). 
H (400 MHz, CDCl3) 0.8 (3H, d, J 6.7, CH3), 1.0 (3H, d, J 6.4, CH3), 1.30-1.45 (2H, m, 
CH2
i
Pr), 1.5 (3H, t, J 7.0, OCH2CH3), 1.77-1.90 (1H, m, CHMe2), 4.19-4.38 (3H, m, 
OCH2CH3 and P

CH), 5.18 (1H, ddd, J 2.9, 11.2, JP 22.0, P

CH), 5.50 (1H, d, JP 14.0, 
OH), 7.15-7.17 (3H, m, Ar H), 7.22-7.28 (4H, m, Ar H), 7.40-7.47 (3H, m, Ar H), 7.59-
7.64 (2H, m, Ar H), 7.67-7.71 (1H, m, Ar H), 7.90-7.95 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.65 (d, JP 5.7, OCH2CH3), 21.36 (CH3), 23.48 (CH3), 24.05 (d, 
JP 11.9, CHMe2), 41.22 (CH2), 62.63 (d, JP 6.8, OCH2CH3), 71.18 (dd, JP 7.5, 121.6, 
PCH), 72.60 (d, JP 101.4, PCH), 126.27 (d, JP 127.2, Ar C), 126.69 (d, JP 5.0, Ar CH), 
126.96 (d, JP 129.0, Ar C), 127.15 (d, JP 3.5, Ar CH), 127.58 (d, JP 12.3, Ar CH), 
127.65 (d, JP 2.7, Ar CH), 128.85 (d, JP 12.7, Ar CH), 132.21 (d, JP 2.7, Ar CH), 132.32 
(d, JP 8.8, Ar CH), 132.84 (d, JP 9.6, Ar CH), 133.46 (d, JP 2.8, Ar CH), 136.04 (d, JP 
2.2, Ar C). 
LRMS m/z (ESI) 509.2 [M+Na]
+
, 487.2 [M+H]
+
.  
HRMS (ESI) calcd. for C26H32O5P2Na 509.1617, found 509.1609 [M+Na]
+
. 
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Compound 365b colourless crystals, (Rf(tlc) 0.59 in ether), 2.5 g (13% over three steps); 
mp 120-125 °C. 
Found: C, 64.08; H, 6.55. C26H32O5P2 requires C, 64.19; H, 6.63.  
νmax/cm
-1
 3236 OH, 2853, 2924 CH, 1590, 1492, 1461, 1441, 1377, 1236, 1221, 1187 
(P=O), 1055 
P (162 MHz, CDCl3) 39.8 (d, JP 14.6), 40.65 (d, JP 14.8). 
H (400 MHz, CDCl3) 0.74 (3H, d, J 6.7, CH3), 0.9 (3H, d, J 6.4, CH3), 1.29-1.43 (2H, 
m, CH2
i
Pr), 1.47 (3H, t, J 7.0, OCH2CH3), 1.57-1.62 (1H, m, CHMe2), 4.19-4.34 (3H, 
m, OCH2CH3 and P

CH), 5.25 (1H, ddd, J 3.1, 10.7, JP 21.8, P

CH), 7.22 (1H, s, OH), 
7.21-7.23 (4H, m, Ar H), 7.30-7.33 (2H, m, Ar H), 7.32-7.37 (2H, m, Ar H), 7.44-7.49 
(3H, m, Ar H), 7.59-7.64 (2H, m, Ar H), 7.68-7.72 (1H, m, Ar H), 7.89-7.94 (2H, m, Ar 
H). 
C (101 MHz, CDCl3) 16.64 (d, JP 5.5, OCH2CH3), 20.91 (CH3), 23.40 (CH3), 23.84 (d, 
JP 12.1, CH), 40.95 (CH2), 62.54 (d, JP 6.7, OCH2CH3), 71.29 (dd, JP 7.6, 120.0, PCH), 
74.36 (d, JP 100.3 PCH), 126.66 (d, JP 128.1, Ar C), 127.72 (d, JP 3.1, Ar CH), 127.88 
(d, JP 5.2, Ar CH), 127.89 (d, JP 2.8, Ar CH), 128.01 (d, JP 12.4, Ar CH), 128.79 (d, JP 
12.7, Ar CH), 129.33 (d, JP 125.7, Ar C), 131.68 (d, JP 9.1, Ar CH), 132.30 (d, JP 2.6, 
Ar CH), 132.77 (d, JP 9.5, Ar CH), 133.30 (d, JP 2.8, Ar CH), 136.05 (Ar C). 
LRMS m/z (ESI) 509.2 [M+Na]
+
, 487.2 [M+H]
+
. 
HRMS (ESI) calcd. for C26H32O5P2Na 509.1617, found 509.1622 [M+Na]
+
. 
Compound 365c and 365d were isolated together as a 1:1 mixture after chromatography 
and crystallisation. (Rf(tlc) 0.2 in ether),  1 g (7% over three steps); 
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νmax/cm
-1 
3263 3061 2869-2958 1714 1592 1493 1469 1439 1389 1369 1216 1120 1056 
1025 
P (243 MHz, CDCl3) 37.84 (d, JP 13.6), 40.82 (d, JP 13.6), and  38.51 (d, JP 14.7), 
40.38 (d, JP 14.7). 
H (600 MHz, CDCl3) 0.50 (3H, d, J 6.5, CH3), 0.61 (6H, d, J 6.5, 2x CH3), 0.70 (3H, d, 
J 6.6, CH3), 0.80 (3H, t, J 7.0, OCH2CH3), 0.86 (3H, t, J 7.1, OCH2CH3), 1.10-1.16 
(1H, m, CH2
i
Pr), 1.28-1.36 (1H, m, CH2
i
Pr), 1.40-1.45 (1H, m, CH2
i
Pr), 1.56-1.62 (1H, 
m, CHMe2), 1.64-1.69 (1H, m, CHMe2), 1.70-1.75 (1H, m, CH2
i
Pr), 3.51-3.56 (1H, m, 
OCH2CH3), 3.57-3.62 (2H, m, OCH2CH3), 3.63-3.70 (1H, m, OCH2CH3), 4.64-4.69 
(1H, m, P
β
CH), 4.70-4.74 (1H, m, P
β
CH), 5.08 (1H, d, J 9.5, P
α
CH), 5.12 (1H, d, J 9.6, 
P
α
CH), 7.13-7.18 (6H, m, Ar H), 7.21-7.22 (2H, m, Ar H), 7.25-7.29 (4H, m, Ar H), 
7.31-7.36 (4H, m, Ar H), 7.37-7.39 (2H, m, Ar H), 7.40-7.43 (2H, m, Ar H), 7.44-7.50 
(2H, m, Ar H), 7.58-7.64 (6H, m, Ar H), 7.72-7.78 (2H, m, Ar H). 
C (151 MHz, CDCl3) 15.82 (d, JP 6.3, OCH2CH3), 15.92 (d, JP 6.2, OCH2CH3), 20.95 
(CH3), 21.08 (CH3), 23.09 (CH3), 23.12 (CH3), 23.53 (d, JP 11.1, CH), 23.92 (d, JP 10.7, 
CH), 39.39 (CH2), 39.42 (CH2), 61.31 (d, JP 6.8, OCH2CH3), 61.46 (d, JP 6.8, 
OCH2CH3), 71.95 (dd, JP 9.8, 119.8, PCH), 72.01 (dd, JP 10.1, 119.4, PCH), 73.80 (d, 
JP 111.0, PCH), 73.88 (d, JP 112.0, PCH), 127.17 (d, JP 5.0, Ar CH), 127.51 (d, JP 
124.4, Ar C), 127.52 (d, JP 121.6, Ar C), 127.62 (d, JP 4.9, Ar CH), 127.67 (d, JP 124.0, 
Ar C), 127.68 (d, JP 120.0, Ar C), 127.75 (d, JP 3.3, Ar CH), 127.85 (d, JP 2.5, Ar CH), 
127.90 (d, JP 8.4, Ar CH), 128.10 (d, JP 5.5, Ar CH), 128.26 (d, JP 6.9, Ar CH), 128.48 
(d, JP 12.1, Ar CH), 128.69 (d, JP 12.4, Ar CH), 128.79 (d, JP 12.5, Ar CH), 132.35 (d, 
JP 2.7, Ar CH), 132.46 (d, JP 9.9, Ar CH), 132.48 (d, JP 9.6, Ar CH), 132.50 (d, JP 9.5, 
Ar CH), 132.93 (d, JP 3.8, Ar CH), 133.01 (d, JP 3.1, Ar CH), 133.00 (d, JP 9.6, Ar CH), 
133.15 (d, JP 9.5, Ar CH), 136.04 (Ar C), 136.37 (Ar C). 
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LRMS m/z (ESI) 509.2 [M+Na]
+
, 487.2 [M+H]
+
. 
Ethyl (1-(((1-hydroxy-3-methylbutyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphinate 366 
  
Triethylamine (10 ml, 72 mmol) was added to a stirred solution of compound 359-360 
(14 g, 40 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (9.1 ml, 72 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. 
Isovaleraldehyde (4.3 ml, 40 mmol) was added and the reaction mixture was left to 
warm up to room temperature overnight under a dry nitrogen atmosphere.  Once the 
reaction was complete the reaction mixture was poured into water (50 ml) and the 
organic layer was separated.  The aqueous phase was washed with dichloromethane (2 x 
25 ml). The combined organic extracts were dried over Na2SO4 and stripped of solvent 
in vacuo to give compound 363 (21 g, 40 mmol, quant. yield) as a yellow oil.  TBAF 
(20 mL of a 1M solution in THF) was added to a stirred solution of this crude product in 
THF (20 ml). After 5 min, the reaction mixture was poured into water (60 ml) and was 
extracted with dichloromethane (3 x 60 ml). The combined organic extracts were dried 
over Na2SO4 and stripped of solvent in vacuo to give the title compound as a mixture of 
diastereomers.  The residue was subjected to chromatography (EtOAc : Pet. Ether 2:1, 
then 1:1,  then neat EtOAc) the appropriate fractions were combined, stripped of solvent 
and crystallised, if appropriate, to afford:  
Compound 366a colourless oil, (Rf(tlc) 0.7 in ether), 3 g (18% over three steps); 
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Found: C, 61.89; H, 7.67. C24H36O5P2 requires C, 61.79; H, 7.78.  
νmax/cm
-1
 3294 OH, 2869, 2957 (CH), 1592, 1468, 1439, 1387, 1368, 1300, 1249, 1218, 
1122 (P=O) 
P (162 MHz, CDCl3) 40.25 (d, JP 14), 46.05 (d, JP 14) 
H (400 MHz, CDCl3) 0.65 (3H, d, J 7.0, CH3), 0.70 (3H, d, J 7.0, CH3), 0.75 (3H, d, J 
7.0, CH3), 0.80 (3H, d, J 7.0, CH3), 1.17-1.27 (2H, m, CH2
i
Pr), 1.34 (3H, t, J 7.0, 
OCH2CH3), 1.70-1.79 (1H, m, CHMe2), 1.84-1.94 (1H, m, CHMe2), 4.05-4.20 (2H, q, 
JH 7.0, OCH2CH3), 4.29-4.38 (1H, ddd, J 2.6, 10.4, JP 22.2, P

CH), 4.97 (1H, ddd, J 
2.8, 10.4, JP 22.2, P

CH), 6.16 (1H, dt, JP  1.5, 4.2, OH), 7.42-7.52 (4H, m, Ar H), 7.57-
7.63 (2H, m, Ar H), 7.72-7.77 (2H, m, Ar H), 7.98-8.03 (2H, m, Ar H). 
C (101 MHz, CDCl3) 17.3 (d, JP 6.0, OCH2CH3), 21.82 (CH3), 21.88 (CH3), 23.84 
(CH3), 24.36 (CH3), 25.5 (CH), 25.8 (CH), 40.8 (CH2), 41.71 (CH2), 64.3 (CH2), 73 (d, 
JP 112.0, CH), 73 (d, JP 117.0, PCH), 126.1 (d, JP 127.0, Ar C), 127.9 (d, JP 126.0, Ar 
C), 128.1 (d, JP 12.2, 2 x Ar H), 128.8 (d, JP 12.6, 2 x Ar CH), 132.2 (d, JP 8.3, 2 x Ar 
CH), 132.3 (d, JP 2.6, Ar CH), 132.8 (d, JP 9.6, 2 x Ar CH), 133.3 (d, JP 2.7, Ar CH). 
LRMS m/z (ESI) 467.3 [M+H]
+
.  
HRMS (ESI) calcd. for C24H36O5P2Na 489.1936, found 489.1923 [M+Na]
+
. 
Compound 366b colourless crystals, (Rf(tlc) 0.4 in ether), 3 g (18% over three steps); 
mp 90-95 °C.  
Found: C, 61.84; H, 7.68. C24H36O5P2 requires C, 61.79; H, 7.78.  
νmax/cm
-1
 3284 OH, 2720-3053 CH, 1589 , 1466, 1441, 1414, 1388, 1377, 1366, 1340, 
1306, 1230, 1194, 1161, 1121 (P=O), 1077, 1034. 
P (162 MHz, CDCl3) 41.0 (d, JP 14), 42.1 (d, JP 14). 
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H (400 MHz, CDCl3) 0.65 (3H, d, J 7.0, CH3), 0.74 (3H, d, J 7.0, CH3), 0.83 (3H, d, J 
7.0, CH3), 0.86 (3H, d, J 7.0, CH3), 1.16-1.34 and 1.76-1.86 (4H, m, 2 x CH2
i
Pr), 1.34 
(3H, t, J 7.0, OCH2CH3), 1.52-1.64 (1H, m, CHMe2), 1.86-1.94 (1H, m, CHMe2), 4.00-
4.19 (3H, m, OCH2CH3 and PCHb), 5.15 (1H, ddd, JHHP 2.9, 11.3, 21.6, PCHa), 5.92 
(1H, dd, JPH 5.8, 1, OH), 7.31-7.80 (10H, m, Ar H). 
C (101 MHz, CDCl3) 16.6 (d, JP 6.0 OCH2CH3), 20.9 (CH3), 21.1 (CH3), 23.4 (CH3), 
23.6 (CH3), 23.7 (d, JP 11.0, CH), 24.2 (d, JP 12.0, CH), 38.8 (d, JP 3.0, CH2), 41.1 (d, 
JP 2.0, CH2), 62.4 (d, JP 7.0, OCH2CH3), 69.3 (d, JP 105.0, PCH), 71.3 (dd, JP 8.0, 
112.0, PCH), 127.0 (d, JP 128.0, Ar C), 128.9 (d, JP 128.0, Ar C), 128.4 (d, JP 12.2, 2 x 
Ar CH), 128.7 (d, JP 12.6, 2 x Ar CH), 131.2 (d, JP 9.2, 2 x Ar CH), 132.3 (d, JP 2.3, Ar 
CH), 132.6 (d, JP 11.6, 2 x Ar CH), 133.2 (d, JP 2.5, Ar CH). 
LRMS m/z (ESI) 489.2 [M+Na]
+
, 467.2 [M+H]
+
.  
HRMS (ESI) calcd. for C24H36O5P2Na 489.1936, found 489.1921 [M+Na]
+
. 
Compound 366c white amorphous solid (Rf(tlc) 0.25 in ether) 2.5 g (15% over three 
steps).  
mp 120-125 °C. 
νmax/cm
-1
 3280 OH, 2853, 2924 (CH), 1591, 1461, 1443, 1377, 1234, 1182, 1121 P=O, 
1073. 
P (162 MHz, CDCl3) 38.8 (d, JP 14), 41.8 (d, JP 14). 
H (400 MHz, CDCl3) 0.51 (3H, d, J 7.0, CH3), 0.74 (3H, d, J 7.0, CH3), 0.92 (6H, d, J 
7.0, CH3), 0.94 (3H, d, J 7.0, CH3), 1.18 (3H, t, J 7.0, OCH2CH3), 1.20-1.95 (6H, m, 2x 
CHMe2 + 2x CH2
i
Pr), 3.95 (2H, quint, J 7.0, JP 7.0, OCH2CH3), 4.24 (1H, m, P

CH), 
4.35 (1H, bs, OH), 4.55 (1H, ddd, JP 3.6, 9.7, JP 17.8, P

CH), 7.48-7.52 (4H, m, Ar H), 
7.57-7.63 (2H, m, Ar H), 7.77-7.78 (2H, m, Ar H), 7.99-8.06 (2H, m, Ar H). 
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C (101 MHz, CDCl3) 16.3 (d, JP 6.0, CH3), 20.9 (CH3), 21.2 (CH3), 23.1 (CH3), 23.5 
(CH3), 23.7 (d, JP 11.0, CH), 24.3 (d, JP 14.0, CH), 38.90 (d, JP 3.0, CH2), 40.17 (CH2), 
61.8 (d, JP 7.0, OCH2CH3), 70.0 (d, JP 115.0, PCH), 72.7 (dd, JP 11.0, 121.0, PCH) 
126.7 (d, JP 112.0, Ar C), 127.1 (d, JP 126.0, Ar C), 128.4 (d, JP 12.2, 2 x Ar CH), 128.7 
(d, JP 12.6, 2 x Ar CH), 132.6 (d, JP 9.4, 2 x Ar CH), 132.7 (d, JP 2.3, Ar CH), 133.1 (d, 
JP 9.2, 2 x Ar CH), 133.1 (d, JP 2.2, Ar CH). 
LRMS m/z (ESI) 489.2 [M+Na]
+
, 467.2 [M+H]
+
.  
HRMS (ESI) calcd. for C24H36O5P2Na 489.1936, found 489.1920 [M+Na]
+
. 
Compound 366d colourless crystals (Rf(tlc) 0.24 in ether) 0.2 g (1%);  
mp 101-107 °C. 
νmax/cm
-1
 3300 OH, 2868, 2957 CH, 1591, 1468, 1439, 1387, 1304, 1221, 1119 (P=O), 
1070, 1025 
P (162 MHz, CDCl3) 38.2 (d, JP 14), 41 (d, JP 14). 
H (400 MHz, CDCl3) 0.55 (3H, d, J 7.0, CH3), 0.75 (3H, d, J 7.0, CH3), 0.92 (6H, d, J 
7.0, CH3), 0.92 (3H, d, J 7.0, CH3), 1.12 (3H, t, J 7.0, OCH2CH3), 1.30-2.0 (6H, m, 2 x 
CHMe2 and CH2
i
Pr), 3.9 (2H, quint, JHP 7.0, 7.0, OCH2CH3), 4.1 (1H, m, P

CH), 4.2 
(1H, bs, OH), 4.62 (1H, ddd, JP 3.6, 9.8, JP 17, P

CH), 7.46-7.49 (4H, m, Ar H), 7.55-
7.59 (2H, m, Ar H), 7.72-7.75 (2H, m, Ar H), 7.99-8.04 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.2 (d, JP 5.8, CH3), 20.9 (CH3), 21 (CH3), 23.2 (CH3), 23.7 
(CH3), 23.8 (d, JP 11.0, CH), 24.3 (d, JP 13.0, CH), 39.25 (CH2), 40.12 (CH2), 61.75 (d, 
JP 6.5, OCH2CH3), 69.55 (d, JP 112.0, PCH), 72.6 (dd, JP 11.0, 122.0, PCH) 127.2 (d, JP 
98.0, Ar C), 127.9 (d, JP 86.0, Ar C), 128.5 (d, JP 12.3, 2 x Ar CH), 128.8 (d, JP 13.0, 2 
x Ar CH), 132.7 (d, JP 2.3, Ar CH), 132.78 (d, JP 9.4, 2 x Ar CH), 133.1 (d, JP 9.4, 2 x 
Ar CH), 133.21 (d, JP 2.2, Ar CH). 
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LRMS m/z (ESI) 489.2 [M+Na]
+
, 467.2 [M+H]
+
.  
HRMS (ESI) calcd. for C24H36O5P2Na 489.1936, found 489.1927 [M+Na]
+
. 
Ethyl (1-(((1-hydroxy-2-methylpropyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphinate 367 
 
Triethylamine (6.7 ml, 48 mmol) was added to a stirred solution of compound 359-360 
(10.2 g, 40 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (6.1 ml, 48 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. 
Isobutyraldehyde (4.4  ml,  48 mmol) was added and the reaction mixture was left to 
warm up to room temperature overnight under a dry nitrogen atmosphere.   Once the 
reaction was complete the reaction mixture was poured into water (50 ml) and the 
organic layer was separated.  The aqueous phase was washed with dichloromethane (2 x 
25 ml). The combined organic extracts were dried over Na2SO4 and stripped of solvent 
in vacuo to give compound 364 (21 g, 40 mmol, quant. yield ) as a colourless oil.  
TBAF (20 ml of a 1M solution in THF) was added to a stirred solution of this crude 
product in THF (20 ml). After 5 min, the reaction mixture was poured into water (60 
ml) and was extracted with dichloromethane (3 x 60 ml). The combined organic extracts 
were dried over Na2SO4 and stripped of solvent in vacuo to give the title compound (  g,  
mmol ) as a .  The residue was subjected to chromatography (EtOAc : Pet. Ether 2:1, 
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then 1:1,  then neat EtOAc) the appropriate fractions were combined, stripped of solvent 
and crystallised, if appropriate, to afford:  
Compound 367a colourless crystals, (Rf(tlc) 0.6 in ether),  0.5 g (3% over three steps); 
mp 104-107 °C. 
νmax/cm
-1
 3303 (OH), 2868, 2955 CH, 1593, 1488, 1438, 1390, 1339, 1225, 1198, 1126 
(P=O), 1047 
P (162 MHz, CDCl3) 41.26 (d, JP 14.6), 45.23 (d, JP 14.6). 
H (400 MHz, CDCl3) 0.73 (3H, d, J 6.7, CH3), 0.86 (3H, d, J 6.5, CH3), 0.95 (3H, d, J 
6.5, CH3), 1.04 (3H, d, J 6.7, CH3), 1.21-1.31 (2H, m, CH2
i
Pr), 1.39 (3H, t, J 7.0, 
OCH2CH3), 1.62-1.70 (1H, m, CHCHMe2), 1.71-1.79 (1H, m, CH2CHMe2), 3.95 (1H, 
ddd, J 3.2, 4.9, JP 13, P

CH), 4.09-4.17 (1H, m, OCH2CH3), 4.18-4.25 (1H, m, 
OCH2CH3), 4.96 (1H, ddd, JHHP 2.6, 11.3, 23.6, P

CH), 6.2 (1H, br s, OH), 7.35-7.39 
(2H, m, Ar H), 7.45-7.48 (1H, m, Ar H), 7.49-7.53 (2H, m, Ar H), 7.57-7.61 (1H, m, Ar 
H), 7.78-7.87 (4H, m, Ar H). 
C (101 MHz, CDCl3) 16.7 (d, JP 5.8, OCH2CH3), 19.4 (d, JP 11.0, CH3), 20 (d, JP 5.0, 
CH3), 21.5 (CH3), 23.5 (CH3), 23.7 (d, JP 12.0, CHMe2), 29.8 (d, JP 7.0, CHMe2), 41.3 
(CH2), 62.5 (d, JP 6.5, OCH2CH3), 70.9 (dd, JP 7.2, 121.0, PCH), 74.7 (d, JP 103.0, 
PCH), 126.3 (d, JP 126.0, Ar C), 128.2 (d, JP 11.6, 2 x Ar CH), 128.8 (d, JP 13.0, 2 x Ar 
CH), 129.2 (d, JP 126.0, Ar C), 132.0 (d, JP 9.4, 2 x Ar CH), 132.4 (d, JP 2.2, Ar CH), 
132.85 (d, JP 10.1, 2 x Ar CH), 133.4 (d, JP 2.2, Ar CH). 
LRMS m/z (ESI) 475.4 [M+Na]
+
, 453.4 [M+H]
+
.  
HRMS (ESI) calcd. for C23H35O5P2 453.1954, found 453.1962 [M+H]
+
. 
Compound 367b colourless crystals, (Rf(tlc) 0.55 in ether),  0.4 g (2% over three steps); 
mp 93-97 °C. 
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νmax/cm
-1
 3235 OH, 2870, 2955 CH, 1591, 1440, 1390, 1321, 1223, 1194, 1123 (P=O), 
1051. 
P (162 MHz, CDCl3) 41.57 (d, JP 15.5), 42.55 (d, JP 15.3). 
H (400 MHz, CDCl3) 0.67 (3H, d, J 6.7, CH3), 0.90 (3H, d, J 6.4, CH3), 0.94 (3H, d, J 
6.7, CH3), 1.09 (3H, d, J 6.7, CH3), 1.16-1.25 (1H, m, CH2
i
Pr), 1.28-1.35 (1H, m, 
CH2
i
Pr), 1.38 (3H, t, J 7.0, OCH2CH3), 1.48-1.57 (1H, m, CHMe2), 1.72-1.81 (1H, m, 
CH2CHMe2), 3.92 (1H, ddd, J 1.0, 4.0, JP 14.0, P

CH), 4.12-4.19 (1H, m, OCH2CH3), 
4.19-4.25 (1H, m, OCH2CH3), 5.23 (1H, ddd, J 2.2, 10.7, JP 21.8, P

CH), 6.1 (1H, br s, 
OH), 7.37-7.42 (2H, m, Ar H), 7.47-7.51 (1H, m, Ar H), 7.52-7.56 (2H, m, Ar H), 7.6-
7.64 (1H, m, Ar H), 7.66-7.71 (2H, m, Ar H), 7.8-7.85 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.7 (d, JP 5.1, OCH2CH3), 17.1 (d, JP 4.3, CH3), 20.8 (d, JP 13.0, 
CH3), 21.1 (CH3), 23.5 (CH3), 23.9 (d, JP 12.3, CHMe2), 29.4 (d, JP 5.8, CHMe2), 41.1 
(CH2), 62.5 (d, JP 6.5, OCH2CH3), 70.9 (dd, JP 8.0, 121.0, PCH), 75.8 (d, JP 103.0, 
PCH), 126.9 (d, JP 128.0, Ar C), 128.5 (d, JP 12.3, 2 x Ar CH), 128.8 (d, JP 13.0, 2 x Ar 
CH), 131 (d, JP 118.0, Ar C), 131.2 (d, JP 9.4, 2 x Ar CH), 132.3 (d, JP 2.2, Ar CH), 
132.8 (d, JP 9.4, 2 x Ar CH), 133.3 (d, JP 2.2, Ar CH). 
LRMS m/z (ESI) 475.2 [M+Na]
+
, 453.2 [M+H]
+
.  
HRMS (ESI) calcd. for C23H35O5P2 453.1954, found 453.1960 [M+H]
+
. 
Compound 367c and 367d were isolated together after chromatography and 
crystallisation. (Rf(tlc) 0.35 in ether),  1.5 g (9% over three steps); 
mp 122-126 °C. 
νmax/cm
-1
 3306 (OH), 2923-2854 (CH), 1590, 1463, 1377, 1236 (P=O), 1222 (P=O) 
P (243 MHz, CDCl3) 39.06 (1P, d, JP 17.8), 39.53 (1P, d, JP 19.3), 41.81 (1P, d, JP 
19.3), 41.81 (1P, JP 17.8). 
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H (600 MHz, CDCl3) 0.46 (3H, d, J 6.5, CH3), 0.53 (3H, d, J 6.5, CH3), 0.70 (6H, d, J 
6.6, CH3), 0.88 (3H, d, J 6.7, CH3), 1.01 (6H, d, J 6.8, CH3), 1.02 (3H, d, J 6.8, CH3), 
1.08 (3H, t, J 7.1, OCH2CH3), 1.15 (3H, t, J 7.1, OCH2CH3), 1.24-1.31 (2H, m, 2x 
CH2
i
Pr), 1.49-1.55 (1H, m, CH2
i
Pr), 1.55-1.62 (1H, m, CH2
i
Pr), 1.68-1.75 (1H, m, 
CH2CHMe2), 1.76-1.83 (1H, m, CH2CHMe2), 1.97 (1H, hex, JP 6.9, CHCHMe2), 2.03 
(1H, hex, J 6.9, CHCHMe2), 3.79 (1H, dd, J 1.9, JP 5.3, PCH), 3.82-3.87 (2H, m, 
OCH2CH3), 3.88-3.95 (3H, m, OCH2CH3 + PCHCH2), 4.04 (1H, br s, OH), 4.44-4.49 
(1H, m, PCHCH), 4.50-4.55 (1H, m, PCHCH), 4.57 (1H, br s, OH), 7.42-7.47 (8H, m, 
Ar H), 7.52-7.58 (4H, m, Ar H), 7.68-7.72 (4H, m, Ar H), 7.94-8.00 (4H, m, Ar H).                                                                                                                                                                                                                                                                  
C (151 MHz, CDCl3) 16.33 (d, JP 5.8, OCH2CH3), 16.43 (d, JP 5.7, OCH2CH3), 17.60 
(d, JP 5.5, CH3), 18.45 (d, JP 8.5, CH3), 20.25 (d, JP 10.8, CH3), 20.57 (d, JP 10.8, CH3), 
21.15 (d, JP 25.8, CH3) 23.15 (d, JP 17.6, CH3) 23.80 (d, JP 10.1, CHMe2), 23.87 (d, JP 
10.8, CMe2), 29.69 (d, JP 1.6, CMe2), 29.72 (d, JP 3.1, CMe2), 40.39 (CH2), 40.40 
(CH2), 61.74 (d, JP 6.7, OCH2CH3), 61.90 (d, JP 6.7, OCH2CH3), 72.78 (dd, JP 10.9, 
120.9, PCH), 72.85 (dd, JP 11.3, 121.2, PCH), 76.03 (d, JP 94.5, PCH),  76.76 (d, JP 
98.8, PCH), 126.85 (d, JP 86.8, Ar C), 127.35 (d, JP 102.4, Ar C), 127.81 (d, JP 111.0, 
Ar C), 128.01 (d, JP 96.1, Ar C), 128.53 (d, JP 8.3, Ar CH), 128.61 (d, JP 8.6, Ar CH), 
128.80 (d, JP 3.1, Ar CH), 128.88 (d, JP 3.4, Ar CH), 132.74 (d, JP 8.7, 2x Ar CH), 
132.75 (d, JP 9.5, 2x Ar CH), 132.80 (d, JP 5.8, Ar CH), 133.20 (d, JP 2.8, Ar CH), 
133.24 (d, JP 2.8, Ar CH), 133.32 (d, JP 9.1, Ar CH). 
LRMS m/z (ESI) 453 [M+H]
+
.  
HRMS (ESI) calcd. for C22H35O5P2 453.1954, found 453.1939 [M+H]
+
. 
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Ethyl (3-methyl-1-(((3-methyl-1-
((phenylhydrophosphoryl)oxy)butyl)(phenyl)phosphoryl)oxy)butyl)(phenyl)phosphina
te 369 
 
Triphosgene (0.45 g, 2 mmol), followed by pyridine (0.36 ml, 5 mmol) were added to a 
stirred solution of compound 366b (1.93 g, 4 mmol) in dichloromethane (100ml) 
maintained at 0 °C and under a dry nitrogen atmosphere.  The mixture was left stirring 
for 3 h at 0 °C. Pyridine (0.36 ml, 4.5 mmol) was slowly added to the stirred solution of 
the chloroformate and phenylphosphinic acid (0.64g, 5 mmol).  (Caution! Exothermic 
reaction; Rapid Effervescence).  Once the effervescence had stopped the stirred solution 
was refluxed for 45 min. until the reaction was complete.  The solution was poured into 
0.1M hydrochloric acid (50 ml) and the organic layer was separated.  The organic 
extracts were washed with water (50 ml) and dried using Na2SO4. The combined 
organic extracts were stripped of solvent in vacuo to give the crude title compound as a 
colourless oil (2.45 g, 4.14 mmol, quant. yield).  
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Ethyl (1-(((1-(((1-hydroxy-3-methylbutyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphoryl)oxy)-3-methylbutyl)(phenyl)phosphinate 371 
 
Triethylamine (0.64 ml, 4.6 mmol) was added to a stirred solution of compound 369 
(2.45 g, 4.1 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (0.58 ml, 4.6 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. 
Isovaleraldehyde (0.56 ml, 4.6 mmol) was added and the reaction mixture was left to 
warm up to room temperature overnight under a dry nitrogen atmosphere.  Once the 
reaction was complete the reaction mixture was poured into water (50 ml) and the 
organic layer was separated.  The aqueous phase was washed with dichloromethane (2 x 
25 ml). The combined organic extracts were dried over Na2SO4 and stripped of solvent 
in vacuo. The residue was subjected to chromatography (EtOAc : Pet. Ether 5:1 - 2:1) to 
give compound 370b (0.1 g, 0.13 mmol, 3% yield) as a colourless oil, containing a 
single diastereomer.  Compound 371b was deprotected using SiO2 to give the title 
compound (0.09 g, 0.13 mmol, quant. yield) as a colourless oil. 
Compound 371b. 
νmax/cm
-1
 3296 OH, 2899, 2958 CH, 1592, 1469, 1437, 1389, 1303, 1228, 1121 (P=O), 
1050. 
P (162 MHz, CDCl3) 36.91 (d, JP 15.8, P
γ
), 41.56 (dd, JP 15.8, JP 22.1, P
β
), 42.52 (d, JP 
22.1, P
α
). 
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H (400 MHz, CDCl3) 0.51 (3H, d, J 6.0, CH3), 0.64 (3H, d, J 6.5, CH3), 0.67 (3H, d, 
6.5, CH3), 0.75 (3H, d, 6.5, CH3), 0.87 (3H, d, 6.5, CH3), 0.91 (3H, d, J 6.0, CH3), 1.31 
(3H, t, J 7.0, OCH2CH3), 1.33-1.62 (7H, m, 3 x CH2 and CHMe2), 1.71-1.78 (1H, m, 
CHMe2), 1.92-1.99 (1H, m, CHMe2), 4.09-4.20 (2H, m, OCH2CH3), 4.32 (1H, apparent 
t, JP 11.0, JP 10.0, P
β
CH), 4.74 (1H, ddd, J 3.6, 9.5, JP 18, P
α
CH), 5.02 (1H, ddd, J 3.1, 
9.9, JP 18, P
γ
CH), 5.64 (1H, bs, OH), 7.37-7.62 (11H, m, Ar H), 7.65-7.7 (2H, m, Ar H), 
7.75-7.8 (2H, m, Ar H), 8.04 8.10 (2H, m, Ar H). 
C (101 MHz, CDCl3) 16.7 (d, JP 5.0, OCH2CH3), 21.0 (CH3), 21.14 (CH3), 21.28 
(CH3), 23.10 (CH3), 23.42 (CH3), 23.64 (CH3), 24.1 (d, JP 12.0, CH), 24.3 (d, JP 14.0, 
CH), 24.4 (d, JP 14.0, CH), 39.3 (CH2), 40.2 (CH2), 40.5 (CH2), 62 (d, JP 8.0, 
OCH2CH3), 69.8 (d, JP 113.0, P
γ
CH), 72.43 (dd, JP 9.0, JP 121.0, PCH), 74.3 (dd, JP 
12.0, JP 118.0, PCH), 126.3 (d, JP 110.0, Ar C), 127.7 (d, JP 126.0, Ar C), 128.1 (d, JP 
110.0, Ar C), 128.45 (d, JP 8.0, Ar CH), 128.53 (d, JP 9.0, Ar CH), 128.84 (d, JP 13.0, 
Ar CH), 132.2-133.5 (overlapping 6 x d, 6 x Ar CH). 
LRMS m/z (ESI) 699.4 [M+Na]
+
, 677.5 [M+H]
+
. 
HRMS (ESI) calcd. for C35H52O7P3 677.2920, found 677.2908 [M+Na]
+
. 
(E)-N-(3-methylbutylidene)-1-phenylmethanamine 379 
 
Benzylamine (5.0 g, 47 mmol), and isovaleraldehyde (3.9 g, 48 mmol), were added to 
toluene (100ml) and the resulting solution was heated under reflux overnight, while 
water was removed by a using Dean-Stark apparatus.  Once the reaction was complete 
the solvent was removed in vacuo to give the title compound as a yellow oil (7.9 g, 45 
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mmol, 96% yield) which was used immediately in the next step without further 
purification. 
H (400 MHz, CDCl3) 0.98 (3H, d, J 7.0, CH3), 0.99 (3H, d, J 7.0, CH3), 1.96 (1H, m, 
CHMe2), 2.23 (2H, q, J 6.0, CH2), 4.59 (2H, s, CH2Ph), 5.15 (1H, t, J 5.2, CH), 7.20-
7.40 (5H, m, Ar H). 
C (101 MHz, CDCl3) 22.64 (CH3), 22.68 (CH3), 26.48 (CHMe2), 44.90 (CH2), 65.46 
(CH2Ph), 126.9-128.5 (Ar CH), 135.3 (Ar C), 165.85 (=CH). 
LRMS m/z (ESI) 176.0 [M+H]
+
.
 
Ethyl (1-(((1-(benzylamino)-3-methylbutyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphinate 380 
 
Triethylamine (5.2 ml, 37 mmol) was added to a stirred solution of compound 359-360 
(8 g, 31 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (4.7 ml, 37 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. Imine 
379 (4 ml, 37 mmol) was added and the reaction mixture was left to warm up to room 
temperature overnight under a dry nitrogen atmosphere.  Once the reaction was 
complete the reaction mixture was poured into water (50 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
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The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:0) to give the 
title compound. 
Diastereomer 1 (380a) (Solid) (3.1 g, 18% yield): 
mp 105-107 °C. 
νmax/cm
-1 
3330 3059 2868-2951 1593 1494 1468 1454 1438 1386 1368 1307 1237 1210 
1190 1162 1119 1056 1022 
P (162 MHz, CDCl3) 36.73 (d, J 14.87, P
α
), 44.94 (d, J 14.86, P
β
). 
H (400 MHz, CDCl3) 0.64 (3H, d, J 6.5, CH3), 0.83 (6H, d, J 6.6, CH3), 0.85 (3H, d, J 
6.5, CH3), 0.94 (3H, t, J 7.1, OCH2CH3), 1.17-1.27 (1H, m, CH2
i
Pr β), 1.34-1.48 (2H, m, 
2x CH2
i
Pr), 1.73-1.81 (1H, m, C
α
HMe2), 1.92-2.03 (2H, m, C
α
HMe2 + C
α
H2
i
Pr), 3.02 
(1H, td, J 3.1, JP 10.9, P
β
CH), 3.65-3.81 (2H, m, OCH2CH3), 4.04 (2H, q, J 13.0, 
CH2Ph), 4.77-4.84 (1H, m, P
α
CH ), 7.23-7.30 (2H, m, Ar H), 7.31-7.35 (3H, m, Ar H), 
7.42-7.48 (4H, m, Ar H), 7.53-7.58 (2H, m, Ar H), 7.72-7.82 (4H, m, Ar H).  
C (101 MHz, CDCl3) 15.92 (d, JP 6.3, OCH2CH3), 20.94 (CH3), 21.23 (CH3), 23.05 
(CH3), 23.55 (CH3), 24.14 (d, JP 12.1, CHMe2), 24.19 (d, JP 10.7, CHMe2), 38.92 (d, JP 
4.3, CH2), 39.39 (t, JP 2.6, CH2), 52.39 (d, JP 1.9, CH2Ar), 55.24 (d, JP 105.0, PCH), 
61.08 (d, JP 6.9, OCH2CH3), 71.16 (dd, JP 9.6, 120.6, PCH), 126.97 (Ar CH), 128.14 (d, 
JP 12.1, Ar CH), 128.23 (Ar CH), 128.54 (Ar CH), 128.64 (d, JP 12.4, Ar CH), 128.58 
(d, JP 122.9, Ar C), 129.20 (d, JP 125.1, Ar C), 132.07 (d, JP 2.6, Ar CH), 132.58 (d, JP 
6.9, Ar CH), 132.67 (d, JP 6.7, Ar CH), 132.77 (d, JP 2.7, Ar CH), 140.32 (Ar C). 
LRMS m/z (ESI) 556 [M+H]
+
. 
 
 
Diastereomer 2 (380b) (Oil) (2.5 g, 15% yield): 
νmax/cm
-1 
3325 2850-2957 1590 1485 1460 1450 1430 1380 1307 1210 1180 1152 1120  
196 
 
P (162 MHz, CDCl3) 37.49 (d, J 15.96, P
α
), 46.31 (d, J 16.19, P
β
). 
H (400 MHz, CDCl3) 0.50 (3H, d, J 7.1, CH3), 0.51 (3H, d, J 6.6, CH3), 0.62 (3H, d, J 
6.5, CH3), 0.81 (3H, d, J 5.3, CH3), 1.27 (3H, t, J 7.1, OCH2CH3), 1.29-1.41 (3H, m, 
CHMe2 + CH2
i
Pr), 1.44-1.55 (2H, m, CH2
i
Pr), 1.69-1.74 (1H, m, CHMe2), 2.97-3.03 
(1H, m, P
β
CH), 3.88 (2H, q, J 15.5, CH2Ph), 4.02-4.15 (2H, m, OCH2CH3), 4.98-5.08 
(1H, m, P
 α
CH), 7.13-7.16 (2H, m, Ar H), 7.19-7.26 (3H, m, Ar H), 7.32-7.45 (4H, m, 
Ar H), 7.47-7.52 (2H, m, Ar H), 7.70-7.79 (4H, m, Ar H).  
C (101 MHz, CDCl3) 16.59 (d, JP 5.9, OCH2CH3), 21.02 (CH3), 21.24 (CH3), 22.91 
(CH3), 23.52 (CH3), 24.30 (d, JP 11.2, CHMe2), 24.59 (d, JP 11.8, CHMe2), 38.34 (d, JP 
4.2, CH2), 38.53 (d, JP 3.9, CH2), 52.49 (d, JP 3.4, CH2Ar), 55.57 (d, JP 102.8, PCH), 
61.68 (d, JP 6.4, OCH2CH3), 70.70 (dd, JP 8.6, 121.7, PCH), 126.86 (Ar CH), 128.13 (d, 
JP 12.1, Ar CH), 128.22 (Ar CH), 128.38 (Ar CH), 128.66 (d, JP 12.4, Ar CH), 128.48 
(d, JP 124.0, Ar C), 130.79 (d, JP 116.9, Ar C), 132.03 (d, JP 5.8, Ar CH), 132.11 (d, JP 
6.6, Ar CH), 132.59 (d, JP 2.1, Ar CH), 132.68 (d, JP 2.2, Ar CH), 140.57 (Ar C). 
LRMS m/z (ESI) 556 [M+H]
+
. 
 
 
Diastereomers 3 and 4 (380c-d) (Oil Mix) (1.5 g, 9% yield): 
νmax/cm
-1 
3320 3055 2854-2965 1469 1430 1370 1237 1210 1180 1155 1116 1050 
P (162 MHz, CDCl3) (1:0.86) 36.74 (d, J 17.7, P
α
), 45.51 (d J 17.7, P
β
) and 36.77 (d, J 
14.8 P
α
), 45.01 (d, J 14.8 P
β
).  
H (400 MHz, CDCl3) 0.77-0.92 (24H, m, CH3), 0.92 (3H, t, J 7.3, OCH2CH3), 0.99 
(3H, t, J 7.1, OCH2CH3), 1.38-1.62 (5H, m, CHMe2 + CH2
i
Pr), 1.82-2.05 (5H, m, 
CHMe2 + CH2
i
Pr), 2.98-3.06 (2H, m, 2x P
β
CH), 3.61-3.79 (4H, m, CH2Ar + 
OCH2CH3), 3.97-4.07 (4H, m, CH2Ar + OCH2CH3), 4.61-4.68 (1H, m, P
α
CH), 4.76-
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4.82 (1H, m, P
α
CH), 7.08-7.11 (2H, m, Ar H), 7.17-7.25 (5H, m, Ar H), 7.26-7.34 (5H, 
m, Ar H), 7.40-7.59 (8H, m, Ar H), 7.71-7.85 (10H, m, Ar H).  
C (101 MHz, CDCl3) 15.91 (d, JP 6.3, OCH2CH3), 16.02 (d, JP 6.4, OCH2CH3), 21.00 
(CH3), 21.22 (CH3), 21.43 (CH3), 21.44 (CH3), 23.01 (CH3), 23.04 (CH3), 23.50 (CH3), 
23.52 (CH3), 24.13 (d, JP 12.0, CHMe2), 24.17 (d, JP 10.1, CHMe2), 24.27 (d, JP 10.2, 
CHMe2), 24.38 (d, JP 11.1, CHMe2), 37.91 (d, JP 2.4, CH2), 38.90 (d, JP 4.3, CH2), 
39.34 (d, JP 2.3, CH2), 39.73 (d, JP 2.3, CH2), 51.99 (d, JP 4.4, CH2Ar), 52.36 (d, JP 2.0, 
CH2Ar), 54.88 (d, JP 108.1, PCH), 55.20 (d, JP 105.0, PCH), 61.09 (d, JP 6.9, 
OCH2CH3), 61.12 (d, JP 6.8, OCH2CH3), 71.16 (dd, JP 9.6, 120.5, PCH), 71.61 (dd, JP 
10.2, 121.1, PCH), 126.96 (Ar CH), 126.97 (Ar CH), 128.16 (d, JP 14.1, Ar CH), 128.24 
(d, JP 9.0, Ar CH), 128.64 (d, JP 12.6, Ar CH), 128.49 (d, JP 8.5, Ar CH), 128.28 (Ar 
CH), 128.53 (Ar CH), 128.44 (d, JP 119.3, Ar C), 128.51 (d, JP 124.0, Ar C), 128.57 (d, 
JP 123.6, Ar C), 129.73 (d, JP 109.4, Ar C), 132.51 (d, JP 3.8, Ar CH), 135.55 (d, JP 5.4, 
Ar CH), 132.61 (d, JP 5.5, Ar CH), 132.65 (d, JP 3.0, Ar CH), 132.67 (d, JP 2.0, Ar CH), 
132.71 (d, JP 4.7, Ar CH), 132.75 (d, JP 4.5, Ar CH), 132.79 (d, JP 2.7, Ar CH), 139.97 
(Ar C), 140.26 (Ar C). 
LRMS m/z (ESI) 556 [M+H]
+
. 
 
 
1-((1-(ethoxy(phenyl)phosphoryl)-3-methylbutoxy)(phenyl)phosphoryl)-3-methylbutyl 
methanesulfonate 383 
 
Triethylamine (4 ml, 30 mmol) was added dropwise to a stirred solution of MsCl (1.6 g, 
20 mmol) and compound 366a (0.94 g, 2 mmol) in dichloromethane (75 ml) maintained 
at 0 °C.  Once the addition was complete the reaction was left to stir for 4 h and 
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monitored by TLC.  Once the reaction was complete the mixture was poured into water 
(30 ml) and the organic layer was extracted.  The aqueous phase was washed with 
dichloromethane (2 x 25 ml).  The combined organic extracts were dried over Na2SO4 
and stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc 
: Pet. Ether 8:1 - 3:1) to give the title compound (1 g, 2 mmol, 91% yield) as a 
colourless oil. 
νmax/cm
-1 
2871-2958 1591 1469 1439 1354 1228 1173 1119 1056  
P (162 MHz, CDCl3) 36.60 (d, J 14.4, P
α
), 37.67 (d, J 14.2, P
β
) 
H (400 MHz, CDCl3) 0.44 (3H, d, J 6.4, CH3), 0.48 (3H, d, J 6.5, CH3), 0.85 (3H, d, J 
6.7, CH3), 0.89 (3H, d, J 6.5, CH3), 1.03-1.10 (1H, m, CHMe2), 1.12-1.17 (1H, m, 
CH2
i
Pr), 1.32 (3H, t, J 7.1, OCH2CH3), 1.50-1.56 (2H, m, CH2
i
Pr), 1.60-1.69 (1H, m, 
CH2
i
Pr), 1.79 (1H, sep, J 6.6, CHMe2), 3.18 (3H, s, OSO2CH3), 3.93-4.01 (1H, m, 
OCH2CH3), 4.14-4.24 (1H, m, OCH2CH3), 4.95-5.02 (1H, m, P
α
CH), 5.08-5.14 (1H, m, 
P
β
CH), 7.42-7.50 (4H, m, Ar H), 7.53-7.58 (2H, m, Ar H), 7.73-7.82 (4H, m, Ar H). 
C (101 MHz, CDCl3) 16.46 (d, JP 6.5, OCH2CH3), 20.53 (CH3), 20.91 (CH3), 22.86 
(CH3), 23.37 (CH3), 23.89 (d, JP 11.7, CH), 24.26 (d, JP 12.0, CH), 38.64 (d, JP 3.9, 
CH2), 38.72 (d, JP 3.3, CH2), 39.36 (CH3), 62.11 (d, JP 6.6, OCH2CH3), 70.99 (dd, JP 
7.9, 119.8, PCH), 72.19 (dd, JP 8.0, 120.0, PCH), 78.27 (d, JP 115.2, PCH), 127.60 (d, 
JP 123.4, 2x Ar C), 128.62 (d, JP 12.8, 2x Ar CH), 129.00 (d, JP 12.5, 2x Ar CH), 
132.35 (d, JP 9.6, 2x Ar CH), 132.60 (d, JP 9.7, 2x Ar CH), 133.29 (d, JP 2.2, Ar CH), 
133.32 (d, JP 2.4, Ar CH). 
LRMS m/z (ESI) 545.2 [M+H]+.  
HRMS (ESI) calcd. for C25H39O7P2S 545.1886, found 545.1887 [M+H]
+
. 
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3,6-diisobutyl-2,5-diphenyl-1,4,2,5-dioxadiphosphinane 2,5-dioxide 385 
 
Triphenylphosphine (0.89 g, 3 mmol) was added to a stirred solution of compound 366a 
(0.75 g, 2 mmol) in CCl4 (50 ml) followed by heating at 60 °C for 3 h.  Once the 
reaction was complete the solvent was removed in vacuo and the residue was diluted 
with dichloromethane and poured into water (20 ml) and the organic layer was 
extracted.  The aqueous phase was washed with dichloromethane (2 x 25 ml).  The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 2:1) to give the 
title compound (0.68 g, 2 mmol, quant. yield) as a colourless solid, that after 
recrystallisation was submitted for X-ray crystallography. 
mp 173-175 °C. 
νmax/cm
-1 
3064 2872-2959 1593 1486 1466 1438 1389 1372 1344 1299 1284 1233 1210 
1155 1121 1065 1003 
P (162 MHz, CDCl3) 29.28 (d, J 5.8, P
α
), 36.48 (d, J 5.8, P
β
). 
H (400 MHz, CDCl3) 0.69 (3H, d, J 6.6, CH3), 0.75 (3H, d, J 6.7, CH3), 0.80 (3H, d, J 
5.3, CH3), 0.82 (3H, d, J 5.4, CH3), 1.18 (1H, m, P
β
CH2
i
Pr), 1.41 (1H, m, P
α
CH2
i
Pr), 
1.61 (1H, m, P
β
CH2
i
Pr), 1.80 (2H, m, 2x CHMe2), 2.17 (1H, m, P
α
CH2
i
Pr), 4.80 (1H, m, 
P
β
CH), 5.11 (1H, m, P
α
CH), 7.47-7.52 (4H, m, Ar H), 7.57-7.62 (2H, m, Ar H), 7.7.79-
7.84(2H, m, Ar H), 7.92-7.97(2H, m, Ar H). 
C (101 MHz, CDCl3) 20.97 (CH3), 22.95 (CH3), 23.93 (CH3), 24.03 (CH3), 37.7 (d, JP 
6.0, CHMe2), 39.9 (CH2
i
Pr), 70.36 (d, JP 7.0, CH), 71.33 (d, JP 7.0, CH), 74.69 (d, JP 
8.0, CH), 75.66 (d, JP 8.0, CH), 125.54 (d, JP 138.0, Ar C), 127.60 (d, JP 131.0, Ar C), 
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128.8 (d, JP 14.0, 2 x Ar CH), 129.2 (d, JP 13.0, 2 x Ar CH), 131.5 (d, JP 10.0, 2 x Ar 
CH), 132.9 (d, JP 10.0, 2 x Ar CH), 133.7 (d, JP 3.0, Ar CH), 133.8 (d, JP 3.0, Ar CH). 
LRMS m/z (ESI) 421.3 [M+H]
+
, 420.2 [M]
+
.  
HRMS (ESI) calcd. for C22H30O4P2 420.1614, found 420.1616 [M]
+
. 
Ethyl (1-(((1-chloro-3-methylbutyl)(phenyl)phosphoryl)oxy)-3-
methylbutyl)(phenyl)phosphinate 387 
 
Triphenylphosphine (0.56 g, 2 mmol) was added to a stirred solution of compound 366b 
(0.2 g, 0.43 mmol) in CCl4 (50 ml) followed by heating at 60 °C for 3 h.  Once the 
reaction was complete the solvent was removed in vacuo and the residue was diluted 
with dichloromethane and poured into water (20 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml).  The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 2:1) to give the 
title compound (0.18 g, 0.43 mmol, quant. yield) as a colourless oil. 
νmax/cm
-1 
3484 2871-2958 1592 1469 1439 1388 1370 1233 1201 1120 1033  
P (162 MHz, CDCl3) 36.92 (d, J 13.4, P
α
), 40.55 (d, 13.4, P
β
). 
H (400 MHz, CDCl3) 0.58 (3H, d, J 6.6, CH3), 0.65 (3H, d J 6.4, CH3),  
0.84 (6H, d, J 6.1, 2x CH3), 1.24-1.29 (1H, m, CHMe2), 1.37-1.42 (2H, m, CH2
i
Pr), 
1.49-1.59 (2H, m, CH2
i
Pr), 1.75-1.85 (1H, m, CHMe2), 4.0-4.1 (1H, m, PCH), 5.02-5.04 
(1H, m, PCH), 7.36-7.41 (2H, m, Ar H), 7.45-7.49 (3H, m, Ar H), 7.52-7.57 (1H, m, Ar 
H), 7.73-7.78 (2H, m, Ar H), 7.84-7.88 (2H, m, Ar H). 
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C (101 MHz, CDCl3) 16.65 (d, JP 5.9, OCH2CH3), 20.39 (CH3), 20.78 (CH3), 23.17 
(CH3), 23.21 (CH3), 24.20 (d, JP 11.6, CHMe2), 24.59 (d, JP 12.3, CHMe2), 39.5 
(CH2
i
Pr), 53.81 (d, JP 103.4, PCH), 61.76 (d, JP 6.6, OCH2CH3), 71.85 (dd, JP 8.0, 
121.2, PCH), 127.86 (d, JP 106.6, Ar C), 127.58 (d, JP 108.0, Ar C), 128.05 (d, JP 12.9, 
Ar CH), 128.63 (d, JP 12.5, Ar CH), 132.76 (d, JP 3.8, Ar CH), 132.82 (d, JP 9.3, Ar 
CH), 132.93 (d, JP 9.7, Ar CH), 132.94 (d, JP 2.8, Ar CH). 
LRMS m/z (ESI) 488.3 [M+H]
+
, 487.3 [M+H]
+
, 485.3[M+H]
+
. 
HRMS (ESI) calcd. for C23H36O4P2
35
Cl 484.1699, found 485.1754 [M+H]
+
. 
(S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoate 1-(ethoxy-phenyl-phosphinoyl)-
3-methyl-butyl ester 388 
 
DCC (3.3 g, 16 mmol), followed by DMAP (0.2 g, 2 mmol) were added to a stirred 
solution of compound 347 (2.05 g, 8 mmol) and Boc-(L)-Leu-OH (1.85 g, 8 mmol) in 
dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring for 3 h and 
the reaction was monitored by TLC. Once complete, the reaction mixture was filtered to 
remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4, stripped of solvent in vacuo. The residue was 
subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title compound 
(3.03 g, 7 mmol, 81% yield) as a colourless oil. 
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νmax/cm
-1 
3310, 2851-2929, 1738, 1706, 1625, 1575, 1530, 1469, 1449, 1438, 1389, 
1365, 1310, 1284, 1243, 1222, 1201, 1161, 1120, 1089, 1019. 
P (162 MHz, CDCl3) 36.84* 37.14 (* denotes the distinguishable signals due to the 
major isomer) 
H (400 MHz, CDCl3) 0.80 (3H, d, J 6.0, CH3), 0.81 (3H, d, J 8.70, CH3), 0.86 (3H, d, J 
2.7, CH3), 0.87 (3H, d, J 3.5, CH3), 0.90 (6H, d, J 5.7, 2 x CH3), 0.92 (6H, d, J 7.2, 2 x 
CH3), 1.31-1.34 (6H, m, 2x OCH2CH3), 1.41 [18H, 2x s, C(CH3)3], 1.46-1.59 (6H, m, 
2x NHCHCH2 + 2x NHCHCH2CH(CH3)2), 1.64-1.68 (2H, m, 2x PCHCH2CHMe2), 
1.76-1.84 (2H, m, PCHCH2), 1.89-1.92 (2H, m, PCHCH2), 3.96-4.04 (2H, m, 
OCH2CH3), 4.10-4.18 (2H, m, OCH2CH3), 4.23-4.27 (1H, m, NHCH*), 4.28-4.32 (1H, 
m, NHCH), 4.74 (1H, d, J 9.0, NH*), 4.79 (1H, d, J 8.8, NH), 5.41 (1H, d, J 11.4, 
PCH*), 5.45-5.48 (1H, m, PCH), 7.46-7.49 (4H, m, Ar H), 7.53-7.57 (2H, m, Ar H), 
7.75-7.79 (4H, m, Ar H).  
C (101 MHz, CDCl3) 16.64 (d, JP 7.0, OCH2CH3), 16.69 (d, JP 6.1, OCH2CH3), 21.04 
(CH3), 21.14 (CH3), 21.65 (CH3), 21.78 (CH3), 23.05 (CH3), 23.19 (CH3), 23.40 (CH3), 
23.42 (CH3), 24.36 (CHMe2), 24.44 (CHMe2), 24.75 (CHMe2), 24.84 (CHMe2), 28.38 
[C(CH3)3], 28.41 [C(CH3)3], 37.02 (CH2),  37.42 (CH2), 41.68 (CH2), 41.86 (CH2), 
52.14 (NHCH), 52.33 (NHCH), 61.73 (d, JP 7.0, 2x OCH2CH3), 69.56 (d, JP 117.4, 2x 
PCH), 79.78 (OCMe3), 79.93 (OCMe3), 128.29 (d, JP 125.7, Ar C), 128.42 (d, JP 118.7, 
Ar C), 128.79 (d, JP 12.9, Ar CH), 128.88 (d, JP 12.8, Ar CH), 132.45 (d, JP 9.8, Ar 
CH), 132.51 (d, JP 9.9, Ar CH), 132.95 (d, JP 2.9, Ar CH), 133.0 (d, JP 2.5, Ar CH), 
155.20 (NCO2), 156.95 (NCO2), 172.35 (CCO2), 172.71 (CCO2). 
LRMS m/z (ESI) 487.4 [M+NH4]
+
, 470.3 [M+H]
+
.  
HRMS (ESI) calcd. for C24H41O6NP 470.2666, found 470.2663 [M+H]
+
. 
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(S)-2-Amino-4-methylpentanoic acid 1-(ethoxyphenylphosphinoyl)-3-methylbutyl 
ester 389 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 388 (1.61 g, 3 
mmol) in dichloromethane (50 ml) maintained at 0 °C for 1 h. On completion of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4, 
stripped of solvent in vacuo. and The residue was subjected to chromatography (EtOAc 
: Pet. Ether 3:1 - 1:0) to give the title compound (1.27 g, 3 mmol, quant. yield) as a 
colourless oil. 
νmax/cm
-1 
3323 2850-2954 1742 1625 1575 1526 1469 1438 1405 1311 1187 1121 1032 
P (162 MHz, CDCl3) 36.84* 37.14 (* denotes the distinguishable signals due to the 
major isomer) 
H (400 MHz, CDCl3) 0.82 (3H, d, J 6.1, CH3), 0.86-0.91 (18H, m, 6x CH3), 1.31-1.34 
(6H, m, 2x OCH2CH3), 1.48-1.58 (4H, m, 2x NH2CHCH2),  1.65-1.69 (2H, m, 2x 
NH2CHCH2CHMe2), 1.70-1.82 (6H, m, 2x PCHCH2CHMe2+ 2x PCHCH2), 3.34 (1H, 
dd, J 5.6, 8.9, NH2CH), 3.40 (1H, dd, J 5.1, 9.3, NH2CH*), 3.97-4.04 (2H, m, 
OCH2CH3), 4.10-4.18 (2H, m, OCH2CH3*), 5.44 (1H, ddd, J 2.4, 4.0, JP 11.5, PCH), 
5.47 (1H, ddd, J 2.4, 4.4, JP 11.0, PCH), 7.46-7.49 (4H, m, Ar H), 7.55-7.57 (2H, m, Ar 
H), 7.75-7.79 (4H, m, Ar H).  
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C (101 MHz, CDCl3) 16.70 (d, JP 5.8, OCH2CH3), 16.71 (d, JP 5.7, OCH2CH3), 21.20 
(CH3), 21.26 (CH3), 21.58 (CH3), 21.85 (CH3), 23.08 (CH3), 23.29 (CH3), 23.35 (CH3), 
23.39 (CH3), 24.61 (CHMe2), 24.62 (CHMe2), 24.69 (CHMe2), 24.79 (CHMe2), 37.20 
(CH2),  37.47 (CH2), 43.46 (CH2), 43.63 (CH2), 52.98 (NH2CH), 53.08 (NH2CH), 61.70 
(d, JP 6.6, OCH2CH3), 61.71 (d, JP 6.7, OCH2CH3), 69.05 (d, JP 118.6, PCH), 69.20 (d, 
JP 118.6, PCH), 128.48 (d, JP 125.6, Ar C), 128.52 (d, JP 125.1, Ar C), 128.76 (d, JP 
12.5, Ar CH), 128.82 (d, JP 12.6, Ar CH), 132.50 (d, JP 10.1, Ar CH), 132.56 (d, JP 9.9, 
Ar CH), 133.01 (d, JP 2.7, 2x Ar CH), 172.35 (d, JP 3.1, CCO2), 172.71 (d, JP 3.4, 
CCO2). 
LRMS m/z (ESI) 370.4 [M+H]
+
.  
HRMS (ESI) calcd. for C19H33O4NP 370.2142, found 370.2140 [M+H]
+
. 
(R)-2-tert-Butoxycarbonylamino-4-methyl-pentanoic acid (S)-1-(ethoxy-phenyl-
phosphinoyl)-3-methyl-butyl ester 392 
 
DCC (4.15 g, 20 mmol), followed by DMAP (0.25 g, 2 mmol) were added to a stirred 
solution of compound 347 (1.03 g, 4.03 mmol) and Boc-(D)-Leu-OH (1.4 g, 6 mmol) in 
dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring for 3 h and 
the reaction monitored by TLC. Once complete (TLC) the reaction mixture was filtered 
to remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4, stripped of solvent in vacuo. The residue was 
subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title compound 
(1.38 g, 3 mmol, 73% yield) as a colourless oil. 
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νmax/cm
-1 
3321 2851-2957 1738 1706 1625 1574 1529 1469 1450 1438 1389 1365 1310 
1281 1254 1221 1201 1161 1119 1095 1045 1018 
P (162 MHz, CDCl3) 36.87*, 37.16 
H (400 MHz, CDCl3) 0.77 (3H, d, J 6.4, CH3), 0.79 (3H, d, J 7.7, CH3), 0.83 (3H, d, J 
3.4, CH3), 0.84 (3H, d, J 5.3, CH3), 0.88 (6H, d, J 6.5, 2x CH3), 0.89 (6H, d, J 8.0, 2x 
CH3), 1.28-1.32 (6H, m, 2x OCH2CH3), 1.38 [9H, s, C(CH3)3], 1.39 [9H, s, C(CH3)3], 
1.41-1.52 (6H, m, 2x NHCHCH2 + 2x NHCHCH2CHMe2), 1.57-1.67 (2H, m, 2x 
PCHCH2CHMe2), 1.70-1.88 (4H, m, 2x PCHCH2), 3.93-4.03 (2H, m, OCH2CH3), 4.08-
4.14 (2H, m, OCH2CH3*), 4.23 (1H, td, J 4.7, 9.5, NHCH), 4.28 (1H, td, J 5.2, 9.2, 
NHCH*) 4.78 (1H, d, J 8.9, NH*), 4.83 (1H, d, J 8.9, NH), 5.39 (1H, d, J 11.3, PCH*), 
5.44 (1H, d, J 11.4, PCH), 7.44-7.46 (4H, m, Ar H), 7.51-7.55 (2H, m, Ar H), 7.72-7.77 
(4H, m, Ar H).  
C (101 MHz, CDCl3) 16.61 (d, JP 6.2, OCH2CH3), 16.65 (d, JP 6.0, OCH2CH3), 21.01 
(CH3), 21.11 (CH3), 21.62 (CH3), 21.74 (CH3), 23.02 (CH3), 23.16 (CH3), 23.37 (CH3), 
23.38 (CH3), 24.32 (CHMe2), 24.40 (CHMe2), 24.72 (CHMe2), 24.80 (CHMe2), 28.35 
[C(CH3)3], 28.38 [C(CH3)3], 37.02 (CH2*),  37.40 (CH2), 41.60 (CH2), 41.78 (CH2*), 
52.12 (NHCH), 52.31 (NHCH maj), 61.69 (d, JP 6.5, OCH2CH3), 61.71 (d, JP 6.7, 
OCH2CH3), 69.55 (d, JP 118.9, 2x PCH), 79.73 (OCMe3*), 79.87 (OCMe3), 128.23 (d, 
JP 125.8, Ar C), 128.38 (d, JP 126.1, Ar C), 128.81 (d, JP 12.5, Ar CH), 128.86 (d, JP 
12.5, Ar CH*), 132.45 (d, JP 9.7, Ar CH*), 132.47 (d, JP 9.8, Ar CH), 132.94 (d, JP 2.8, 
Ar CH*), 132.99 (d, JP 2.6, Ar CH), 155.21 (NCO2*), 155.43 (NCO2), 172.33 (d, JP 3.7, 
CCO2), 172.69 (d, JP 4.03, CCO2). 
LRMS m/z (ESI) 487.4 [M+NH4]
+
, 470.3 [M+H]
+
.  
HRMS (ESI) calcd. for C24H41O6N1P1 470.2666, found 470.2667 [M+H]
+
. 
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 (R)-2-Amino-4-methyl-pentanoic acid (S)-1-(ethoxy-phenyl-phosphinoyl)-3-methyl-
butyl ester 393 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 392 (1.38 g, 2.94 
mmol) in dichloromethane (75 ml) maintained at 0 °C for 1 h.  On completion (TLC) 
the reaction mixture was poured into saturated NaHCO3 (50 ml) and the organic layer 
was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  The 
combined organic extracts were washed with brine and then dried over Na2SO4, stripped 
of solvent in vacuo. The residue was subjected to chromatography (EtOAc : Pet. Ether 
3:1 - 1:0) to give the title compound (1.09 g, 3 mmol, quant. yield) as a colourless oil. 
νmax/cm
-1 
3325 2840-2960 1740 1620 1570 1520 1440 1410 1306 1183 1120 1030 
P (162 MHz, CDCl3) 36.83*, 37.02 
H (400 MHz, CDCl3) 0.84 (6H, d, J 5.8, 2x CH3), 0.87-0.92 (18H, m, 6x CH3), 1.28-
1.32 (6H, m, 2x OCH2CH3), 1.23-1.28 (2H, m, NH2CHCH2), 1.29-1.32 (2H, m, 
NH2CHCH2), 1.34 (6H, tdd, J 1.7, 5.4, 7.0, 2x OCH2CH3), 1.44-1.50 (2H, m, 2x 
NH2CHCH2CHMe2), 1.51-1.60 (2H, m, 2x PCHCH2CHMe2), 1.70-1.83 (4H, m, 2x 
PCHCH2), 3.36 (1H, ddd, J 1.1, 5.6, 8.8, NH2CH), 3.41 (1H, ddd, J 1.1, 5.1, 9.3, 
NH2CH*), 3.98-4.06 (2H, m, OCH2CH3), 4.12-4.20 (2H, m, OCH2CH3*), 5.47 (1H, 
ddd, J 1.8, 4.0, JP 12.1, PCH), 5.47 (1H, dddd, J 1.7, 2.5, 4.1, JP 32.8, PCH), 7.47-7.50 
(4H, m, Ar H), 7.56-7.59 (2H, m, Ar H), 7.76-7.80 (4H, m, Ar H).  
C (101 MHz, CDCl3) 16.69 (d, JP 5.9, OCH2CH3), 16.72 (d, JP 5.8, OCH2CH3), 21.20 
(CH3), 21.26 (CH3), 21.58 (CH3), 21.86 (CH3), 23.09 (CH3), 23.30 (CH3), 23.37 (CH3), 
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23.40 (CH3), 24.55 (CHMe2), 24.63 (CHMe2), 24.69 (CHMe2), 24.79 (CHMe2), 37.19 
(CH2),  37.46 (CH2), 43.47 (CH2), 43.65 (CH2), 52.98 (NH2CH), 53.09 (NH2CH), 61.70 
(d, JP 6.7, OCH2CH3), 61.71 (d, JP 6.7, OCH2CH3), 69.04 (d, JP 118.6, PCH), 69.19 (d, 
JP 118.4, PCH), 128.77 (d, JP 125.7, Ar C), 128.50 (d, JP 125.8, Ar C), 128.77 (d, JP 
12.4, Ar CH), 128.82 (d, JP 12.6, Ar CH), 132.50 (d, JP 9.9, Ar CH), 132.57 (d, JP 10.1, 
Ar CH), 133.01 (d, JP 2.8, 2x Ar CH), 175.51 (d, JP 3.1, C=O), 175.73 (d, JP 3.4, C=O). 
LRMS m/z (ESI) 370.4 [M+H]
+
.  
Boc-(S)-Leu-OBn 397 
 
Caesium carbonate (14.8 g, 45 mmol) was added to a stirred solution of Boc-(L)-Leu-
OH (10.5 g, 45 mmol) in DMF and the resulting solution was heated to 60 °C for 1 h.  
The reaction was cooled to 0 °C, benzyl bromide (5.4 ml, 45 mmol) was added slowly 
and the reaction mixture was again heated at 60 °C for a further 3 h.  The solvent was 
removed in vacuo and the residue was diluted with dichloromethane and poured into 
water (50 ml) and the mixture was extracted with dichloromethane (2 x 25 ml). The 
combined organic extracts were washed with saturated NaHCO3 then dried over Na2SO4 
and stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc 
: Pet. Ether 8:1 - 4:1) to give the title compound (13.9 g, 43 mmol, 95% yield) as a 
colourless oil. 
νmax/cm
-1 
3362, 2871-2959, 1711, 1499, 1455, 1389, 1366, 1249, 1157, 1047, 1019. 
H (600 MHz, CDCl3) 0.91 (3H, d, J 6.3, CH3), 0.91 (3H, d, J 6.3, CH3), 1.42 [9H, s, 
[C(CH3)3], 1.45-1.50 (2H, m, CH2), 1.65-1.68 (1H, m, CHMe2), 4.33-4.36 (1H, m, 
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NHCHCO2), 4.90 (1H, d, J 8.1, NH), 5.11-5.19 (2H, 2 x d, J 12.3, CH2Ph), 7.31-7.36 
(5H, m, Ar H). 
C (151 MHz, CDCl3) 22.95 (2 x CH3), 24.88 (CHMe2), 28.43 [C(CH3)3], 41.82 (CH2), 
52.30 (CHCO2), 67.01 (CH2Ph), 79.96 (OCMe3), 128.29 (2 x Ar CH), 128.49 (Ar CH), 
128.68 (2 x Ar CH), 135.62 (Ar C), 155.54 (NCO2), 173.51 (CCO2). 
LRMS m/z (ESI) 339.1 [M+NH4]
+
, 322.1 [M+H]
+
.  
HRMS (ESI) calcd. for C18H31O4N2 339.2278, found 339.2285 [M+NH4]
+
. 
H2N-(S)-Leu-OBn 398 
 
TFA (10 ml, 131 mmol) was added to a stirred solution of compound 397 (9.0 g, 28 
mmol) in dichloromethane (100 ml) maintained at 0 °C and the solution was stirred for 
1 h. On completion (TLC), the reaction mixture was poured into saturated NaHCO3 (50 
ml) and the organic layer was separated.  The organic phase was washed with NaHCO3 
(2 x 25 ml).  The combined organic extracts were washed with brine and then dried over 
Na2SO4 and stripped of solvent in vacuo to give the title compound (5.95 g, 27 mmol, 
96% yield) colourless oil. 
νmax/cm
-1 
3039 2870-2956 1743 1665 1609 1581 1515 1454 1406 1386 1367 1345 1322 
1297 1255 1188 1142 1090 1033 1003 
H (400 MHz, CDCl3) 0.93 (3H, d, J 6.7, CH3), 0.94 (3H, d, J 6.7, CH3), 1.56-1.59 (2H, 
m, CH2), 1.60-1.65 (1H, m, CHMe2), 1.84-1.92 (1H, m, CHCH2), 5.21 (2H, d, J 6.0, 
CH2Ph), 7.34-7.40 (5H, m, Ar H). 
209 
 
C (101 MHz, CDCl3) 17.71 (CH3), 19.45 (CH3), 20.59 (CHMe2), 37.44 (CHCO2), 
39.58 (CH2), 63.48 (CH2Ph), 124.50 (Ar CH), 124.57 (Ar CH), 124.73 (Ar CH), 124.84 
(Ar CH), 124.90 (Ar CH), 131.37 (Ar C), 171.94 (CCO2). 
LRMS m/z (ESI) 222.1 [M+H]
+
 
 Boc-(S)-Leu-(S)-Leu-OBn 399 
 
DCC (7.92 g, 38 mmol), followed by DMAP (0.47 g, 4 mmol ) were added to a stirred 
solution of compound 398 (6.34 g, 35 mmol ) and Boc-(L)-Leu-OH (8.88 g, 38 mmol ) 
in dichloromethane (100 ml) maintained at 0
 
°C.  The mixture was left stirring for 3 h 
and the reaction monitored by TLC.  The reaction mixture was filtered to remove DHU 
and then stripped of solvent in vacuo.  The residue was diluted with dichloromethane 
and poured into water (50 ml) and the organic layer was separated.  The aqueous phase 
was washed with dichloromethane (2 x 25 ml). The combined organic extracts were 
dried over Na2SO4 and stripped of solvent in vacuo. The residue was subjected to 
chromatography (EtOAc : Pet. Ether 4:1 - 2:1) to give the title compound (13.47 g, 31 
mmol, 89% yield) as a white solid. 
mp 92-95 °C;  
νmax/cm
-1 
3337 2870-2957 1727 1681 1661 1518 1454 1389 1366 1322 1292 1271 1248 
1208 1163 1045 1022 
H (600 MHz, CDCl3) 0.89 (12H, d, J 4.4, CH3), 1.42 [9H, s, C(CH3)3], 1.43-1.45 (2H, 
m, CH2), 1.61-1.65 (4H, m, CH2 + 2x CHMe2), 4.08-4.10 (1H, m, CHCH2), 4.62-4.66 
(1H, m, CHCH2), 5.14 (2H, 2x d, J 12.0, CH2Ph), 7.31-7.36 (5H, m, Ar H). 
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C (151 MHz, CDCl3) 21.89 (CH3), 21.97 (CH3), 22.25 (CH3), 22.97 (CH3), 24.76 
(CHMe2), 24.81 (CHMe2), 28.38 [C(CH3)3], 40.96 (CH2), 41.55 (CH2), 50.85 
(NCHCO), 53.03 (CHCO2), 67.16 (CH2Ar), 80.16 (OCMe3), 128.36 (Ar CH), 128.52 
(Ar CH), 128.71 (Ar CH), 135.47 (Ar C), 155.82 (NCO2), 172.30 (CON), 172.63 
(CCO2). 
LRMS m/z (ESI) 452.1 [M+NH4]
+
.  
HRMS (ESI) calcd. for C24H42O5N3 452.3119, found 452.3116 [M+NH4]
+
. 
Boc-(S)-Leu-(S)-Leu-OH 400 
 
A mixture of compound 399 (10.82 g, 25 mmol) and 5% Pd/C (2.16 g, 20% wt) in 
EtOAc (150ml) was stirred under a hydrogen atmosphere overnight. The catalyst was 
filtered through celite and the solvent was removed in vacuo to give the title compound 
(8.37 g, 24 mmol, 98% yield) as a white solid. 
mp 150-153 °C; lit 153-155 °C 
νmax/cm
-1 
3310 2872-2959 1659 1517 1452 1390 1367 12491160 1123 1047 1021 
H (400 MHz, CDCl3) 0.88-0.93 (12H, m, CH3), 1.40 [9H, s, C(CH3)3], 1.45-1.55 (2H, 
m, CH2), 1.52-1.61 (2H, m, CH2), 1.63-1.67 (2H, m, 2x CHMe2), 4.15-4.20 (1H, m, 
NCHCO), 4.56-4.60 (1H, m, CHCO2), 5.32 (1H, d, J 7.5, NH), 6.95 (1H, d, J 5.9, NH), 
9.24 (1H, br s, CO2H). 
C (101 MHz, CDCl3) 21.80 (CH3), 22.31 (CH3), 22.82 (CH3), 23.05 (CH3), 24.71 
(CHMe2), 24.83 (CHMe2), 28.36 [C(CH3)3], 40.82 (CH2), 41.33 (CH2), 50.93 
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(NCHCO), 53.12 (CHCO2), 80.50 (OCMe3), 156.21 (NCO2), 173.11 (CON), 176.36 
(CCO2). 
LRMS m/z (ESI) 343.2 [M+H]
+
.  
HRMS (ESI) calcd. for C17H32O5N2Na 367.2203, found 367.2203 [M+Na]
+
. 
Boc-(R)-Leu-(S)-Leu-OBn 401 
 
DCC (2.81 g, 14 mmol), followed by DMAP (0.17 g, 1 mmol) were added to a stirred 
solution of compound 398 (1.51 g, 7 mmol) and Boc-(D)-Leu-OH (1.64 g, 7 mmol) in 
dichloromethane (100 ml) maintained at 0
 
°C.  The mixture was left stirring for 3 h and 
the reaction monitored by TLC. Once complete (TLC) the reaction mixture was filtered 
to remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo The residue 
was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title 
compound (2.61 g, 6 mmol, 88% yield) as a white solid. 
mp 88-91 °C. 
νmax/cm
-1 
3320 2868-2951 1722 1686 1651 1524 1469 1456 1385 1366 1348 1320 1292 
1274 1251 1237 1207 1165 1124 1047 1025 
H (400 MHz, CDCl3) 0.90-0.96 (12H, m, 4x CH3), 1.46 [9H, s, C(CH3)3], 1.55-1.69 
(6H, m, 2x CHMe2 + 2x CH2), 4.15 (1H, m, NCHCO), 4.66 (1H, m, CHCO2), 4.81 (1H, 
br s, NH), 5.17 (2H, q, J 12.3, CH2Ph), 6.59 (1H, br s, NH), 7.33-7.41 (5H, m, Ar H). 
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C (101 MHz, CDCl3) 21.82 (CH3), 22.85 (2x CH3), 23.00 (CH3), 24.80 (CHMe2), 
25.45 (CHMe2), 28.25 [C(CH3)3], 41.37 (2x CH2), 50.73 (CHCO2), 53.08 (CHCO2), 
67.03 (CH3), 80.22 (OCMe3), 128.23 (Ar CH), 128.40 (Ar CH), 128.60 (Ar CH), 
135.38 (Ar C), 139.90 (NCO2), 172.65 (CON + CCO2). 
LRMS m/z (ESI) 435.2 [M+H]
+
. 
Boc-(R)-Leu-(S)-Leu-OH 402 
 
A mixture of compound 401 (3.13 g, 7 mmol) and 5% Pd/C (0.63 g, 20 % wt) in EtOAc 
was stirred under a hydrogen atmosphere overnight.  The catalyst was filtered through 
celite and the solvent was removed in vacuo to give the title compound (2.48 g, 7 mmol, 
quant. yield) as a white solid. 
mp 154-157 °C. 
νmax/cm
-1 
3301 2870-2957 1697 1657 1521 1453 1388 1366 1248 1158 1046 1022 
H (400 MHz, CDCl3) 0.94 (6H, d, J 6.3, 2x CH3), 0.98 (6H, d, J 6.4, 2x CH3), 1.46 
[9H, s, C(CH3)3], 1.58-1.62 (2H, m, CH2), 1.76-1.84 (4H, m, 2x CHMe2 + CH2), 3.95-
3.97 (2H, m, NCHCO + CHCO2). 
C (101 MHz, CDCl3) 21.27 (2x CH3), 23.41 (2x CH3), 24.35 (2x CHMe2), 28.38 
[C(CH3)3], 43.69 (2x CH2), 53.44 (NCHCO + CHCO2), 80.22 (OCMe3), 155.50 
(NCO2), 169.19 (CON + CCO2). 
LRMS m/z (ESI) 343.2 [M+H]
+
.  
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[1-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-methyl-butyl]-
phenyl-phosphinic acid ethyl ester 405 
 
Triethylamine (0.7 ml, 4.7 mmol) was added to a stirred solution of Boc-(L)-Leu-OH 
(0.73 g, 3.1 mmol) and HBTU (1.4 g, 3.8 mmol) in THF (80 ml) maintained at 0
 
°C.  
After 30 min compound 354 (0.8 g, 3.14 mmol ) was added and the mixture was left 
stirring for 3 h and the reaction monitored by TLC.  Once complete the reaction mixture 
was filtered and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title 
compound (1.35 g, 2.9 mmol, 95% yield) as a colourless oil. 
νmax/cm
-1 
3279 3211 3054 2867-2957 1730 1706 1681 1657 1517 1467 1438 1388 1364 
1299 1275 1245 1225 1198 1164 1121 1097 1014 
P (162 MHz, CDCl3) (1.6:1) 40.65*, 40.76  
H (400 MHz, CDCl3) 0.65-0.72 (6H, m, CH3), 0.88-0.91 (6H, m, CH3 ), 1.07-1.08 (2H, 
m, 2x CHMe2), 1.20 (3H, t, J 7.1, OCH2CH3), 1.32 [9H, s, C(CH3)3], 1.64-1.72 (4H, m, 
CH2
i
Pr), 3.73-3.86 (2H, m, NCHCO + OCH2CH3), 3.95-4.07 (1H, m, OCH2CH3), 4.62-
4.72 (1H, m, PCH), 6.38 (1H, d, J 9.3, NH), 7.36-7.41 (2H, m, Ar H), 7.44-7.49 (1H, m, 
Ar H), 7.71-7.77 (2H, m, Ar H).   
C (101 MHz, CDCl3) 16.37 (d, JP 6.2, OCH2CH3), 16.41 (d, JP 6.0, OCH2CH3), 21.21 
(CH3), 22.78 (CH3), 23.46 (CH3), 23.55 (CH3), 24.26 (CHMe2), 24.31 (CHMe2), 24.38 
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(CHMe2), 24.59 (CHMe2), 28.26 [C(CH3)3], 36.69 (CH2), 36.93 (CH2), 41.10 (CH2), 
41.12 (CH2), 45.32 (d, JP 116.8, PCH), 45.33 (d, JP 118.8, PCH), 52.80 (NCH), 61.36 
(d, JP 7.3, OCH2CH3), 79.75 (OCMe3), 128.14 (d, JP 120.0, Ar C), 128.30 (d, JP 12.1, 
Ar CH), 128.42 (d, JP 12.0, Ar CH), 128.43 (d, JP 123.2, Ar C), 132.40 (d, JP 4.4, Ar 
CH), 132.42 (d, JP 9.0, Ar CH), 132.52 (d, JP 9.7, Ar CH), 132.59 (d, JP 4.4, Ar CH), 
172.01 (NCO2), 172.06 (NCO2). 
LRMS m/z (ESI) 491.4 [M+Na]+, 469.4 [M+H]+.  
HRMS (ESI) calcd. for C24H42O5N2P 469.2826, found 469.2830 [M+H]
+
. 
[1-((R)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-methyl-butyl]-
phenyl-phosphinic acid ethyl ester 406 
 
Triethylamine (0.7 ml, 4.7 mmol) was added to a stirred solution of Boc-(D)-Leu-OH 
(0.73 g, 3.1 mmol) and HBTU (1.4 g, 3.8 mmol) in THF (80 ml) maintained at 0
 
°C.  
After 30 min compound 354a (0.8 g, 3.14 mmol ) was added and the mixture was left 
stirring for 3 h and the reaction monitored by TLC.  Once complete the reaction mixture 
was filtered and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title 
compound (1.31 g, 2.8 mmol, 92% yield) as a colourless oil. 
νmax/cm
-1
 3281 2867-3053 1729 1706 1681 1659 1516 1364 1245 1198 1164 1121 1014 
P (162 MHz, CDCl3) (0.65:1) 41.29, 41.42* (* denotes the distinguishable signals due 
to the major isomer) 
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H (400 MHz, CDCl3) 0.67-0.74 (6H, m, CH3), 0.86-0.93 (6H, m, CH3), 1.24 (3H, t, J 
7.2, OCH2CH3), 1.34 [9H, s, C(CH3)3], 1.37-1.40 (2H, m, 2x CHMe2), 1.60-1.72 (4H, 
m, CH2
i
Pr), 3.76-3.96 (2H, m, NCH + OCH2CH3), 3.95-4.07 (1H, m, OCH2CH3), 4.60-
4.70 (1H, m, PCH), 7.01 (1H, d, J 10.0, NH), 7.38-7.46 (2H, m, Ar H), 7.49-7.52 (1H, 
m, Ar H), 7.70-7.76 (2H, m, Ar H).   
C (101 MHz, CDCl3) 16.27 (d, JP 6.2, OCH2CH3), 16.31 (d, JP 6.1, OCH2CH3), 21.10 
(CH3), 22.75 (CH3), 23.37 (CH3), 23.47 (CH3), 24.21 (CHMe2), 24.31 (CHMe2), 24.43 
(CHMe2), 24.49 (CHMe2), 28.18 [C(CH3)3], 36.53 (CH2), 36.72 (CH2), 40.82 (CH2), 
41.12 (CH2), 45.01 (d, JP 116.7, PCH), 45.24 (d, JP 116.7, PCH), 52.82 (NCH), 61.60 
(d, JP 7.1, OCH2CH3), 79.62 (OCMe3), 128.39 (d, JP 12.21, Ar CH), 128.51 (d, JP 
12.14, Ar CH), 129.31 (d, JP 120.2, Ar C), 129.39 (d, JP 118.7, Ar C), 132.25 (d, JP 
10.0, Ar CH), 132.38 (d, JP 10.1, Ar CH), 132.79 (d, JP 3.0, Ar CH), 132.84 (d, JP 3.2, 
Ar CH), 172.49 (NCO2), 172.92 (NCO2). 
LRMS m/z (ESI) 491.4 [M+Na]+, 469.4 [M+H]+.  
HRMS (ESI) calcd. for C24H42O5N2P 469.2826, found 469.2828 [M+H]
+
. 
{1-[(S)-2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-4-methyl-
pentanoylamino]-3-methyl-butyl}-phenyl-phosphinic acid ethyl ester 407 
 
Triethylamine (0.24 ml, 2 mmol) was added to a stirred solution of compound 400 (0.57 
g, 1.65 mmol) and HBTU (0.66 g, 1.7 mmol) in THF (100 ml) maintained at 0 °C.  
After 30 min compound 354a (0.4 g, 2 mmol) was added and the mixture was left 
stirring for 3 h and the reaction monitored by TLC.  Once complete the reaction mixture 
was filtered and then stripped of solvent in vacuo.  The residue was diluted with 
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dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 1:1) to give the title 
compound (0.82 g, 1 mmol, 90% yield) as a colourless oil. 
νmax/cm
-1
 3221 2850-2957 1689 1528 1439 1366 1208 1161 1121 1025 
P (162 MHz, CDCl3) 40.98 
H (400 MHz, CDCl3) 0.70 (3H, d, J 6.5, 
β
CH3), 0.74 (3H, d, J 6.6, 
β
CH3), 0.86-0.87 
(1H, m, 
γ
CHMe2), 0.89 (3H, d, J 6.5, 
γ
CH3), 0.90 (3H, d, J 6.6, 
γ
CH3), 0.91 (3H, d, J 
7.0, 
α
CH3), 0.93 (3H, d, J 6.6, 
α
CH3), 1.00-1.06 (1H, m, 
γ
CH2
i
Pr), 1.07-1.21 (1H, m, 
γ
CH2
i
Pr), 1.24 (3H, t, J 7.0, OCH2CH3), 1.31-1.35 (1H, m, 
β
CHMe2), 1.40-1.43 (2H, m, 
β
CH2
i
Pr), 1.45 [9H, s, C(CH3)3], 1.63-1.68 (1H, m, 
α
CHMe2), 1.74-1.82 (2H, m, 
α
CH2
i
Pr), 3.80-3.87 (1H, m, OCH2CH3), 4.02-4.09 (1H, m, OCH2CH3), 4.13-4.18 (1H, 
m, 
β
NHCH), 4.67 (1H, q, J 10.6, P
α
CH), 4.86 (1H, dd, J 7.3, 20.4, 
γ
NCHCO), 6.58 (1H, 
d, J 8.4, NH), 7.41-7.43 (2H, m, Ar H), 7.49-7.52 (1H, m, Ar H), 7.77-7.88 (2H, m, Ar 
H).   
C (101 MHz, CDCl3) 16.52 (d, JP 6.2, OCH2CH3), 21.22 (CH3), 21.70 (CH3), 22.97 
(CH3), 23.03 (CH3), 23.57 (CH3), 24.33 (CH3), 24.42 (CHMe2), 24.49 (CHMe2), 24.88 
(CHMe2), 28.50 [C(CH3)3], 36.47 (CH2), 40.65 (CH2), 41.00 (CH2), 45.36 (d, JP 116.0, 
P
α
CH), 52.42 (
β
CHCO2), 61.33 (d, JP 7.2, OCH2CH3), 74.04 (
γ
CHCO2), 80.54 (OCMe3), 
128.29 (d, JP 12.5, Ar CH), 128.45 (d, JP 124.4, Ar C), 128.48 (d, JP 124.1, Ar C), 
128.53 (d, JP 12.2, Ar CH), 132.08 (d, JP 2.7, Ar CH), 132.41 (d, JP 9.9, Ar CH), 132.54 
(d, JP 2.4, Ar CH), 132.71 (d, JP 9.9, Ar CH), 155.93 (NCO2), 169.71 (CCO), 172.08 
(CCO). 
LRMS m/z (ESI) 604.4 [M+Na]+, 582.5 [M+H]+.  
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HRMS (ESI) calcd. for C30H53O6N3P 582.3666, found 582.3670 [M+H]
+
. 
{1-[(S)-2-((S)-2-Amino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-3-
methyl-butyl}-phenyl-phosphinic acid ethyl ester 408 
 
TFA (2 ml, 26 mmol) was added to a stirred solution of compound 407 (0.18 g, 0.3 
mmol) in dichloromethane (20 ml) maintained at 0 °C for 1 h.  On completion of the 
reaction (TLC), the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo.  The residue was subjected to chromatography (EtOAc : 
Pet. Ether 4:1 - 1:0) to give the title compound (0.15 g, 0.31 mmol, quant. yield) as a 
colourless oil. 
νmax/cm
-1 
3217 2871-2957 1706 1666 1545 1469 1439 1387 1368 1207 1154 1122 1033 
P (162 MHz, CDCl3) 41.04, 41.52. 
H (400 MHz, CDCl3) 0.62-0.77 (6H, m, CH3), 0.81-0.96 (12H, m, CH3),1.28 (3H, t, J 
7.0, OCH2CH3), 1.41-1.48 (2H, m, CH2
i
Pr), 1.56-1.76 (4H, m, 2x CH2
i
Pr + CHMe2), 
1.95-2.08 (1H, m, CHMe2), 3.69-3.81 (1H, m, OCH2CH3), 3.83-3.91 (1H, m, NH2CH), 
3.92-4.02 (1H, m, OCH2CH3), 4.39-4.51 (1H, m, NHCH), 4.62-4.71 (1H, m, PCH), 
7.38-7.40 (2H, m, Ar H), 7.54-7.52 (1H, m, Ar H), 7.62-7.76 (2H, m, Ar H).   
C (101 MHz, CDCl3) 16.39 (d, JP 6.4, OCH2CH3), 21.09 (CH3), 21.20 (CH3), 21.32 
(CH3), 21.64 (CH3), 23.14 (CH3), 23.50 (CH3),  25.00 (CHMe2), 25.11 (CHMe2), 25.85 
(CHMe2), 29.71 (CH2), 34.23 (CH2), 40.99 (CH2), 45.24 (d, JP 107.3, PCH), 51.19 
(CHCO), 51.73 (CHCO), 61.63 (d, JP 7.7, OCH2CH3), 126.33 (d, JP 159.5, Ar C), 
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128.41 (d, JP 13.3, Ar CH), 132.51 (d, JP 10.3, Ar CH), 132.66 (d, JP 2.7, Ar CH), 
170.51 (CCO), 174.70 (CCO). 
LRMS m/z (ESI) 504.4 [M+Na]+, 482.4 [M+H]+.  
HRMS (ESI) calcd. for C25H44N3O4P 482.3142, found 482.3146 [M+H]
+
. 
{1-[(S)-2-((R)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-4-methyl-
pentanoylamino]-3-methyl-butyl}-phenyl-phosphinic acid ethyl ester 409 
 
Triethylamine (0.14 ml, 0.99 mmol) was added to a stirred solution of compound 402 
(0.28 g, 0.82 mmol) and HBTU (0.33 g, 0.87 mmol) in THF (80 ml) maintained at 0 °C.  
After 30 min compound 354a (0.2 g, 0.78 mmol) was added and the mixture was left 
stirring for 3 h and the reaction monitored by TLC.  Once complete (TLC) the reaction 
mixture was filtered and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was extracted.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo.  The residue 
was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 2:1) to give the title 
compound (0.43 g, 0.74 mmol, 95% yield) as a colourless oil. 
νmax/cm
-1 
3262 3060 2871-2957 1644 1527 1469 1439 1388 1366 1248 1210 1165 1122 
1033 
P (162 MHz, CDCl3) 40.98 
H (400 MHz, CDCl3) 0.64 (3H, d, J 6.1, 
β
CH3), 0.67 (3H, d, J 6.5, 
β
CH3), 0.88-0.94 
(12H, d, J 6.5, 
α,γ
CH3), 1.06-1.11 (1H, m, 
γ
CHMe2), 1.23 (3H, t, J 6.9, OCH2CH3), 1.26-
1.28 (1H, m, 
β
CHMe2), 1.41 [9H, s, C(CH3)3], 1.47-1.49 (2H, m, 
γ
CH2
i
Pr), 1.54-1.77 
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(5H, m, 
α
CHMe2 + 2x 
α,β
CH2
i
Pr), 3.76-3.88 (1H, m, OCH2CH3), 3.99-4.11 (2H, m, J 
7.0, OCH2CH3 + 
γ
NHCH), 4.44-4.45 (0.5H, m, 
β
NHCH), 4.52-4.57 (0.5H, m, 
β
NHCH), 
4.60-4.76 (1H, m, P
α
CH), 6.36 (0.5H, d, J 8.0, 
β
NH), 6.56 (0.5H, d, J 8.0, 
β
NH), 7.43-
7.47 (2H, m, Ar H), 7.52-755 (1H, m, Ar H), 7.76-7.88 (2H, m, Ar H), 7.72 (0.5H, br s, 
NH a), 7.97 (0.5H, br s, NH a).      
C (101 MHz, CDCl3) 16.34 (d, JP 6.1, OCH2CH3), 16.36 (d, JP 6.2, OCH2CH3), 21.12 
(CH3), 21.22 (CH3), 21.28 (CH3), 21.77 (CH3), 22.10 (CH3), 22.30 (CH3), 22.64 (CH3), 
22.76 (CH3), 22.81 (CH3), 22.93 (CH3), 23.44 (CH3), 23.50 (CH3),  24.31 (CHMe2), 
24.36 (CHMe2), 24.42 (CHMe2), 24.47 (CHMe2), 24.63 (CHMe2), 24.71 (CHMe2), 
28.31 [C(CH3)3], 36.54 (CH2), 40.94 (CH2), 41.66 (CH2), 45.16 (d, JP 117.3, P
α
CH), 
50.87 (
β
CHCO), 53.16 (
γ
CHCO), 61.30 (d, JP 6.8, OCH2CH3), 61.37 (d, JP 6.5, 
OCH2CH3), 79.34 (OCMe3), 79.82 (OCMe3), 128.32 (d, JP 11.9, Ar CH), 128.44 (d, JP 
11.8, Ar CH), 128.48 (d, JP 4.0, Ar CH), 128.59 (d, JP 124.2, Ar C), 132.38 (d, JP 10.1, 
Ar CH), 132.56 (d, JP 4.0, Ar CH), 132.59 (d, JP 10.0, Ar CH), 155.82 (NCO2), 171.82 
(CCO), 172.33 (2x CCO), 172.74 (CCO). 
LRMS m/z (ESI) 604.4 [M+Na]
+
, 582.5 [M+H]
+
.  
HRMS (ESI) calcd. for C30H53O6N3P 582.3666, found 582.3668 [M+H]
+
. 
{1-[(S)-2-((R)-2-Amino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-3-
methyl-butyl}-phenyl-phosphinic acid ethyl ester 410 
 
TFA (2.5 ml, 33 mmol) was added to a stirred solution of compound 409 (1.07 g, 2 
mmol) in dichloromethane (40 ml) maintained at 0 °C for 1 h.  On completion of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
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The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc : 
Pet. Ether 4:1 - 1:0) to give the title compound (0.88 g, 12 mmol, 99% yield) as 
colourless crystals, a mixture of diastereomers. 
mp 172-174 °C. 
νmax/cm
-1 
3271 3056 2868-2956 1674 1653 1641 1539 1469 1438 1385 1367 1255 1195 
1121 1012 
P (162 MHz, CDCl3) 40.19, 40.23. 
H (400 MHz, CDCl3) 0.74 (3H, d, J 6.7, 
β
CH3), 0.77 (3H, d, J 6.3, 
β
CH3), 0.90 (3H, d, J 
6.4, 
γ
CH3), 0.92 (3H, d, J 6.4, 
γ
CH3), 0.93 (3H, d, J 6.4, 
α
CH3), 0.97 (3H, d, J 7.8, 
α
CH3), 1.00-1.06 (1H, m, 
β
CH2
i
Pr), 1.10-1.20 (2H, m, 
β
CHMe2 + 
β
CH2
i
Pr), 1.24-1.32 
(1H, m, 
γ
CHMe2), 1.26 (3H, t, J 7.0, OCH2CH3), 1.59 (2H, ddd, J 4.5, 9.3, JP 18.4 
γ
CH2
i
Pr), 1.65-1.76 (3H, m, 
α
CH2
i
Pr + 
α
CHMe2), 3.32 (1H, dt, J 3.8, 9.7, 
γ
NH2CH), 
3.81-3.91 (1H, m, OCH2CH3), 4.03-4.13 (1H, m, OCH2CH3), 4.27-4.35 (1H, m, 
β
NHCH), 4.68-4.77 (1H, m, P
α
CH), 7.08-7.14 (1H, m, 
α
NH), 7.38 (1H, t, J 8.4, 
β
NH), 
7.45-7.49 (2H, m, Ar H), 7.54-7.57 (1H, m, Ar H), 7.79-7.84 (2H, m, Ar H).   
C (101 MHz, CDCl3) 16.38 (d, JP 6.3, OCH2CH3), 21.18 (CH3), 21.22 (CH3), 21.30 
(CH3), 21.33 (CH3), 21.83 (CH3), 22.08 (CH3),  22.89 (CH3),  23.04 (CH3),  23.40 
(CH3),  23.41 (CH3),  23.47 (CH3),  23.55 (CH3),  24.42 (CHMe2), 24.73 (CHMe2), 
24.82 (CHMe2), 36.73 (CH2), 36.84 (CH2), 41.06 (CH2), 41.44 (CH2), 43.90 (CH2), 
44.00 (CH2), 44.66 (d, JP 116.4, P
α
CH), 45.28 (d, JP 116.3, P
α
CH), 50.71 (
β
NHCH), 
50.82 (
β
NHCH), 53.34 (
γ
NH2CH), 53.51 (
γ
NH2CH), 61.29 (d, JP 7.1, OCH2CH3), 61.36 
(d, JP 6.9, OCH2CH3), 128.37 (d, JP 12.5, Ar CH), 128.51 (d, JP 123.9, Ar C), 132.51 (d, 
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JP 10.2, Ar CH), 132.58 (d, JP 3.5, Ar CH), 171.65 (d, JP 4.3, CCO), 171.84 (d, JP 4.2, 
CCO), 175.39 (CCO), 175.50 (CCO). 
LRMS m/z (ESI) 504.4 [M+Na]+, 482.4 [M+H]+.  
HRMS (ESI) calcd. for C25H44N3O4P 482.3142, found 482.3148  [M+H]
+
. 
(S)-2-hydroxy-4-methylpentanoic acid 416
113
 
 
A solution of sodium nitrite (31.0 g, 0.45 mol) in water (100 ml) was added dropwise 
over 3 h to a stirred solution of L-Leucine (9.84 g, 75 mmol) in 0.5M sulphuric acid 
(300 ml) maintained at 0 ºC.  Once the addition was complete the reaction was left to 
stir for 24 h at room temperature. The reaction mixture was extracted with diethyl ether 
(4 x 250 ml).  The combined organic extracts were dried over Na2SO4 and stripped of 
solvent in vacuo to give a yellow oil which on standing crystallised to afford the title 
compound (7.52 g, 56.9 mmol, 76 % yield) as colourless crystals.  
mp 79-81 °C. (lit. 79-80 °C) 
[]D (c 1 g/ 100 ml) -2740.5° (lit., -2760.5) 
νmax/cm
-1 
3419 2875-2932 1701 1468 1389 1362 1343 1268 1228 1170 1137 1120 1077 
H (600 MHz, CDCl3) 0.95 (6H, d, J 6.0, 2 x CH3), 1.57-1.65 (2H, m, CH2), 1.86-1.93 
(1H, m, CHMe2), 4.27-4.29 (1H, dd, J 5.1, 8.4, CHCH2).  
C (151 MHz, CDCl3) 21.52 (CH3), 23.31 (CH3), 24.57 (CHMe2), 43.29 (CH2
i
Pr), 69.02 
(CHCO2H), 180.75 (CCO2). 
LRMS m/z (ESI) 131.07 [M-H]
- 
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(S)-2-Hydroxy-4-methylpentanoic acid methyl ester 417
113
 
 
Acetyl chloride (0.30 ml, 4.16 mmol), was slowly added to a stirred solution of 
compound 416 (0.5 g, 3.8 mmol) in methanol (80 ml) maintained at 0 
o
C. Once the 
addition was complete the reaction was left to stir at room temperature for 1 h. After 
confirmation that the reaction was complete by TLC, the solution was concentrated in 
vacuo and poured into sat. NaHCO3 to neutralise the acid.  The reaction mixture was 
extracted with dichloromethane (2 x 25 ml).  The combined extracts were dried over 
Na2SO4 and stripped of solvent in vacuo to give the title compound (396 mg, 72% yield) 
as a colourless oil. 
νmax/cm
-1 
3250 2890-2965 1670 1386 1224 1207 1165 1121  
H (400 MHz, CDCl3) 0.93 (3H, d, J 6.7, CH3), 0.98 (3H, d, J 6.7, CH3), 1.55 (2H, m, 
CH2), 1.86 (1H, m, CHMe2), 3.76 (3H, s, OCH3), 4.20 (1H, m, CHCO2), 4.30 (1H, s, 
OH). 
C (101 MHz, CDCl3) 21.92 (CH3), 23.59 (CH3), 24.60 (CHMe2), 43.5 (CH2), 52.6 
(OCH3), 69.1 (CHCO2), 176.48 (CCO2). 
LRMS m/z (ESI) 147.0 [M+H]
+ 
(S)-2-Hydroxy-4-methyl-pentanoic acid ethyl ester 418 
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Acetyl chloride (4.7 ml, 67 mmol), was added to a stirred solution of  compound 416 
(8.0 g, 61 mmol) in ethanol (100 ml) maintained at 0
 
°C.  The solution was allowed to 
stir for 1 h and monitored by TLC. On completion of the reaction, the solvent was 
removed in vacuo.  The reaction mixture was poured into water (50 ml) and was washed 
with dichloromethane (2 x 25 ml).  The combined organic extracts were washed with 
saturated NaHCO3, followed by brine and then dried over Na2SO4 and stripped of 
solvent in vacuo to give the title compound (9.07 g, 57 mmol, 93 % yield) as a 
colourless oil. 
νmax/cm
-1 
3258 2899-2957 1672 1590 1437 1386 1224 1207 1162 1121 1099 1049 1018 
H (400 MHz, CDCl3) 0.97 (6H, d, J 5.8, CH3), 1.29 (3H, t, J 7.1, OCH2CH3), 1.59-1.69 
(1H, m, CHMe2), 1.86-1.96 (2H, m, CH2
i
Pr), 4.25-4.32 (2H, m, OCH2CH3), 5.11-5.15 
(1H, m, CHCO2). 
C (101 MHz, CDCl3) 14.10 (OCH2CH3), 21.43 (CH3), 21.53 (CH3), 28.96 (CHMe2), 
39.89 (CH2), 52.71 (OCH), 61.46 (OCH2CH3), 170.18 (C=O). 
LRMS m/z (ESI) 161.1 [M+H]
+ 
(S)-2-Hydroxy-4-methyl-pentanoic acid benzyl ester 419 
 
NaHCO3 (0.35 g, 4.2 mmol), was added to a stirred solution of compound 416 (0.50 g, 
3.8 mmol) in DMF heated to 60 °C for 1 h.  The reaction was cooled to 0 °C, benzyl 
bromide (0.5 ml, 4.2 mmol) was added slowly and the reaction mixture was heated at 60 
°C for a further 3 h.  The solvent was removed in vacuo and the residue was diluted 
with dichloromethane and poured into water (50 ml) and the organic layer was 
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separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were washed with saturated NaHCO3 then dried over Na2SO4 
and stripped of solvent in vacuo.  The residue was subjected to chromatography (EtOAc 
: Pet. Ether 10:1 - 4:1) to give the title compound (0.67 g, 3 mmol, 80% yield) as a 
colourless oil. 
νmax/cm
-1
 3360 2860-2957 1731 1455 1368 1195 1137 1081 
H (400 MHz, CDCl3) 0.85 (3H, d, J 6.7, CH3), 0.86 (3H, d, J 6.7, CH3), 1.48-1.52 (2H, 
m, CH2), 1.79-1.88 (1H, m, CHMe2), 4.18 (1H, dd, J 5.7, 7.6, CH
i
Pr), 5.13 (2H, s, 
CH2Ar), 7.25-7.31 (5H, m, Ar H). 
C (101 MHz, CDCl3) 21.54 (CH3), 23.22 (CH3), 24.40 (CHMe2), 43.36 (CH2), 67.34 
(CH2Ar), 128.33 (Ar CH), 128.57 (Ar CH), 128.67 (Ar CH), 135.18 (Ar C), 175.83 
(CCO2). 
LRMS m/z (ESI) 223.1 [M+H]
+ 
(S)-methyl 2-((chlorocarbonyl)oxy)-4-methylpentanoate 420 
 
Triphosgene (0.295 g, 0.99 mmol), followed by pyridine (0.24 ml, 2.98 mmol) were 
slowly added to a solution of compound 417 (396 mg, 2.71 mmol) in diethyl ether (80 
ml) and the resulting mixture was stirred for 3 h at 0 °C under a dry nitrogen  
atmosphere. Once the reaction was complete (TLC) the solution was concentrated in 
vacuo.  The residue was poured into 0.1M HCl (60 ml) and the mixture was extracted 
with dichloromethane (2 x 50 ml).  The organic extracts were washed with water and 
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were dried over Na2SO4.  The solvent was removed in vacuo to give the title compound 
as an oil (450 mg, 79% yield). 
H (400 MHz, CDCl3) 0.74 (3H, d, J 6.5, CH3), 0.81 (3H, d, J 6.5, CH3), 1.68 (2H, m, 
CH2), 1.75 (1H, m, CHMe2), 5.18 (3H, s, OCH3), 4.10 (1H, m, CH
i
Pr). 
C (101 MHz, CDCl3) 21.56 (CH3), 22.46 (CH3), 24.74 (CHMe2), 39.32 (CH2), 69.24 
(CH), 53.67 (OCH3), 149.9 (COCl), 167.91 (CCO2). 
LRMS m/z (ESI) 210.6 [M+H]
+
 
(2S)-methyl 4-methyl-2-((phenylhydrophosphoryl)oxy)pentanoate 422 
 
Phenylphosphinic acid (0.34 g, 2.38 mmol) was added to a solution of compound 420 
(450 mg, 2.16 mmol) in dichloromethane (80 ml) followed by careful addition of 
pyridine (0.20 ml, 2.38 mmol) (Caution! Exothermic reaction; Rapid Effervescence) at 
0 °C.  The solution was removed from the ice bath and left to stir for 30 min.  The 
reaction was then warmed to 40 °C and left to stir for 1 h.  The solution was poured into 
0.1M HCl (20 ml) and the organic layer was extracted with dichloromethane (2 x 50 
ml).  The organic extracts were washed with water and were dried using Na2SO4.  The 
solvent was removed in vacuo to give the title compound as a colourless oil. (520 mg, 
89% yield). 
P (162 MHz, CDCl3) 45.86, 45.93. 
H (400 MHz, CDCl3) 0.77 (3H, d, J 6.7, CH3), 0.79 (3H, d, J 6.7, CH3), 1.50 (2H, m, 
CH2), 1.66 (1H, m, CHMe2), 3.58 (3H, s, OCH3), 4.83 (1H, m, CH
i
Pr), 7.27-7.65 (5H, 
m, Ar H), 7.55 (1H, d, JP 560.0, PH). 
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C (101 MHz, CDCl3) 21.42 (CH3), 22.84 (CH3), 24.37 (CHMe2), 39.67 (CH2), 52.11 
(OCH3), 74.42 (d, JP 100.6, PCH), 128.42 (d, JP 13.2, Ar CH), 130.19 (d, JP 11.5, Ar 
CH), 131.55 (d, JP 2.8, Ar CH), 135.79 (d, JP 128.4, Ar C), 170.63 (CCO2). 
LRMS m/z (ESI) 271.3 [M+H]
+
.
 
(2S)-ethyl 4-methyl-2-((phenylhydrophosphoryl)oxy)pentanoate 423 
 
Triphosgene (3.07 g, 10 mmol), followed by pyridine (2.5 ml, 31 mmol) were added to 
a stirred solution of compound 421 (4.52 g, 28 mmol) in dichloromethane (100 ml) 
maintained at 0 °C under a dry nitrogen atmosphere.  The mixture was left stirring for 
approximately 3 h at 0 °C until formation of the chloroformate was complete.  Pyridine 
(2.5 ml, 31 mmol) was slowly added to the stirred solution of the chloroformate and 
phenylphosphinic acid (4.41 g, 31 mmol).  (Caution! Exothermic reaction; Rapid 
Effervescence).  Once the effervescence had stopped the stirred solution was left to 
warm up to room temperature under a dry nitrogen atmosphere then refluxed for 1-2 h.  
Once the reaction was confirmed complete the solution was poured into 0.1M 
hydrochloric acid (50 ml) and the organic layer was separated.  The organic extracts 
were washed with water (2 x 25 ml) and dried using Na2SO4.  The combined organic 
extracts were stripped of solvent in vacuo to give the title compound (7.60 g, 27 mmol, 
95 % yield) as a colourless oil. 
 
 
P (162 MHz, CDCl3) 26.05, 26.49*. 
H (400 MHz, CDCl3) 0.87 (6H, d, J 6.7, 2x CH3), 1.25 (3H, t, J 7.0, OCH2CH3), 1.50-
1.54 (2H, m, CH2), 1.83 (1H, sep, 6.7, CHMe2), 4.02-4.08 (1H, m, OCH2CH3), 4.17-
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4.21 (2H, m, CHCH2 + OCH2CH3), 7.40-7.44 (2H, m, Ar H), 7.49-7.53 (1H, m, Ar H), 
7.59 (1H, d, JPH 561.2, P-H), 7.69-7.75 (2H, m, Ar H).  
C (101 MHz, CDCl3) 16.8 (d, JP 6.2, OCH2CH3), 21.46 (CH3), 23.33 (CH3), 24.43 
(CH), 43.12 (CH2), 62.35 (d, JP 7.3, OCH2CH3), 68.82 (CH), 128.63 (d, JP 13.8, 2x Ar 
H), 130.63 (d, JP 12.0, 2x Ar H), 131.26 (Ar C), 132.58 (d, JP 132.6, Ar H).      
LRMS m/z (ESI) 285.1 [M+H]
+
 
(2S)-methyl 2-(((1-hydroxy-3-methylbutyl)(phenyl)phosphoryl)oxy)-4-
methylpentanoate 426  
 
Triethylamine (2.1 ml, 15.1 mmol) was added to a stirred solution of compound 422 
(3.70 g, 13.7 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry 
nitrogen  atmosphere. After 15 min TMSCl (1.9 ml, 15.1 mmol) was slowly added 
(Caution!: Excessive fuming) and the reaction mixture was left stirring for a further 15 
min. Isovaleraldehyde (1.47 ml, 13.7 mmol) was added and the reaction mixture was 
left to warm up to room temperature overnight under a dry nitrogen atmosphere.  Once 
the reaction was complete the reaction mixture was poured into water (50 ml) and the 
organic layer was separated.  The aqueous phase was washed with dichloromethane (2 x 
25 ml). The combined organic extracts were dried over Na2SO4 and stripped of solvent 
in vacuo to give crude compound 422 (5.55 g, 12.9 mmol, 95 % yield) as a colourless 
oil.  Tetrabutylammonium fluoride (5 ml of a 1M solution in THF) was added to a 
stirred solution of compound 422 (5.55 g, 12.9 mmol) in diethyl ether (75 ml) / THF (75 
ml).  The reaction mixture was poured into water (50 ml) and was extracted with 
dichloromethane (3 x  25 ml). The combined organic extracts were dried over Na2SO4 
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and stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc 
: Pet. Ether 6:1 - 1:0) to give the title compound (4.59 g, 12.9 mmol, quant. yield) as a 
colourless oil. (see Appendix II) 
νmax/cm
-1 
3260 2855-2965 1750 1580 1460 1430 1355 1270 1192 1119 1068  
P (162 MHz, CDCl3) 41.87, 42.10, 42.27, 43.40 (1 : 1.7 : 2.5 : 1.6). 
H (400 MHz, CDCl3) 0.72-0.93, 1.20-1.87, 3.16-5.10, 7.14-7.85. 
LRMS m/z (ESI) 357.2 [M+H]
+ 
(2S)-ethyl 2-(((1-hydroxy-3-methylbutyl)(phenyl)phosphoryl)oxy)-4-
methylpentanoate 427  
 
Triethylamine (7.7 ml, 56 mmol) was added to a stirred solution of compound 423 
(14.36 g, 51 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry 
nitrogen atmosphere. After 15 min TMSCl (7 ml, 56 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. 
Isovaleraldehyde (6 ml, 56 mmol) was added and the reaction mixture was left to warm 
up to room temperature overnight under a dry nitrogen atmosphere.  Once the reaction 
was complete the reaction mixture was poured into water (50 ml) and the organic layer 
was separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo to 
give crude compound 425 (20.68 g, 47 mmol, 93% yield) as a colourless oil.  
Tetrabutylammonium fluoride (10 ml of a 1M solution in THF) was added to a stirred 
solution of compound 425 (20.68 g, 47 mmol) in diethyl ether (75 ml) / THF (75 ml).  
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The reaction mixture was poured into water (50 ml) and was extracted with 
dichloromethane (3 x 25 ml). The combined organic extracts were dried over Na2SO4 
and stripped of solvent in vacuo. The residue was subjected to chromatography (EtOAc 
: Pet. Ether 4:1 - 1:1) to give the title compound as a colourless oil (17.32 g, 47 mmol, 
quant. yield), a mixture of diastereomers. (see Appendix II) 
νmax/cm
-1 
3282 2870-2957 1754 1593 1468 1438 1369 1272 1193 1120 1068 1025 
P (162 MHz, CDCl3) 41.97, 42.55, 42.59, 43.19 (ratio 1 : 0.42 : 0.56 : 0.63) 
H (400 MHz, CDCl3) 0.67-0.77 (26H, m, CH3), 0.80-0.87 (8H, m, CH3), 0.89-0.93 
(3H, m, OCH2CH3), 1.13-1.18 (6H, m, OCH2CH3), 1.20-1.88 (17H, m, CH + CH2), 
3.78-3.90 (2H, OCH2CH3), 3.93-4.02 (2H, CH), 4.04-4.16 (5H, m, CH + OCH2CH3), 
4.61-4.66 (1H, m, CH), 4.72-4.77 (1H, m, CH), 4.89-4.94 (2H, m, CH), 7.27-7.33 (6H, 
m, Ar H), 7.36-7.41 (3H, m, Ar H), 7.70-7.78 (6H, m, Ar H). 
C (101 MHz, CDCl3) 13.70 (OCH2CH3), 13.95 (OCH2CH3), 13.99 (OCH2CH3), 20.78 
(CH3), 20.86 (CH3), 20.97 (CH3), 21.02 (CH3), 21.06 (CH3), 21.10 (CH3), 21.64 (CH3), 
21.66 (CH3), 22.89 (CH), 22.93 (CH), 23.33 (CH), 23.42 (CH), 23.49 (CH), 23.81 
(CH), 23.95 (CH), 24.02 (CH), 24.21 (CH), 38.45 (d, JP 2.2, CH2), 38.57 (d, JP 3.9, 
CH2), 39.01 (d, JP 3.5, CH2), 39.31 (d, JP 3.4, CH2), 41.85 (d, JP 4.7, CH2), 42.00 (d, JP 
4.7, CH2), 42.22 (d, JP 4.6, CH2), 42.26 (d, JP 4.4, CH2), 60.96 (OCH2CH3), 61.40 
(OCH2CH3), 61.83 (OCH2CH3), 67.18 (d, JP 116.3, PCH), 68.00 (d, JP 108.9, PCH), 
68.47 (d, JP 115.1, PCH), 69.09 (d, JP 108.6, PCH), 70.94 (d, JP 6.7, OCH), 71.65 (d, JP 
7.0, OCH), 71.72 (d, JP 7.4, OCH), 71.79 (d, JP 7.3, OCH), 127.96 (d, JP 9.3, Ar CH), 
128.04 (d, JP 7.1, Ar CH), 128.11 (d, JP 123.2, Ar C), 128.18 (d, JP 117.6, Ar C), 128.19 
(d, JP 12.3, Ar CH), 128.28 (d, JP 12.0, Ar CH), 128.40 (d, JP 117.4, Ar C), 128.86 (d, 
JP 121.6, Ar C), 131.79 (d, JP 9.4, Ar CH), 131.96 (d, JP 9.2, Ar CH), 132.42 (d, JP 5.6, 
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Ar CH), 132.52 (d, JP 5.5, Ar CH), 170.78 (d, JP 2.8, CCO2), 171.82 (d, JP 1.9, CCO2), 
172.76 (d, JP 1.6, CCO2). 
LRMS m/z (ESI) 372 [M+H]
+ 
Ethyl 2-(((1-(benzylamino)-3-methylbutyl)(phenyl)phosphoryl)oxy)-4-
methylpentanoate 431  
 
Triethylamine (4.5 ml, 32 mmol) was added to a stirred solution of compound 423 (7.60 
g, 27 mmol) in dichloromethane (150 ml) maintained at 0 °C under a dry nitrogen 
atmosphere. After 15 min TMSCl (4 ml, 32 mmol) was slowly added (Caution! 
Excessive fuming) and the reaction mixture was left stirring for a further 15 min. Imine 
379 (6.06 g, 32 mmol) was added and the reaction mixture was left to warm up to room 
temperature overnight under a dry nitrogen atmosphere.  Once the reaction was 
complete the reaction mixture was poured into water (50 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
The residue was subjected to chromatography (EtOAc : Pet. Ether 8:1 - 1:1) to give the 
title compound (12.2 g, 27 mmol, quant. yield) as a colourless oil. (see Appendix II) 
νmax/cm
-1 
2869-2956 1751 1669 1592 1495 1453 1438 1386 1368 1270 121 1119 1068 
1025 
P (162 MHz, CDCl3) (2.13:1:1.61:3.59) 44.88, 45.04, 45.26, 45.48.  
H (400 MHz, CDCl3) 0.50-0.94 (?H, m, CH3, OCH2CH3), 1.06-1.16 (?H, m, 
OCH2CH3), 1.19-1.82 (?H, CH + CH2), 2.94-3.06 (?H, m, PCH), 3.41-3.91 (?H, CH2Ar 
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+ OCH2CH3), 3.97-4.13 (?H, m, OCH2CH3), 4.60-4.75 (?H, m, PCH), 6.87-7.76 (?H, m, 
Ar H). 
C (101 MHz, CDCl3) 13.90 (OCH2CH3), 14.17 (OCH2CH3), 21.05 (CH3), 21.19 (CH3), 
21.34 (CH3), 21.44 (CH3), 21.50 (CH3), 21.95 (CH3), 21.98 (CH3), 22.07 (CH3), 22.94 
(CMe2), 23.42 (CMe2), 23.49 (CMe2), 24.06 (CMe2), 24.23 (CMe2), 24.42 (CMe2), 
24.53 (CMe2), 37.90 (d, JP 2.6, CH2), 38.00 (d, JP 3.5, CH2), 38.31 (d, JP 5.2, CH2), 
42.21 (d, JP 5.4, CH2), 42.30 (d, JP 5.0, CH2), 42.66 (d, JP 3.9, CH2), 52.11 (d, JP 3.9, 
CH2Ar), 52.17 (d, JP 4.8, CH2Ar), 52.36 (d, JP 2.8, CH2Ar), 52.54 (d, JP 4.3, CH2Ar), 
54.55 (d, JP 134.3, PCH), 54.59 (d, JP 134.6, PCH), 54.71 (d, JP 101.5, PCH), 54.92 (d, 
JP 107.3, PCH), 61.06 (OCH2CH3), 61.09 (OCH2CH3), 61.34 (OCH2CH3), 71.45 (d, JP 
7.5, PCH), 71.53 (d, JP 7.6, PCH), 71.57 (d, JP 7.7, PCH), 71.60 (d, JP 7.7, PCH), 
126.94 (Ar CH), 127.01 (Ar CH), 127.86-128.94 (Ar CH), 128.23 (Ar CH), 128.37 (Ar 
CH), 130.42 (d, JP 115.9, Ar C), 130.20 (d, JP 115.4, Ar C), 131.97-132.81 (Ar CH), 
140.28 (Ar C), 140.40 (Ar C), 171.51 (CCO2), 171.53 (CCO2), 171.56 (CCO2), 171.58 
(CCO2). 
LRMS m/z (ESI) 460.4 [M+H]
+
.  
HRMS (ESI) calcd. for C26H39O4NP 460.2611, found 460.2608 [M+H]
+
. 
(2S)-4-methyl-2-((phenylhydrophosphoryl)oxy)pentanoic acid 434 
 
Triphosgene (2.52 g, 9 mmol), followed by pyridine (2 ml, 26 mmol) were added to a 
stirred solution of compound 416 (3.06 g, 23 mmol) in dichloromethane (150 ml) 
maintained at 0 °C under a dry nitrogen atmosphere.  The mixture was left stirring for 
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approximately 3 h at 0 °C and compound 322 (3.62 g, 26 mmol) was added.  Pyridine 
(2.1 ml, 26 mmol) was then slowly added to the stirred solution (Caution! Exothermic 
reaction; Rapid Effervescence).  Once the effervescence had stopped the stirred solution 
was left to warm up to room temperature under a dry nitrogen atmosphere and was then 
refluxed for 1-2 h.  Once the reaction was complete (TLC), the solution was poured into 
0.1M hydrochloric acid (50 ml) and the organic layer was separated.  The organic 
extracts were washed with water (2 x 25 ml) and dried over Na2SO4.  The combined 
organic extracts were stripped of solvent in vacuo to give the title compound (5.93 g, 23 
mmol, quant. yield) as a colourless oil. 
νmax/cm
-1 
2870-2959, 2586, 2408, 2162, 1680, 1589, 1483, 1439, 1402, 1313, 1168, 
1147, 1095, 1003. 
P (162 MHz, CDCl3) 27.80, 28.74.  
H (400 MHz, CDCl3) 0.81 (3H, d, J 6.1, CH3), 0.84 (3H, d, J 6.3, CH3), 1.67-1.72 (3H, 
m, CHMe2 + CH2), 4.86-4.93 (1H, m, CH
i
Pr), 7.40-7.49 (2H, m, Ar H), 7.53-7.58 (1H, 
m, Ar H), 7.70-7.81 (2H, m, Ar H), 7.71 (1H, d, JP 577.3, PH).
C (101 MHz, CDCl3) 21.09 (CH3), 23.09 (CH3), 24.32 (CH), 41.23 (CH2), 73.20 (d, JP 
7.6, CH),  74.52 (d, JP 7.3, CH), 128.81 (d, JP 137.0, Ar C), 128.87 (d, JP 14.4, 2x Ar 
H), 128.93 (d, JP 136.0, Ar C),  130.72 (d, JP 12.7, Ar CH),  130.85 (d, JP 12.9, Ar CH),  
133.50 (d, JP 2.9, Ar CH), 133.60 (d, JP 2.8, Ar CH), 173.04 (CCO2). 
LRMS m/z (ESI) 257.1 [M+H]
+
. 
(2S)-2-(((1-((tert-butyldimethylsilyl)oxy)-3-methylbutyl)(phenyl)phosphoryl)oxy)-4-
methylpentanoic acid 437  
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TBDMSCl (2.12 g, 14 mmol) was added in small portions to a stirred solution of 
imidazole (0.96 g, 14 mmol) and compound 436 (3.21 g, 9 mmol) in dichloromethane 
(100ml) cooled to 0 °C for the addition.  The reaction mixture was left to warm to rt and 
stirred for 5 h.  Once the reaction was complete the solid was filtered and the remaining 
solvent removed in vacuo. The residue was subjected to chromatography (EtOAc : Pet. 
Ether 10:1 - 1:1) to give the title compound (4.28 g, 9 mmol, quant. yield) as a 
colourless oil. (see Appendix II) 
νmax/cm
-1 
2858-2956 1740 1470 1439 1387 1368 1251 1173 1119 1064 1003 
P (162 MHz, CDCl3) 42.98, 43.55, 44.39, (1 : 1.1 : 0.5) 
H (400 MHz, CDCl3) -0.02, 0.00, 0.001 (18H, 3x s, C(CH3)3Si(CH3)2), 0.64-0.97 (36H, 
m, CH3), 0.71, 0.75, 0.78 [27H, 3x s, C(CH3)3SiMe2], 4.02-4.17 (2H, m, 2x PCH), 4.34 
(1H, td, J 3.17, 9.89, PCH), 4.65-4.70, 4.76-4.85 (3H, m, CHCH2), 7.30-7.35 (4H, m, 
Ar-H), 7.37-7.46 (4H, m, Ar-H), 7.48-7.51 (1H, m, Ar-H), 7.67-7.72 (1H, m, Ar-H), 
7.74-7.79 (5H, m, Ar-H), 9.76 (3H, s, OH). 
C (101 MHz, CDCl3) -5.22, -5.01, -4.86, -4.57, -4.45, -4.41, 18.17, 18.23, 21.42 (CH3), 
21.77 (CH3), 21.84 (CH3), 21.97 (CH3), 22.93 (CH3), 23.13 (CH3), 23.42 (CH3), 23.56 
(CH3), 23.64 (CH3), 23.77 (CH3), 23.88 (CH3), 24.28 (CHMe2), 24.32 (CHMe2), 24.36 
(CHMe2), 25.78 ([C(CH3)3]), 25.81 ([C(CH3)3]), 25.85 ([C(CH3)3]), 41.25 (d, JP 4.9, 
CH2), 42.02 (d, JP 5.0, CH2), 42.30 (d, JP 4.3, CH2), 70.02 (d, JP 121.7, PCH), 69.98 (d, 
JP 120.8, PCH), 69.78 (d, JP 121.6, PCH), 73.07 (d, JP 8.2, CH), 73.04 (d, JP 7.2, CH), 
72.91 (d, JP 8.3, CH), 127.99 (d, JP 12.8, Ar CH), 128.06 (d, JP 12.5, Ar CH), 128.11 (d, 
JP 13.3, Ar CH), 127.97 (d, JP 123.2, Ar C), 127.88 (d, JP 120.8, Ar C), 127.75 (d, JP 
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122.3, Ar C), 132.34 (d, JP 2.9, Ar CH), 132.50 (d, JP 2.7, Ar CH), 132.44 (d, JP 3.7, Ar 
CH), 132.80 (d, JP 9.8, Ar CH), 132.67 (d, JP 9.9, Ar CH), 132.65 (d, JP 9.4, Ar CH), 
172.32 (CCO2), 172.80 (CCO2), 172.89 (CCO2). 
LRMS m/z (ESI) 457.4 [M+H]
+
.  
HRMS (ESI) calcd. for C23H42O5PSi 457.2534, found 457.2537 [M+H]
+
. 
H2N-(S)-Leu-(S)-Leu-OBn 443 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 399 (5.39 g, 12 
mmol) in dichloromethane (100 ml) maintained at 0 °C for 1 h. On completion of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo to give the title compound (3.36 g, 10 mmol, 81% yield) as 
a colourless oil. 
νmax/cm
-1 
3195 3058 2870-2957 1672 1585 1513 1443 1412 1385 1367 1321 1260 1234 
1173 1149 
H (600 MHz, CDCl3) 0.94 (6H, d, J 6.3, CH3), 0.98 (6H, d, J 6.4, CH3), 1.57-1.62 (2H, 
m, CH2), 1.75-1.84 (4H, m, CH2 + 2x CHMe2), 3.94-3.97 (2H, dt, J 2.9, 6.4, 2x 
NCHCO), 4.69 (2H, s, CH2Ph), 6.77 (2H, br s, NH2), 7.26-7.31 (1H, m, Ar H), 7.34-
7.37 (4H, m, Ar H). 
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C (151 MHz, CDCl3) 21.25 (CH3), 23.40 (CH3), 24.36 (2x CHMe2), 43.64 (2x CH2), 
53.44 (2 x NCHCO2), 65.48 (CH2Ar), 127.12 (2x Ar CH), 127.78 (Ar CH), 128.69 (2x 
Ar CH), 141.02 (Ar C), 169.11 (CON + CCO2). 
LRMS m/z (ESI) 335.2 [M+H]
+
.  
HRMS (ESI) calcd. for C19H31O3N2 335.2329, found 335.2333 [M+H]
+
. 
Boc-(S)-Leu-(S)-Leu-(S)-Leu-OBn 444 
 
DCC (2.79 g, 14 mmol), followed by DMAP (0.17 g, 1 mmol) were added to a stirred 
solution of compound 443 (4.11 g, 12 mmol ) and Boc-(L)-Leu-OH (3.13 g, 14 mmol) 
in dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring for 3 h 
and the reaction monitored by TLC. Once complete the reaction mixture was filtered to 
remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 1:1) to give the title 
compound (6.5 g, 12 mmol, 96% yield) as a white solid. 
mp 142-144 °C. 
νmax/cm
-1 
3276 3069 2871-2957 1715 1636 1536 1455 1387 1366 1249 1162 1046 1018 
H (400 MHz, CDCl3) 0.85 (6H, d, J 6.5, CH3), 0.86 (6H, d, J 5.3, CH3), 0.88 (6H, d, J 
6.3, CH3), 1.41 [9H, s, C(CH3)3], 1.44-1.49 (2H, m, 2x CHMe2), 1.51-1.62 (6H, m, 3x 
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CH2), 1.67-1.69 (1H, m, CHMe2), 4.48-4.53 (1H, m, CHCO2), 4.48-4.53 (2H, m, 
CHCO2), 5.08 (2H, s, CH2Ph), 7.29-7.35 (5H, m, Ar H). 
C (101 MHz, CDCl3) 21.35 (CH3), 21.83 (CH3), 22.05 (CH3), 22.31 (CH3), 22.89 
(CH3), 22.95 (CH3), 24.36 (2x CHMe2), 28.40 [C(CH3)3], 40.49 (CH2), 40.97 (CH2), 
41.37 (CH2), 50.84 (CHCO), 51.47 (CHCO), 51.87 (CHCO2), 66.94 (CH2Ar), 80.16 
(OCMe3), 128.28 (2x Ar CH), 128.30 (Ar CH), 128.62 (2 x Ar CH), 135.69 (Ar C), 
155.42 (NCO2), 171.94 (CON), 172.61 (CON), 172.91 (CCO2). 
LRMS m/z (ESI) 570.3 [M+Na]
+
. 
H2N-(S)-Leu-(S)-Leu-(S)-Leu-OBn 445 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 444 (1.9 g, 3 mmol) 
in dichloromethane (50 ml) maintained at 0 °C for 1 h. On completion (TLC) of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo to give the title compound (1.54 g, 3 mmol, quant. yield) as 
a colourless oil. 
νmax/cm
-1 
3280 3068 2870-2955 1742 1641 1545 1467 1455 1385 1367 1253 1153  
H (600 MHz, CDCl3) 0.86 (3H, d, J 7.0, CH3), 0.87 (3H, d, J 6.3, CH3), 0.88 (3H, d, J 
6.6, CH3), 0.90 (3H, d, J 6.4, CH3), 0.91 (3H, d, J 6.3, CH3), 0.94 (3H, d, J 6.34, CH3), 
1.29-1.34 (1H, m, 
γ
CH2
i
Pr), 1.50-1.56 (2H, m, 2x 
αβ
CH2
i
Pr), 1.57-1.73 (1H, m, 3x 
CHMe2 + 3x CH2
i
Pr), 3.36 (1H, dd, J 3.8, 9.9, 
γ
NH2CH), 4.40-4.44 (1H, m, 
β
NHCH), 
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4.55-4.59 (1H, m, 
β
NHCH), 5.13 (2H, 2x d, J 12.3, CH2Ph), 6.70 (1H, d, J 7.6, 
α
NH), 
7.30-7.36 (5H, m, Ar H), 7.64 (1H, d, J 8.4, 
β
NH). 
C (151 MHz, CDCl3) 21.42 (CH3), 22.02 (CH3), 22.17 (CH3), 22.88 (CH3), 23.01 
(CH3), 23.53 (CH3), 24.85 (CHMe2), 24.92 (CHMe2), 24.96 (CHMe2),  40.65 (CH2), 
41.30 (CH2), 44.01 (CH2), 51.05 (NHCO), 51.24 (NHCO), 53.52 (CHCO2), 67.14 
(CH2Ar), 127.09 (Ar C), 128.35 (2x Ar CH), 128.49 (Ar CH), 128.70 (2x Ar CH), 
135.51 (Ar C), 172.02 (CON), 172.60 (CON), 175.99 (CCO2). 
LRMS m/z (ESI) 470.5 [M+Na]
+
, 448.4 [M+H]
+
.  
HRMS (ESI) calcd. for C25H42O4N3 448.3170, found 448.3172 [M+H]
+
. 
Boc-(S)-Leu-(S)-Leu-(S)-Leu-(S)-Leu-OBn 446 
 
DCC (1.74 g, 8.44 mmol), followed by DMAP (0.10 g, 0.844 mmol) were added to a 
stirred solution of Boc-(L)-Leu-OH (1.95 g, 8.44 mmol) and compound 445 (3.44 g, 
7.68 mmol) in dichloromethane (100 ml) maintained at 0
 
°C.  The mixture was left 
stirring for 3 h and the reaction monitored by TLC.  The reaction mixture was filtered to 
remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 2:1) to give the title 
compound (2.01 g, 3.04 mmol, 40% yield) as a colourless oil. 
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νmax/cm
-1 
3237 3104 2854-2934 1768 1702 1647 1549 1431 1387 1370 1349 1320 1260 
1208 1166 1102 
H (400 MHz, CDCl3) 0.83 (6H, d, J 6.5, CH3), 0.87 (6H, d, J 5.3, CH3), 0.88 (6H, d, J 
6.2, CH3), 0.90 (6H, d, J 6.4, CH3), 1.43 [9H, s, C(CH3)3], 1.40-1.51 (3H, m, 3x 
CHMe2), 1.53-1.63 (8H, m, 4x CH2), 1.64-1.68 (1H, m, CHMe2), 4.36-4.50 (2H, m, 2x 
CHCH2), 4.52-4.57 (2H, m, 2x CHCH2), 5.11 (2H, s, CH2Ph), 7.27-7.35 (5H, m, Ar H). 
C (151 MHz, CDCl3) 21.35 (CH3), 21.43 (CH3), 21.56 (CH3), 22.05 (CH3), 22.30 
(CH3), 22.70 (CH3), 22.82 (CH3), 23.07 (CH3), 24.36 (CHMe2), 24.80 (CHMe2), 25.15 
(CHMe2),  25.22 (CHMe2),  40.18 (CH2), 40.49 (CH2), 40.99 (CH2), 41.83 (CH2), 50.85 
(NHCO), 51.45 (NHCO), 51.87 (NHCO), 55.46 (CHCO2), 66.86 (CH2Ar), 127.22 (Ar 
C), 128.28 (Ar CH), 128.65 (Ar CH), 128.75 (Ar CH), 135.64 (Ar C), 155.32 (NCO2), 
171.85 (CON), 172.65 (CON), 172.85(CON), 174.40 (CCO2). 
LRMS m/z (ESI) 683.7 [M+Na]
+
, 661.7 [M+H]
+
.  
HRMS (ESI) calcd. for C36H64O7N5 678.4800, found 678.4808 [M+NH4]
+
. 
H2N-(S)-Leu-(S)-Leu-(S)-Leu-(S)-Leu-OBn 447 
 
TFA (3 ml, 39 mmol) was added to a stirred solution of compound 446 (2.0 g, 3 mmol) 
in dichloromethane (75 ml) maintained at 0 °C for 1 h. On completion of the reaction 
(TLC) the reaction mixture was poured into saturated NaHCO3 (50 ml) and the organic 
layer was extracted with dichloromethane (2 x 25 ml).  The organic phase was washed 
with NaHCO3 (2 x 25 ml).  The combined organic extracts were washed with brine and 
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then dried over Na2SO4 and stripped of solvent in vacuo to give the title compound 
(1.38 g, 2 mmol, 82% yield) as a colourless oil. 
νmax/cm
-1 
3270 3068 2860-2958 1735 1540 1460 1450 1380 1370 1257 1150 
H (600 MHz, CDCl3) 0.80-0.95 (24H, m, 8x CH3), 1.45-1.57 (2H, m, CH2
 i
Pr), 1.62-
1.64 (4H, m, 2x CH2
 i
Pr), 1.67-1.73 (2H, m, 2x CHMe2), 1.74-1.85 (4H, m, 2x CHMe2 
+ CH2
i
Pr), 3.83-3.89 (1H, m, NH2CH), 3.92-3.95 (1H, m, NHCH), 4.12-4.16 (1H, m, 
NHCH), 4.54-4.61 (1H, m, NHCH), 5.10 (2H, 2x d, J 12.33, CH2Ph), 7.28-7.35 (5H, m, 
Ar H). 
C (151 MHz, CDCl3) 21.70 (CH3), 21.72 (CH3), 21.82 (CH3), 22.19 (CH3), 22.31 
(CH3), 22.72 (CH3), 22.80 (CH3), 23.19 (CH3), 24.39 (CHMe2), 24.85 (CHMe2), 25.11 
(CHMe2),  25.19 (CHMe2),  40.14 (CH2), 41.01 (CH2), 41.11 (CH2), 45.30 (CH2), 50.95 
(NCHCO), 51.15(NCHCO), 51.47 (NCHCO), 55.30 (CHCO2), 67.22 (CH2Ar), 127.15 
(Ar C), 128.23 (2x Ar CH), 128.52 (Ar CH), 128.70 (2x Ar CH), 135.37 (Ar C), 171.73 
(CON), 172.46 (CON), 172.81(CON), 174.54 (CCO2). 
LRMS m/z (ESI) 561.5 [M+H]
+
.  
HRMS (ESI) calcd. for C31H53O5N4 561.4010, found 561.4015 [M+H]
+
. 
(S)-2-Benzyloxy-4-methyl-pentanoic acid 448 
 
Sodium hydride (1.77 g, 76 mmol) was added to a stirred solution of compound 416 
(2.43 g, 19 mmol) in DMF heated to 60 °C for 1 h.  The reaction was cooled to 0 °C, 
benzyl bromide (4.37 ml, 37 mmol) was added slowly and the reaction mixture was 
again heated at 60 °C for a further 3 h.  The solvent was removed in vacuo and the 
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residue was diluted with dichloromethane and poured into water (50 ml) and the organic 
layer was extracted with dichloromethane (2 x 25 ml).  The combined organic extracts 
were washed with saturated NaHCO3 then dried over Na2SO4 and stripped of solvent in 
vacuo. The residue was subjected to chromatography (EtOAc : Pet. Ether 6:1 - 1:1) to 
give the title compound (3.12 g, 14 mmol, 76% yield) as a colourless oil. 
νmax/cm
-1 
3032 2855-2955 1722 1603 1497 1453 1367 1314 1269 1175 1098 1070 1026 
H (400 MHz, CDCl3) 0.85 (3H, d, J 6.6, CH3), 0.93 (3H, d, J 6.6, CH3), 1.50-1.62 (1H, 
m, CH2), 1.74-1.80 (1H, m, CH2), 1.83-1.91 (1H, m, CHMe2), 4.04 (1H, dd, J 4.1, 9.5, 
CHCO2), 4.59 (2H, s, CH2Ph), 7.31-7.35 (5H, m, Ar H). 
C (101 MHz, CDCl3) 21.50 (CH3), 23.18 (CH3), 24.40 (CHMe2), 41.79 (CH2), 72.12 
(CH2Ph), 76.67 (CH), 127.67 (Ar CH), 127.82 (2x Ar CH), 128.43 (2x Ar CH), 129.73 
(Ar C), 173.28 (CCO2). 
LRMS m/z (ESI) 221.1 [M+H]
+
.  
HRMS (ESI) calcd. for C13H17O3 221.1183, found 221.1183 [M+H]
+
. 
(S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-Benzyloxy-4-methyl-pentanoylamino)-4-methyl-
pentanoylamino]-4-methyl-pentanoylamino}-4-methyl-pentanoylamino)-4-methyl-
pentanoic acid benzyl ester 449 
 
DCC (0.61 g, 3 mmol), followed by DMAP (0.04 g, 0.3 mmol) were added to a stirred 
solution of compound 447 (1.38 g, 2.47 mmol) and compound 448 (0.66 g, 3 mmol) in 
dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring for 3 h and 
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the reaction monitored by TLC.  Once complete the reaction mixture was filtered to 
remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the title 
compound (1.86 g, 2 mmol, 98% yield) as a white solid. 
mp 145-148 °C; 
νmax/cm
-1 
3268 2869-2954 1739 1706 1632 1547 1467 1453 1386 1368 1214 1151 1128 
1098 1028 
H (400 MHz, CDCl3) 0.75-0.92, 1.0-1.34, 1.36-1.87, 3.76-3.96, 4.28-4.72, 5.02-5.12, 
7.24-7.30. 
C (101 MHz, CDCl3) 21.50, 21.60, 21.74, 22.08, 22.29, 22.65, 22.93, 23.32, 24.57, 
24.76, 24.95, 25.21, 25.60, 25.85, 27.65, 29.30, 29.58, 30.32, 33.31, 33.88, 35.50, 
39.83, 40.88, 42.28, 42.36, 47.25, 49.22, 50.65, 50.85, 51.32, 51.47, 55.13, 55.49, 
66.93, 72.08, 73.02, 78.93, 136.89, 150.26, 157.06, 161.02, 172.04, 172.44, 173.93, 
174.61, 180.28. 
LRMS m/z (ESI) 787.7 [M+Na]
+
.  
HRMS (ESI) calcd. for C44H72O7N5 782.5426, found 782.5429 [M+NH4]
+
. 
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Attempted synthesis of (S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-Hydroxy-4-methyl-
pentanoylamino)-4-methylpentanoylamino]-4-methylpentanoylamino}-4-methyl-
pentanoylamino)-4-methyl-pentanoic acid 450  
 
Compound 449 (1.86 g, 2 mmol) and 5% Pd/C (0.8 g, 40% wt) in EtOAc were 
subjected to hydrogenation conditions overnight.  The catalyst was filtered through 
celite and the solvent was removed in vacuo. The residue was subjected to 
chromatography (EtOAc : Pet. Ether 4:1 - 1:0) to give the title compound (1.62 g, 2 
mmol, 99% yield) as a colourless oil. 
νmax/cm
-1 
3285 2854-2927 1706 1644 1541 1452 1430 1386 1369 1258 1216 1128 1089 
1033 
H (600 MHz, CDCl3) 0.81-0.97 (30H, m, 10x CH3), 1.09-1.22 (9H, m, ), 1.25 (10H, s, 
), 1.28-1.37 (8H, m, ), 1.41-1.52 (4H, m, ), 1.56-1.77 (19H, m, ), 1.81-1.83 (4H, m, ), 
1.85-1.88 (2H, m, ), 1.92-1.94 (3H, m, ), 2.08-2.17 (2H, m, ), 3.18 (0.5H, s, ), 3.43 (1H, 
t, J 10.47, ), 3.88 (1H, tt, J 3.68, 12.30, ), 3.95 (1H, dd, J 3.37, 9.43, ), 3.99 (0.5H, dd, J 
3.99, 9.64, ), 4.20 (0.3H, dd, J 3.49, 9.81, ), 4.37 (0.5H, d, J 11.95, ), 4.42 (1H, d, J 
11.28, ), 4.47-4.60 (2H, m, ), 4.65 (0.3H, d, J 11.88, ), 4.73 (0.6H, d, J 11.41, ), 5.10 
(0.2H, dd, J 3.33, 10.05, ), 5.85 (0.7H, d, J 11.52, ), 6.65 (0.3H, d, J 6, ), 7.29-7.31 (1H, 
m, ), 7.32-7.36 (5H, m, ), 8.07-8.09 (0.3H, m, ), 8.31 (0.2H, d, J 6.26, ).   
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C (151 MHz, CDCl3) 21.43 21.63 21.78 21.79 22.82 23.19 23.25 23.33 25.00 25.11 
25.32 25.68 25.95 29.35 29.41 29.49 29.78 29.82 32.05 33.91 39.92 41.02 41.88 41.97 
49.45 51.50 55.27 128.05 128.27 128.54 172.41 173.61 174.62 175.17 
LRMS m/z (ESI) 697.5 [M+Na]
+
.  
HRMS (ESI) calcd. for C37H66O7N5 692.4957, found 692.4962 [M+NH4]
+
. 
Boc-(S)-Leu-OEt 451 
 
DCC (7.9 g, 38 mmol ), followed by DMAP (0.47 g, 4 mmol) were added to a stirred 
solution of Boc-(L)-Leu-OH (8.04 g, 35 mmol) and EtOH (2.2 ml, 38 mmol) in 
dichloromethane (100 ml) maintained at 0
 
°C.  The mixture was left stirring for 3 h and 
the reaction monitored by TLC. Once complete (TLC) the reaction mixture was filtered 
to remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was extracted with 
dichloromethane (2 x 25 ml). The combined organic extracts were dried over Na2SO4 
and stripped of solvent in vacuo The residue was subjected to chromatography (EtOAc : 
Pet. Ether 4:1 - 2:1) to give the title compound (7.86 g, 30 mmol, 87% yield) as a 
colourless oil. 
νmax/cm
-1 
3322 2852-2929 2117 1714 1625 1568 1531 1449 1390 1366 1346 1310 1271 
1243 1160 1088 1046 1024  
H (400 MHz, CDCl3) 0.95 (3H, d, J 6.5, CH3), 0.96 (3H, d, J 6.5, CH3), 1.29 (3H, t, J 
7.1, OCH2CH3), 1.45 [9H, s, C(CH3)3], 1.48-1.53 (2H, m, CH2
i
Pr), 1.64-1.70 (1H, m, 
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CHMe2), 4.19 (2H, q, J 7.0, OCH2CH3), 4.27-4.33 (1H, m, HNCH), 4.91 (1H, d, J 7.8, 
NH). 
C (101 MHz, CDCl3) 14.18 (OCH2CH3), 21.94 (CH3), 22.84 (CH3), 24.71 (CHMe2), 
28.32 [C(CH3)3]  41.94 (CH2), 52.12 (NCHCO), 55.76 (CHCO2), 61.16 (CH2), 79.75 
(OCMe3), 156.95 (NCO2), 173.47 (CCO2). 
LRMS m/z (ESI) 260.2 [M+H]
+
.  
H2N-(S)-Leu-OEt 452 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 451 (3.59 g, 14 
mmol) in dichloromethane (75ml) maintained at 0 °C for 1 h. On completion of the 
reaction (TLC) the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was extracted with dichloromethane (2 x 25 ml).  The organic phase was 
washed with NaHCO3 (2 x 25 ml).  The combined organic extracts were washed with 
brine and then dried over Na2SO4 and stripped of solvent in vacuo to give the title 
compound (1.90 g, 12 mmol, 86% yield) as a colourless oil. 
νmax/cm
-1 
3322 2850-2927 1709 1624 1569 1536 1448 1436 1310 1271 1242 1229 1185 
1159 1087 1046    
H (400 MHz, CDCl3) 0.86-0.91 (6H, m, 2x CH3), 1.21 (3H, t, J 8.0, OCH2CH3), 1.51-
1.56 (2H, m, CH2), 1.60-1.64 (1H, m, CHMe2), 3.79-3.89 (1H, m, H2NCH), 4.11 (2H, q, 
J 11.0, OCH2CH3). 
C (101 MHz, CDCl3) 16.71 (OCH2CH3), 21.62 (CH3), 21.95 (CH3), 25.85 (CHMe2), 
40.92 (CH2), 51.38 (CHCO2), 61.34 (OCH2), 172.63 (CCO2). 
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LRMS m/z (ESI) 160.2 [M+H]
+
.  
HRMS (ESI) calcd. for C8H17O2N 160.1330, found 160.1332 [M+H]
+
. 
Boc-(S)-Leu-(S)-Leu-OEt 453 
 
DCC (4.5 g, 21.7 mmol), followed by DMAP (0.27 g, 2.17 mmol) were added to a 
stirred solution of compound 452 (3.14 g, 19.7 mmol) and Boc-(L)-Leu-OH (5.0 g, 21.7 
mmol ) in dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring 
for 3 h and the reaction monitored by TLC. Once complete (TLC) the reaction mixture 
was filtered to remove DHU and then stripped of solvent in vacuo.  The residue was 
diluted with dichloromethane and poured into water (50 ml) and the organic layer was 
separated.  The aqueous phase was washed with dichloromethane (2 x 25 ml). The 
combined organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. 
The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:1) to give the 
title compound (7.1 g, 19 mmol, 96% yield) as a white solid. 
mp 134-136°C. 
νmax/cm
-1 
3356 3263 3084 2870-2959 1754 1685 1654 1558 1514 1466 1450 1391 1365 
1318 1294 1271 1227 1250 1153 1044 1016 
H (400 MHz, CDCl3) 0.85-0.89 (12H, m, 4x CH3), 1.20 (3H, t, J 7.2, OCH2CH3), 1.38 
[9H, s, C(CH3)3], 1.44-1.52 (2H, m, CH2
i
Pr), 1.54-1.67 (4H, m, 2x CHMe2 + CH2
i
Pr), 
4.03-4.05 (1H, m, NHCH), 4.11 (2H, q, J 7.1, OCH2CH3), 4.49-4.55 (1H, td, J 4.8, 8.9, 
NHCH), 4.87-4.89 (1H, m, NH), 6.39 (1H, d, J 8.2, NH).  
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C (101 MHz, CDCl3) 14.14 (OCH2CH3), 21.83 (CH3), 22.16 (CH3), 22.85 (CH3), 22.88 
(CH3), 24.66 (CHMe2), 24.88 (CHMe2), 28.27 [C(CH3)3], 40.88 (CH2), 41.54 (CH2), 
50.70 (NCHCO), 52.97 (CHCO2), 61.34 (CH2), 80.10 (OCMe3), 155.74 (NCO2), 172.29 
(CON), 172.70 (CCO2). 
LRMS m/z (ESI) 373.4 [M+H]
+
.  
HRMS (ESI) calcd. for C19H40O5N3 390.2962, found 390.2961 [M+NH4]
+
. 
H2N-(S)-Leu-(S)-Leu-OEt 454 
 
TFA (10 ml, 131 mmol) was added to a stirred solution of compound 453 (7.22 g, 19 
mmol) in dichloromethane (100 ml) maintained at 0 °C for 1 h. On completion of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo to give the title compound (3.73 g, 14 mmol, 71% yield) as 
a colourless oil. 
νmax/cm
-1 
3194 2870-2956 1665 1553 1452 1387 1369 1347 1324 1169 1094 1033 
H (400 MHz, CDCl3) 0.94 (6H, d, J 6.4, CH3), 0.98 (6H, d, J 6.4, CH3), 1.20 (3H, t, J 
7.0, OCH2CH3), 1.58-1.63 (3H, m, CHMe2 + CH2
i
Pr), 1.75-1.85 (4H, m, CHMe2 + 
CH2
i
Pr + amide NH), 3.95-3.96 (1H, m, CHCH2), 3.97-3.98 (1H, m, CHCH2), 4.10 (2H, 
q, J 7.1, OCH2CH3), 6.73 (2H, s, NH2). 
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C (101 MHz, CDCl3) 16.24 (OCH2CH3), 21.24 (CH3), 23.40 (CH3), 24.37 (2 x 
CHMe2), 43.61 (2x CH2), 53.45 (NCHCO + CHCO2), 61.34 (OCH2), 169.05 (CON + 
CCO2).  
LRMS m/z (ESI) 273.1 [M+H]
+
.  
HRMS (ESI) calcd. for C14H29O3N2 273.2173, found 273.2173 [M+H]
+
. 
Boc-(S)-Leu-(S)-Leu-(S)-Leu-(S)-Leu-OEt 455 
 
DCC (1.07 g, 5 mmol), followed by DMAP (0.06 g, 0.5 mmol) were added to a stirred 
solution of compound 400 (1.78 g, 5 mmol) and compound 454 (1.39 g, 5.17 mmol ) in 
dichloromethane (100 ml) maintained at 0 °C.  The mixture was left stirring for 3 h and 
the reaction monitored by TLC. Once complete (TLC) the reaction mixture was filtered 
to remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
was subjected to chromatography (EtOAc : Pet. Ether 5:1 - 1:1) to give the title 
compound (3 g, 5 mmol, 98% yield) as a white solid. 
mp 164-167 °C; 
νmax/cm
-1 
33102871-2957 1718 1634 1544 1468 1387 1366 1250 1162 1121 1044 1032 
H (600 MHz, CDCl3) 0.82-0.89 (24H, m, 8x CH3), 1.21 (3H, t, J 6.5, OCH2CH3), 1.38 
[9H, s, C(CH3)3], 1.41-1.54 (4H, m, 2x CH2
i
Pr), 1.57-1.61 (6H, m, 2x CHMe2 + 2x 
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CH2
i
Pr), 1.63-1.74 (2H, m, 2x CHMe2), 4.09-4.17 (2H, m, OCH2CH3), 4.49-4.54 (2H, 
m, CHCH2), 4.60-4.66 (2H, m, CHCH2). 
C (151 MHz, CDCl3) 14.21 (OCH2CH3), 21.86 (CH3),  22.10 (CH3),  22.43 (CH3),  
22.54 (CH3),  22.72 (CH3),  22.81 (CH3),  22.92 (CH3),  23.07 (CH3),  24.75 (CHMe2),  
24.78 (CHMe2), 24.82 (CHMe2), 24.87 (CHMe2), 28.45 (CH3),  40.90 (CH2), 41.05 
(CH2), 41.68 (CH2), 41.82 (CH2), 50.57 (NHCO2), 50.84 (NHCO), 51.51 (NHCO), 
51.56 (NHCO), 51.76 (CHCO2), 61.21 (OCH2CH3), 79.81 (OCMe3), 155.99 (NCO2) 
171.99 (CON), 172.10 (CON), 172.81 (CON), 172.96 (CCO2). 
LRMS m/z (ESI) 599.4 [M+H]
+
. 
H2N-(S)-Leu-(S)-Leu-(S)-Leu-(S)-Leu-OEt 456 
 
TFA (5 ml, 65 mmol) was added to a stirred solution of compound 455 (2.05 g, 3 
mmol) in dichloromethane (75 ml) maintained at 0 °C for 1 h. On completion of the 
reaction the reaction mixture was poured into saturated NaHCO3 (50 ml) and the 
organic layer was separated.  The organic phase was washed with NaHCO3 (2 x 25 ml).  
The combined organic extracts were washed with brine and then dried over Na2SO4 and 
stripped of solvent in vacuo to give the title compound (1.28 g, 2.57 mmol, 75% yield) 
as a white solid. 
mp 108-111 °C; 
νmax/cm
-1 
3277 3076 2871-2956 1740 1635 1544 1467 1386 1368 1243 1196 1158 1093 
1032 
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H (600 MHz, CDCl3) 0.78-0.90 (24H, m, 8x CH3), 1.22 (3H, t, J 7.2, OCH2CH3), 1.29-
1.33 (1H, m, CH2), 1.41-1.48 (1H, m, CH2 ), 1.49-1.54 (3H, m, 2x CH2
i
Pr), 1.55-1.61 
(5H, m, 2x CHMe2 + 2x CH2
i
Pr), 1.63-1.68 (2H, m, 2x CHMe2), 3.37-3.40 (1H, m, 
CHCH2), 4.09-4.16 (2H, m, OCH2CH3), 4.42-4.49 (1H, m, CHCH2), 4.50-4.55 (2H, m, 
2x CHCH2). 
C (151 MHz, CDCl3) 14.22 (OCH2CH3), 21.62 (CH3), 21.98 (CH3), 22.34 (CH3), 22.56 
(CH3), 22.76 (CH3), 22.95 (2x CH3), 23.41 (CH3), 24.78 (CHMe2), 24.87 (CHMe2), 
24.88 (CHMe2), 24.89 (CHMe2), 40.98 (CH2), 41.30 (CH2), 41.33 (CH2), 43.95 (CH2), 
50.86 (NHCO), 51.29 (NHCO), 51.70 (NHCO), 53.58 (CHCO2), 61.31 (OCH2CH3), 
171.82 (2x NCO), 172.29 (CON), 172.83 (CCO2). 
LRMS m/z (ESI) 521.5 [M+Na]+, 499.5 [M+H]+.  
HRMS (ESI) calcd. for C26H51O5N4 499.3854, found 499.3856 [M+H]
+
. 
Boc-(S)-Leu-(S)-Leu-OMe 461 
 
DCC (6.98 g, 34 mmol), followed by DMAP (0.413 g, 3 mmol) were added to a stirred 
solution of compound 460 (4.47 g, 31 mmol) and Boc-(L)-Leu-OH (7.83 g, 34 mmol) in 
acetonitrile (75 ml) / tetrahydrofuran (75 ml) maintained at 0 °C.  The mixture was left 
stirring for 3 h and the reaction monitored by TLC.  The reaction mixture was filtered to 
remove DHU and then stripped of solvent in vacuo.  The residue was diluted with 
dichloromethane and poured into water (50 ml) and the organic layer was separated.  
The aqueous phase was washed with dichloromethane (2 x 25 ml). The combined 
organic extracts were dried over Na2SO4 and stripped of solvent in vacuo. The residue 
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was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:0) to give the title 
compound (8.27 g, 23 mmol, 75% yield) as a colourless oil. 
νmax/cm
-1 
3348 3267 3088 2870-2956 1759 1683 1654 1560 1516 1464 1436 1364 1273 
1250 1198 1153 1121 1096 1044 1029 
H (600 MHz, CDCl3) 0.84-0.88 (12H, m, CH3), 1.37 [9H, s, [C(CH3)3], 1.45-1.54 (2H, 
m, CH2), 1.56-1.63 (4H, m, 2x CHMe2 + CH2), 3.65 (3H, s, OCH3), 4.03-4.06 (1H, m, 
CHMe2), 4.54 (1H, td, J 4.8, 8.8, CH), 4.87 (1H, d, J 7.7, NH), 6.45 (1H, d, J 7.7, NH). 
C (151 MHz, CDCl3) 21.78 (CH3), 22.13 (CH3), 22.85 (2x CH3), 24.64 (CHMe2), 
24.69 (CHMe2), 28.26 [C(CH3)3], 41.47 (2x CH2), 50.57 (NHCO), 52.27 (NHCO), 
52.89 (CHCO2), 80.03 (OCMe3),  155.72 (NCO2), 172.26 (CON), 173.19 (CCO2). 
LRMS m/z (ESI) 381.4 [M+Na]
+
, 359.5 [M+H]
+
.  
HRMS (ESI) calcd. for C18H35O5N2 359.2540, found 359.2541 [M+H]
+
. 
H2N-(S)-Leu-(S)-Leu-OMe 458 
 
Trifluoroacetic acid (5 ml, 65 mmol) was added to a stirred solution of compound 461 
(1.4286 g, 4 mmol) in dichloromethane maintained at 0 °C. The reaction was monitored 
by TLC until completion.  The solution was poured into saturated NaHCO3 (50 ml) and 
the organic layer was separated.  The organic extracts were washed with water (2 x 25 
ml) and dried using Na2SO4.  The combined organic extracts were stripped of solvent in 
vacuo. The residue was subjected to chromatography (EtOAc : Pet. Ether 4:1 - 1:0) to 
give the title compound (1 g, 3.87 mmol, 97% yield) as a white solid. 
mp 253-255 °C; 
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νmax/cm
-1 
2871-2957 2319 1648 1455 1388 1369 1348 1327 1266 1227 1171 1137 1120 
1034 
H (600 MHz, CDCl3) 0.94 (6H, d, J 6.6, CH3), 0.96 (6H, d, J 6.6, CH3), 1.57-1.62 (2H, 
ddd, J 5.3, 9.2, 13.8, CH2), 1.67-1.71 (2H, ddd, J 4.6, 8.9, 13.6, CH2), 1.79-1.86 (2H, m, 
CHMe2), 3.87-3.89 (2H, dd, J 4.6, 9.1, CH). 
C (151 MHz, CDCl3) 20.61 (2x CH3), 22.31 (2x CH3), 24.03 (2x CHMe2), 44.59 
(NHCO), 53.37 (CHCO2), 169.92 (CON + CCO2). 
LRMS m/z (ESI) 281.4 [M+Na]
+
. 
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